0001558370-22-012979.txt : 20220810 0001558370-22-012979.hdr.sgml : 20220810 20220810064552 ACCESSION NUMBER: 0001558370-22-012979 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 70 CONFORMED PERIOD OF REPORT: 20220630 FILED AS OF DATE: 20220810 DATE AS OF CHANGE: 20220810 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Enfusion, Inc. CENTRAL INDEX KEY: 0001868912 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-PREPACKAGED SOFTWARE [7372] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-40949 FILM NUMBER: 221150334 BUSINESS ADDRESS: STREET 1: 125 SOUTH CLARK STREET, SUITE 750 CITY: CHICAGO STATE: IL ZIP: 60603 BUSINESS PHONE: (312) 253-9800 MAIL ADDRESS: STREET 1: 125 SOUTH CLARK STREET, SUITE 750 CITY: CHICAGO STATE: IL ZIP: 60603 10-Q 1 enfn-20220630x10q.htm 10-Q
0.030.1384581000839890000001868912--12-312022Q2false0.030.136558328947470971P1Y46069153670016520001868912enfn:PreferredUnitsMember2021-03-310001868912enfn:PreferredUnitsMember2020-12-310001868912us-gaap:CommonClassAMember2022-05-062022-05-060001868912us-gaap:CapitalUnitsMember2021-10-012021-10-310001868912us-gaap:RetainedEarningsMember2022-06-300001868912us-gaap:NoncontrollingInterestMember2022-06-300001868912us-gaap:AdditionalPaidInCapitalMember2022-06-300001868912us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001868912us-gaap:RetainedEarningsMember2022-03-310001868912us-gaap:NoncontrollingInterestMember2022-03-310001868912us-gaap:AdditionalPaidInCapitalMember2022-03-310001868912us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-3100018689122022-03-310001868912us-gaap:RetainedEarningsMember2021-12-310001868912us-gaap:NoncontrollingInterestMember2021-12-310001868912us-gaap:AdditionalPaidInCapitalMember2021-12-310001868912us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001868912us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001868912enfn:PreferredUnitsMember2021-06-300001868912us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-3100018689122021-03-310001868912us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001868912us-gaap:CommonClassBMemberus-gaap:CommonStockMember2022-06-300001868912us-gaap:CommonClassAMemberus-gaap:CommonStockMember2022-06-300001868912us-gaap:CommonClassBMemberus-gaap:CommonStockMember2022-03-310001868912us-gaap:CommonClassAMemberus-gaap:CommonStockMember2022-03-310001868912us-gaap:CommonClassBMemberus-gaap:CommonStockMember2021-12-310001868912us-gaap:CommonClassAMemberus-gaap:CommonStockMember2021-12-310001868912us-gaap:MemberUnitsMember2021-06-300001868912us-gaap:MemberUnitsMember2021-03-310001868912us-gaap:MemberUnitsMember2020-12-310001868912enfn:EmployeeStockPurchasePlan2021Memberus-gaap:CommonClassAMember2021-10-012021-10-310001868912us-gaap:EmployeeStockOptionMember2022-04-012022-06-300001868912srt:MinimumMember2022-07-012022-06-300001868912srt:MaximumMember2026-01-012022-06-3000018689122022-07-012022-06-300001868912country:US2022-04-012022-06-300001868912country:US2022-01-012022-06-300001868912country:US2021-04-012021-06-300001868912country:US2021-01-012021-06-300001868912country:US2022-06-300001868912country:US2021-12-310001868912us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2022-06-300001868912us-gaap:LeaseholdImprovementsMember2022-06-300001868912us-gaap:FurnitureAndFixturesMember2022-06-300001868912us-gaap:ComputerEquipmentMember2022-06-300001868912us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2021-12-310001868912us-gaap:LeaseholdImprovementsMember2021-12-310001868912us-gaap:FurnitureAndFixturesMember2021-12-310001868912us-gaap:ComputerEquipmentMember2021-12-3100018689122021-10-310001868912us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001868912us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-06-300001868912us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001868912us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-06-300001868912enfn:EnfusionLtd.LlcMember2022-06-300001868912us-gaap:EmployeeStockOptionMember2022-06-300001868912enfn:RestrictedStockAndClassaCommonStockVestedMember2022-06-300001868912us-gaap:EmployeeStockOptionMember2022-01-012022-06-300001868912enfn:RestrictedStockAndClassaCommonStockVestedMember2022-01-012022-06-300001868912enfn:PlatformSubscriptionsMember2022-04-012022-06-300001868912enfn:OtherServicesMember2022-04-012022-06-300001868912enfn:ManagedServicesMember2022-04-012022-06-300001868912enfn:PlatformSubscriptionsMember2022-01-012022-06-300001868912enfn:OtherServicesMember2022-01-012022-06-300001868912enfn:ManagedServicesMember2022-01-012022-06-300001868912enfn:PlatformSubscriptionsMember2021-04-012021-06-300001868912enfn:OtherServicesMember2021-04-012021-06-300001868912enfn:ManagedServicesMember2021-04-012021-06-300001868912enfn:PlatformSubscriptionsMember2021-01-012021-06-300001868912enfn:OtherServicesMember2021-01-012021-06-300001868912enfn:ManagedServicesMember2021-01-012021-06-300001868912us-gaap:EMEAMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2022-04-012022-06-300001868912srt:AsiaPacificMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2022-04-012022-06-300001868912srt:AmericasMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2022-04-012022-06-300001868912us-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2022-04-012022-06-300001868912us-gaap:EMEAMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2022-01-012022-06-300001868912srt:AsiaPacificMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2022-01-012022-06-300001868912srt:AmericasMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2022-01-012022-06-300001868912us-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2022-01-012022-06-300001868912us-gaap:EMEAMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2021-04-012021-06-300001868912srt:AsiaPacificMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2021-04-012021-06-300001868912srt:AmericasMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2021-04-012021-06-300001868912us-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2021-04-012021-06-300001868912us-gaap:EMEAMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2021-01-012021-06-300001868912srt:AsiaPacificMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2021-01-012021-06-300001868912srt:AmericasMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2021-01-012021-06-300001868912us-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2021-01-012021-06-300001868912us-gaap:CommonClassBMember2022-06-300001868912us-gaap:CommonClassAMember2022-06-300001868912us-gaap:CommonClassBMember2021-12-310001868912us-gaap:CommonClassAMember2021-12-3100018689122021-06-3000018689122020-12-310001868912us-gaap:RestrictedStockUnitsRSUMember2022-04-012022-06-300001868912us-gaap:EmployeeStockOptionMember2022-04-012022-06-300001868912us-gaap:CommonClassBMember2022-04-012022-06-300001868912enfn:ContingentlyIssuableClassCommonStockMember2022-04-012022-06-300001868912us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-06-300001868912us-gaap:EmployeeStockOptionMember2022-01-012022-06-300001868912us-gaap:CommonClassBMember2022-01-012022-06-300001868912enfn:ContingentlyIssuableClassCommonStockMember2022-01-012022-06-300001868912us-gaap:SellingAndMarketingExpenseMember2022-04-012022-06-300001868912us-gaap:ResearchAndDevelopmentExpenseMember2022-04-012022-06-300001868912us-gaap:GeneralAndAdministrativeExpenseMember2022-04-012022-06-300001868912us-gaap:CostOfSalesMember2022-04-012022-06-300001868912us-gaap:SellingAndMarketingExpenseMember2022-01-012022-06-300001868912us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-06-300001868912us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-06-300001868912us-gaap:CostOfSalesMember2022-01-012022-06-300001868912enfn:PreferredUnitsMember2021-04-012021-06-300001868912enfn:PreferredUnitsMember2021-01-012021-06-300001868912srt:MinimumMember2022-01-012022-06-300001868912srt:MaximumMember2022-01-012022-06-300001868912us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001868912us-gaap:AdditionalPaidInCapitalMember2022-01-012022-06-300001868912us-gaap:CommonClassBMemberus-gaap:CommonStockMember2022-04-012022-06-300001868912us-gaap:CommonClassAMemberus-gaap:CommonStockMember2022-04-012022-06-300001868912us-gaap:CommonClassBMemberus-gaap:CommonStockMember2022-01-012022-06-300001868912us-gaap:CommonClassAMemberus-gaap:CommonStockMember2022-01-012022-06-3000018689122021-10-202021-10-200001868912us-gaap:IPOMember2021-10-202021-10-200001868912us-gaap:CommonClassBMember2021-10-310001868912us-gaap:CommonClassAMember2021-10-310001868912enfn:MajorCustomerMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2022-04-012022-06-300001868912enfn:MajorCustomerMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-06-300001868912enfn:MajorCustomerMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-06-300001868912enfn:MajorCustomerMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2021-04-012021-06-300001868912enfn:MajorCustomerMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-12-310001868912enfn:MajorCustomerMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-06-300001868912us-gaap:RetainedEarningsMember2022-04-012022-06-300001868912us-gaap:NoncontrollingInterestMember2022-04-012022-06-300001868912us-gaap:RetainedEarningsMember2022-01-012022-06-300001868912us-gaap:NoncontrollingInterestMember2022-01-012022-06-300001868912us-gaap:MemberUnitsMember2021-04-012021-06-3000018689122021-04-012021-06-300001868912us-gaap:MemberUnitsMember2021-01-012021-06-3000018689122021-01-012021-06-3000018689122022-05-062022-05-0600018689122022-04-012022-06-3000018689122022-06-3000018689122021-12-310001868912us-gaap:CommonStockMember2022-08-090001868912us-gaap:CommonClassBMember2022-08-090001868912us-gaap:CommonClassAMember2022-08-0900018689122022-01-012022-06-30xbrli:sharesiso4217:USDenfn:customerenfn:subsidiaryenfn:Votexbrli:pureiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2022

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

For the transition period from                      to                     

Commission File Number: 001-40949

Enfusion, Inc.

(Exact name of registrant as specified in its charter)

Delaware

  

87-1268462

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification Number)

125 South Clark Street, Suite 750

Chicago, Illinois 60603

(Address of Principal Executive Offices)

(312) 253-9800

(Registrant’s telephone number)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading symbol

Name of Exchange on which registered

Class A common stock, par value $0.001
per share

ENFN

New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   Yes      No  

As of August 9, 2022, the registrant had 113,070,805 shares of common stock outstanding, consisting of 67,001,652 outstanding shares of Class A common stock and 46,069,153 outstanding shares of Class B common stock.

TABLE OF CONTENTS

    

    

Page

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

3

Part I.

FINANCIAL INFORMATION

5

Item 1.

Condensed Consolidated Interim Financial Statements (Unaudited)

5

Condensed Consolidated Interim Balance Sheets

5

Condensed Consolidated Interim Statements of Operations

6

Condensed Consolidated Interim Statements of Comprehensive (Loss) Income

7

Condensed Consolidated Interim Statements of Preferred Units, Stockholders’ Equity and Members’ Deficit

8

Condensed Consolidated Interim Statements of Cash Flows

9

Notes to Condensed Consolidated Interim Financial Statements

10

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

19

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

31

Item 4.

Controls and Procedures

31

Part II.

OTHER INFORMATION

33

Item 1.

Legal Proceedings

33

Item 1A.

Risk Factors

33

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

34

Item 3.

Defaults Upon Senior Securities

34

Item 4.

Mine Safety Disclosures

34

Item 5.

Other Information

34

Item 6.

Exhibits

35

Signatures

37

2

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations, financial condition, business strategy, plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. These forward-looking statements are based on management’s current expectations and assumptions about future events, which are inherently subject to uncertainties, risks, and changes in circumstances that are difficult to predict. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements concerning the following:

our future financial performance, including our revenues, costs of revenues, gross profit or gross profit margin and operating expenses;
the sufficiency of our cash, cash to meet our liquidity needs;
anticipated trends and growth rates in our business and in the markets in which we operate;
our ability to maintain the security and availability of the products and services that comprise our solution;
our ability to increase the number of clients using our solution;
our ability to sell additional products and services to and retain our existing clients;
our ability to successfully expand in our existing markets and into new markets;
our ability to effectively manage our growth and future expenses;
our market opportunity and the potential growth of that market, our liquidity and capital needs and other similar matters;
our ability to maintain, protect and enhance our intellectual property;
our ability to comply with modified or new laws and regulations applying to our business;
the attraction and retention of qualified employees and key personnel;
our anticipated investments in sales and marketing and research and development;
our ability to successfully defend litigation brought against us;
the increased expenses associated with being a public company;
the impact of the COVID-19 pandemic and other global financial, economic, and political events on our business and industry; and
our ability to compete effectively with existing competitors and new market entrants.

3

You should not rely upon forward-looking statements as predictions of future events. We have based the forward-looking statements contained in this Quarterly Report on Form 10-Q primarily on our current expectations and projections about future events and trends that we believe may affect our business, financial condition, results of operations and prospects. The outcome of the events described in these forward-looking statements is subject to risks, uncertainties and other factors described in Item 1A. Risk Factors in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2021. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Quarterly Report on Form 10-Q. The results, events and circumstances reflected in the forward-looking statements may not be achieved or occur, and actual results, events, or circumstances could differ materially from those described in the forward-looking statements.

The forward-looking statements made in this Quarterly Report on Form 10-Q relate only to events as of the date on which the statements are made. We undertake no obligation to update any forward-looking statements made in this Quarterly Report on Form 10-Q to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q or to reflect new information or the occurrence of unanticipated events, except as required by law. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, or investments we may make.

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report on Form 10-Q. And while we believe such information provides a reasonable basis for such statements, such information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements.

4

PART I – FINANCIAL INFORMATION

Item 1.  Financial Statements

Condensed Consolidated Interim Balance Sheets

(dollars in thousands)

    

As of

    

As of

June 30, 2022

December 31, 2021

    

(Unaudited)

    

ASSETS

 

  

 

  

Current Assets:

 

  

 

  

Cash

$

56,559

$

64,365

Accounts receivable, net

 

28,771

 

18,223

Prepaid expenses

 

3,634

 

6,030

Other current assets

1,287

1,060

Total current assets

 

90,251

 

89,678

Property and equipment, net

 

16,093

 

13,051

Other assets

 

3,783

 

3,356

Total assets

$

110,127

$

106,085

LIABILITIES AND STOCKHOLDERS' EQUITY

 

  

 

  

Current liabilities:

 

  

 

  

Accounts payable

$

879

$

2,528

Accrued expenses and other current liabilities

 

8,963

 

5,578

Total current liabilities

 

9,842

 

8,106

Other liabilities

 

479

 

538

Total liabilities

 

10,321

 

8,644

Stockholders' Equity:

 

  

 

  

Class A common stock, $0.001 par value; 1,000,000,000 shares authorized, 67,001,652 and 65,583,289 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively

67

66

Class B common stock, $0.001 par value; 150,000,000 shares authorized, 46,069,153 and 47,470,971 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively

46

47

Additional paid-in capital

 

240,501

 

226,717

Accumulated deficit

(180,896)

(171,209)

Accumulated other comprehensive loss

 

(582)

 

(325)

Total stockholders’ equity attributable to Enfusion, Inc.

 

59,136

 

55,296

Non-controlling interests

40,670

42,145

Total stockholders' equity

99,806

97,441

Total liabilities and stockholders' equity

$

110,127

$

106,085

See Notes to Condensed Consolidated Interim Financial Statements.

5

ENFUSION, INC.

Condensed Consolidated Interim Statements of Operations

(dollars in thousands)

(Unaudited)

    

Three Months Ended June 30, 

Six Months Ended June 30, 

    

2022

    

2021

2022

    

2021

REVENUES:

 

  

 

  

  

 

  

Platform subscriptions

$

33,560

$

24,324

$

65,111

$

46,747

Managed services

 

2,396

 

1,729

 

4,626

 

3,263

Other

 

584

 

396

 

944

 

792

Total revenues

 

36,540

 

26,449

 

70,681

 

50,802

COST OF REVENUES:

 

  

 

  

 

  

 

  

Platform subscriptions

 

9,065

 

5,709

 

18,376

 

11,661

Managed services

 

1,668

 

1,015

 

3,283

 

1,843

Other

 

114

 

53

 

171

 

82

Total cost of revenues

 

10,847

 

6,777

 

21,830

 

13,586

Gross profit

 

25,693

 

19,672

 

48,851

 

37,216

OPERATING EXPENSES:

 

  

 

 

  

 

  

General and administrative

 

18,302

 

7,457

 

40,597

 

13,838

Sales and marketing

 

7,575

 

4,264

 

16,007

 

7,422

Technology and development

 

3,722

 

2,041

 

8,524

 

4,243

Total operating expenses

 

29,599

 

13,762

 

65,128

 

25,503

(Loss) income from operations

 

(3,906)

 

5,910

 

(16,277)

 

11,713

NON-OPERATING INCOME (EXPENSE):

 

  

 

  

 

  

 

  

Interest expense

 

(1)

 

(1,410)

 

(7)

 

(2,802)

Other income (expense)

 

1

 

 

4

 

Total non-operating income (expense)

 

 

(1,410)

 

(3)

 

(2,802)

(Loss) income before income taxes

 

(3,906)

 

4,500

 

(16,280)

 

8,911

Income taxes

 

219

 

249

 

369

 

551

Net (loss) income

$

(4,125)

$

4,251

$

(16,649)

$

8,360

Net loss attributable to non-controlling interests

(1,703)

(6,962)

Net (loss) income attributable to Enfusion, Inc.

$

(2,422)

$

4,251

$

(9,687)

$

8,360

Net loss per Class A common shares attributable to Enfusion, Inc.:

Basic and diluted

$

(0.03)

$

(0.13)

Weighted Average number of Class A common shares outstanding:

Basic and diluted

84,581

83,989

See Notes to Condensed Consolidated Interim Financial Statements.

6

ENFUSION, INC.

Condensed Consolidated Interim Statements of Comprehensive (Loss) Income

(dollars in thousands)

(Unaudited)

    

Three Months Ended June 30, 

Six Months Ended June 30, 

    

2022

    

2021

2022

    

2021

Net (loss) income

$

(4,125)

$

4,251

$

(16,649)

$

8,360

Other comprehensive loss, net of income tax:

 

 

 

 

Foreign currency translation loss

 

(353)

 

(16)

 

(439)

 

(77)

Total other comprehensive (loss) income

(4,478)

4,235

(17,088)

8,283

Comprehensive loss attributable to non-controlling interests

(1,849)

(7,144)

Total comprehensive (loss) income attributable to Enfusion, Inc.

$

(2,629)

$

4,235

$

(9,944)

$

8,283

See Notes to Condensed Consolidated Interim Financial Statements.

7

ENFUSION, INC.

Condensed Consolidated Interim Statements of Preferred Units, Stockholders’ Equity and Members’ Deficit

(dollars in thousands)

(Unaudited)

    

  

Accumulated

Class A

Class B

Additional

Other

Total

Common Stock

Common Stock

Paid-in

Accumulated

Comprehensive

Non-Controlling

Stockholders'

    

Shares

  

Amount

Shares

  

Amount

Capital

Deficit

Loss

Interest

Equity

March 31, 2022

 

65,583,289

$

66

47,470,971

$

47

$

233,607

$

(178,474)

$

(375)

$

41,837

$

96,708

Net loss

 

(2,422)

 

(1,703)

 

(4,125)

Stock-based compensation, net of taxes paid

4,441

3,135

7,576

Share exchange

1,401,818

1

(1,401,818)

(1)

2,453

(2,453)

Issuance of restricted shares

16,545

Foreign currency translation loss

 

 

(207)

(146)

 

(353)

June 30, 2022

 

67,001,652

$

67

46,069,153

$

46

$

240,501

$

(180,896)

$

(582)

$

40,670

$

99,806

January 1, 2022

65,583,289

$

66

47,470,971

$

47

$

226,717

$

(171,209)

$

(325)

$

42,145

$

97,441

Net loss

 

(9,687)

 

(6,962)

 

(16,649)

Stock-based compensation, net of taxes paid

11,331

8,122

19,453

Share exchange

1,401,818

1

(1,401,818)

(1)

2,453

(2,453)

Issuance of restricted shares

16,545

Foreign currency translation loss

 

 

(257)

(182)

 

(439)

June 30, 2022

 

67,001,652

$

67

46,069,153

$

46

$

240,501

$

(180,896)

$

(582)

$

40,670

$

99,806

Other

Preferred Units

Members’ Deficit

Comprehensive

Total

    

Units

Amount

  

Units

    

Amount

Loss

Members’ Deficit

March 31, 2021

 

53.774

$

167,523

47.968

$

(231,410)

$

(273)

$

(231,683)

Net income

 

 

2,247

 

2,004

 

 

2,004

 

Foreign currency translation loss

(16)

(16)

Distributions to members

 

(1,401)

 

(1,188)

 

 

(1,188)

 

June 30, 2021

 

53.774

$

168,369

47.968

$

(230,594)

$

(289)

$

(230,883)

January 1, 2021

53.774

$

165,515

47.968

$

(233,347)

$

(212)

$

(233,559)

Net income

 

 

4,419

 

3,941

 

 

3,941

 

Foreign currency translation loss

 

 

 

 

(77)

 

(77)

 

Distributions to members

 

 

(1,565)

(1,188)

 

 

(1,188)

 

June 30, 2021

 

53.774

$

168,369

47.968

$

(230,594)

$

(289)

$

(230,883)

See Notes to Condensed Consolidated Interim Financial Statements.

8

ENFUSION, INC.

Condensed Consolidated Interim Statements of Cash Flows

(dollars in thousands)

(Unaudited)

    

Six Months Ended June 30, 

    

2022

    

2021

Cash flows from operating activities:

 

  

 

  

Net (loss) income

$

(16,649)

$

8,360

Adjustments to reconcile net (loss) income to net cash provided by operating activities:

 

 

Depreciation and amortization

 

2,955

 

1,672

Provision for bad debts

 

459

 

174

Amortization of debt-related costs

 

13

 

148

Stock-based compensation expense

20,350

Change in operating assets and liabilities:

 

 

Accounts receivable

 

(11,007)

 

(3,466)

Prepaid expenses and other current assets

 

1,316

 

(1,481)

Accounts payable

 

(1,970)

 

763

Accrued expenses and other liabilities

 

3,326

 

1,633

Net cash (used) provided by operating activities

 

(1,207)

 

7,803

Cash flows from investing activities:

 

  

 

  

Purchases of property and equipment

 

(5,263)

 

(4,401)

Net cash used in investing activities

 

(5,263)

 

(4,401)

Cash flows from financing activities:

 

  

 

  

Payment of Member distributions

 

 

(2,745)

Payment of withholding taxes on stock-based compensation

(897)

Net cash used in financing activities

 

(897)

 

(2,745)

Effect of exchange rate changes on cash

 

(439)

 

(80)

Net decrease in cash

 

(7,806)

 

577

Cash, beginning of period

 

64,365

 

13,938

Cash, end of period

$

56,559

$

14,515

Supplemental disclosure of non-cash investing activities:

Accrued Property, Plant and Equipment

$

321

$

Supplemental disclosure of cash flow information:

 

  

 

  

Interest paid in cash

$

$

2,712

Income taxes paid in cash

$

333

$

See Notes to Condensed Consolidated Interim Financial Statements.

9

ENFUSION, INC.

Notes to Condensed Consolidated Interim Financial Statements (Unaudited)

Note 1   Organization and Description of Business

Enfusion, Inc. (“Enfusion” or the “Company”) is a leading provider of cloud-based order and execution management, portfolio management and risk systems. Enfusion’s clients include large global hedge fund managers, institutional asset managers, family offices and other institutional investors. Enfusion provides its clients with innovative real-time performance, risk calculations, and accounting capabilities for some of the most sophisticated financial products. The Company is headquartered in Chicago, Illinois and has offices in Chicago, New York, London, Dublin, Hong Kong, Singapore, São Paulo, Mumbai, Bengaluru, and Sydney.

Enfusion, Inc. was incorporated in Delaware on June 11, 2021 for the purpose of facilitating an initial public offering (“IPO”), which was completed on October 25, 2021, and other related transactions in order to carry on the business of Enfusion Ltd. LLC.

Enfusion, Inc. has three wholly-owned subsidiaries: Enfusion US 1, Inc., Enfusion US 2, Inc. and Enfusion US 3, Inc.; as well as a substantial financial interest in Enfusion Ltd. LLC and its majority-owned subsidiary, Enfusion Softech India Private Limited, as well as the wholly-owned subsidiaries of Enfusion Ltd. LLC: Enfusion Systems UK Ltd, Enfusion HK Limited, Enfusion Software Limited, Enfusion (Singapore) Pte. Ltd., Enfusion do Brasil Tecnologia da Informacao Ltda, Enfusion (Australia) Pty. Ltd. and Enfusion (Shanghai) Co., Ltd. Enfusion, Inc., through its control over the managing member of Enfusion Ltd. LLC, manages and operates Enfusion Ltd. LLC’s business and controls its strategic decisions and day-to-day operations. As such, Enfusion, Inc. consolidates the financial results of Enfusion Ltd. LLC, and a portion of Enfusion, Inc.’s net income will be allocated to non-controlling interests to reflect the entitlement to a portion of Enfusion Ltd. LLC’s net income by the unitholders that held Enfusion Ltd. LLC’s common units prior to the Company’s IPO and following the reorganization transactions (the “Pre-IPO Common Unitholders”). As of June 30, 2022, Enfusion, Inc. owned approximately 59% of Enfusion Ltd. LLC.

Note 2    Basis of Presentation

Principles of Consolidation

These statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and in accordance with rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Accordingly, the financial statements do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments necessary for a fair presentation of the Company’s financial position and results of operations, and all adjustments are of a normal recurring nature. The operating results for the three and six months ended June 30, 2022 are not necessarily indicative of the results expected for the full year ending December 31, 2022. The condensed consolidated interim financial information should be read in conjunction with the consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021. The unaudited condensed consolidated interim financial statements include the accounts of Enfusion, Inc. and its wholly or majority-owned subsidiaries.  All intercompany balances and transactions are eliminated in consolidation.

Use of Estimates

The preparation of condensed consolidated interim financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated interim financial statements and accompanying notes. Actual results could differ from those estimates. The effect of the change in the estimates will be recognized in the current period of the change.

In order to better align with industry standards, the Company revised the presentation of its condensed  consolidated interim statement of operations for the three and six months ended June 30, 2021 to reclassify certain

10

immaterial expenses to cost of sales for Platform subscriptions.  These expenses were previously classified in cost of sales for Managed services and Other revenues.  This change in presentation has no effect on our gross profit or other consolidated results.  In addition, the Company revised the presentation of certain credit charges that were previously recorded in Other revenues to reclassify these charges to Platform subscription and Managed services revenues, respectively.  This change in presentation has no effect on the Company’s total revenues or other consolidated results.  

Note 3   Summary of Significant Accounting Policies

A description of the Company’s significant accounting policies is included in the audited financial statements within its Annual Report on Form 10-K for the year ended December 31, 2021. There have been no material changes in the Company’s significant accounting policies during the three and six months ended June 30, 2022.

Revenue Recognition

The Company recognizes revenue in accordance with Accounting Standards Codification 606 (“ASC 606”), Revenue from Contracts with Customers. The Company derives its revenues primarily from fees for platform subscription and managed services provided to clients. Revenues are recognized when control of these services are transferred to the Company’s clients in an amount that reflects the consideration the Company expects to be entitled to in exchange for these services. Revenues are recognized net of taxes that will be remitted to governmental agencies applicable to service contacts.

Historically, platform subscription contracts have typically had a one-year term and were cancellable with 30 days’ notice.  Beginning in the first quarter of 2021, our default platform subscription contract has had a multi-year term and did not allow termination for convenience, though each contract has and can be negotiated with varying term lengths, with or without a termination for convenience clause.  Clients are invoiced each month for the services provided in accordance with the stated terms of their service contracts. Fees for partial term service contracts are prorated, as applicable. Payment of fees are due from clients within 30 days of the invoice date. The Company does not provide financing to clients. The Company determines revenue recognition through the following five-step framework:

Identification of the contract, or contracts, with a client;
Identification of the performance obligation in the contract;
Determination of transaction price;
Allocation of the transaction price to the performance obligations in the contract; and
Recognition of revenue when, or as, performance obligations are satisfied.

Platform subscription revenues

Platform subscription revenues consist primarily of fees for providing clients with access to the Company’s cloud-based platform. Platform subscription clients do not have the right to take possession of the platform’s software, and do not have any general return rights. Platform subscription revenues are generally recognized ratably over the period of contractually enforceable rights and obligations, beginning on the date that the client gains access to the platform. Installment payments are invoiced at the end of each calendar month during the subscription term.

Managed services revenues

Managed services revenues primarily consist of client-selected middle and back-office services provided on our clients’ behalf using the Company’s platform. Revenue is recognized monthly as the managed services are performed, with invoicing occurring at the end of the calendar month.

11

Other revenues

Other revenues consists of non-subscription-based revenues, such as software enhancements developed for individual, sponsoring clients, but received by all clients, and data conversion and services that integrate a client’s historical data into our solution. The Company recognizes revenues as these services are performed with invoicing occurring at the end of each month.

Service contracts with multiple performance obligations

Our service contracts with clients can include multiple performance obligations. For these contracts, we account for individual performance obligations separately if they are distinct. However, all distinct performance obligations within a contract are satisfied over a similar period of time with the same measure of progress. Accordingly, each distinct performance obligation within a contract has the same pattern of revenue recognition. The Company has determined that implementation services are not distinct from the ongoing platform subscription services due to the highly specialized knowledge required to execute on our solution. Such services are recognized with the platform subscription services revenue over time.

Remaining performance obligations

For the Company’s contracts that exceed one year and do not include a termination for convenience clause, the amount of the transaction price allocated to remaining performance obligations as of June 30, 2022 and December 31, 2021 was $28.5 million and $23.4 million, respectively. The Company expects to recognize this amount over the next one to five years.

Disaggregation of revenue

The Company’s total revenues by geographic region, based on the client’s physical location is presented in the following tables (in thousands):

    

Three Months Ended June 30, 

 

2022

2021

 

Geographic Region

Amount

    

Percent

    

Amount

    

Percent

 

Americas*

$

23,339

 

63.9

%  

$

17,141

 

64.8

%

Europe, Middle East and Africa (EMEA)

 

4,639

 

12.7

%  

 

3,263

 

12.3

%

Asia Pacific (APAC)

 

8,562

 

23.4

%  

 

6,045

 

22.9

%

Total revenues

$

36,540

 

100.0

%  

$

26,449

 

100.0

%

*

The Company’s total revenues in the United States were $22.8 million and $16.6 million for the three months ended June 30, 2022 and 2021, respectively.

    

Six Months Ended June 30, 

 

2022

2021

 

Geographic Region

Amount

    

Percent

    

Amount

    

Percent

 

Americas*

$

45,277

 

64.1

%  

$

33,399

 

65.7

%

Europe, Middle East and Africa (EMEA)

 

8,949

 

12.6

%  

 

5,976

 

11.8

%

Asia Pacific (APAC)

 

16,455

 

23.3

%  

 

11,427

 

22.5

%

Total revenues

$

70,681

 

100.0

%  

$

50,802

 

100.0

%

*   The Company’s total revenues in the United States were $44.3 million and $32.6 million or the six months ended June 30, 2022 and 2021, respectively.

12

Accounts Receivable

As of June 30, 2022 and December 31, 2021, no individual client represented more than 10% of accounts receivable. For the three and six months ended June 30, 2022 and 2021, respectively, no individual client represented more than 10% of the Company’s total revenues.

Recent Accounting Pronouncements Not Yet Adopted

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes the guidance in former ASC 840, Leases, to increase transparency and comparability among organizations by requiring recognition of right-of-use assets and lease liabilities on the balance sheet and disclosure of key information about leasing arrangements (with the exception of short-term leases). In July 2018, the FASB issued ASU 2018-10, Codification Improvements to Topic 842, Leases, to clarify how to apply certain aspects of the new Leases (Topic 842) standard. ASU 2016-02, as subsequently amended for various technical issues, is effective for private companies and emerging growth companies in fiscal years beginning after December 15, 2021, and interim periods within annual periods beginning after December 15, 2022, and early adoption is permitted. For leases existing at, or entered into after, the beginning of the earliest comparative period presented in the consolidated financial statements, lessees and lessors must apply a modified retrospective transition approach. While the Company expects the adoption of this standard to result in an increase to the reported assets and liabilities, it has not yet determined the full impact the adoption of this standard will have on its consolidated financial statements and related disclosures.  However, the Company expects the adjustment to retained earnings to be immaterial.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which changes the impairment model for most financial assets. The new model uses a forward-looking expected loss method, which will generally result in earlier recognition of allowances for losses. ASU 2016-13, as subsequently amended for various technical issues is effective for annual reporting periods beginning after December 15, 2022, for private entities and emerging growth companies. The Company is evaluating the impact of this standard on its consolidated financial statements.

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for private entities and emerging growth companies in fiscal years beginning after December 15, 2021, and interim periods within annual periods beginning after December 15, 2022, with early adoption permitted, including adoption in an interim period. The Company is evaluating the effect of adopting this new accounting guidance but does not expect adoption will have a material impact on its consolidated financial statements.

Note 4   Property and Equipment, Net

Property and equipment, net consists of the following (in thousands):

    

June 30, 2022

    

December 31, 2021

Computer equipment and software

$

17,195

$

14,163

Software development costs

 

7,423

 

4,866

Leasehold improvements

 

1,897

 

1,947

Furniture and fixtures

 

542

 

540

Total property and equipment, cost

 

27,057

 

21,516

Less accumulated depreciation and amortization

 

(10,964)

 

(8,465)

Total property and equipment, net

$

16,093

$

13,051

As of June 30, 2022 and December 31, 2021, property and equipment, net located in the United States was $13.7 million and $10.4 million, respectively. The remainder was located in our various international locations. Included in property and equipment are the capitalized costs of software development. Software development costs capitalized during the three months ended June 30, 2022 and 2021 were $1.4 million and $501 thousand, respectively.  Software development costs capitalized during the six months ended June 30, 2022 and 2021 were $2.6 million and $1.0 million, respectively.  

13

Depreciation and amortization expense related to property and equipment, excluding software development costs, was $849 thousand and $516 thousand for the three months ended June 30, 2022 and 2021, respectively. Depreciation and amortization expense related to property and equipment, excluding software development costs, was $1.6 million and $1.0 million for the six months ended June 30, 2022 and 2021, respectively. Amortization expense related to software development costs was $507 thousand and $305 thousand for the three months ended June 30, 2022 and 2021, respectively. Amortization expense related to software development costs was $915 thousand and $577 thousand for the six months ended June 30, 2022 and 2021, respectively.

Note 5   Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):

    

June 30, 2022

    

December 31, 2021

Accrued compensation

$

7,041

$

3,180

Accrued expenses

 

1,354

 

1,182

Accrued taxes

 

568

 

1,216

Total accrued expenses and other current liabilities

$

8,963

$

5,578

Note 6   Operating Leases and Service Agreements

Operating Leases and Service Agreements

The Company leases office space in various locations under operating lease agreements in the normal course of business, which expire at various dates through 2025. Certain operating leases are secured with cash security deposits or letters of credit.

The Company has service agreements for the use of data processing facilities. These service agreements expire at various dates through 2023. Monthly base payments as of June 30, 2022 range from $6 thousand to $16 thousand.

Future aggregate minimum rental payments under the noncancelable operating leases and service agreements noted above, excluding the Company’s share of real estate taxes and other operating costs, are as follows (in thousands):

    

Amount

2022 (remaining six months)

$

2,111

2023

 

3,344

2024

 

2,385

2025

 

901

Total

$

8,741

Total expense related to these lease agreements, which is included in Cost of revenues and Operating expenses, was $1.2 million and $2.2 million for the three and six months ended June 30, 2022, respectively, and $1.0 million and $1.9 million for the three and six months ended June 30, 2021, respectively.

Note 7   Commitments and Contingencies

The Company records accruals for contingencies when it is probable that a liability will be incurred, and the amount of loss can be reasonably estimated based on historical claim activity and loss development factors. No accruals for contingencies were recorded as of June 30, 2022 and December 31, 2021, respectively.

Note 8   Preferred Units, Stockholders’ Equity and Members’ Deficit

Prior to the organizational restructuring consummated in connection with the Company’s IPO and the application of the net proceeds therefrom (the “Reorganization Transactions”), Enfusion Ltd. LLC was organized as a limited liability company owned by its members, each of whose membership interests consisted of an equal number of: (i) “Economic

14

Units”, which represented a Member’s economic interest in Enfusion Ltd. LLC; and (ii) “Participation Units”, which represented a Member’s right to participate (vote) in the affairs of Enfusion Ltd. LLC.

As a limited liability company, the Enfusion Ltd. LLC issued more than one class of Units. The Class A Units were considered to be Members’ Equity, whereas all of the other Unit classes were considered to be Preferred Units because of provisions in the Company’s former Operating Agreement that conferred certain rights and privileges to the members owning these Units, such as voting rights, redemption rights and liquidation preferences.

Holders of the Class C-1, C-2 and D Preferred Units had the option to require the Company to redeem their Units. In accordance with the guidance in ASC 480, Distinguishing Liabilities from Equity, outstanding Class C-1, C-2 and D Preferred Units were classified outside of permanent equity and within temporary equity due to their optional redemption features and liquidation preferences.

In connection with the Reorganization Transactions, the Amended and Restated Operating Agreement of Enfusion Ltd. LLC (the “LLC Operating Agreement”) was amended and restated to, among other things, modify its capital structure by reclassifying each of the outstanding Class A Units and C-1, C-2 and D Preferred Units into a new class of LLC interests (or “Common Units”) through a stock split on a 1,000,000 to 1 basis. The number of Common Units outstanding following the Reorganization Transaction reflect the 1,000,000 to 1 stock split. Pursuant to the adoption of the LLC Operating Agreement, Enfusion US 1, Inc., a newly-formed wholly owned subsidiary of Enfusion, Inc., was appointed the sole managing member of Enfusion Ltd. LLC.

Amendment and Restatement of Certificate of Incorporation

In October 2021, the Company amended its certificate of incorporation. The amended and restated certificate of incorporation of Enfusion, Inc. provides for 1,000,000,000 authorized shares of Class A common stock, 150,000,000 authorized shares of Class B common stock and 100,000,000 shares of preferred stock. Each share of the Company’s Class A common stock is entitled to one vote per share and is not convertible into any other shares of the Company’s capital stock. Holders of shares of the Company’s Class A common stock are entitled to receive dividends when, as and if declared by the Company’s board of directors. Upon the Company’s liquidation, dissolution or winding up and after payment in full of all amounts required to be paid to creditors, and subject to the rights of the holders of one or more outstanding series of preferred stock, as applicable, having liquidation preferences, the holders of shares of the Company’s Class A common stock will be entitled to receive pro rata the Company’s remaining assets available for distribution. Each share of the Company’s Class B common stock is entitled to one vote per share and is not convertible or exchangeable for a share of Class A common stock or any other security. Holders of the Company’s Class B common stock do not have any right to receive dividends or to receive a distribution upon a liquidation, dissolution or winding up of Enfusion, Inc.

Preferred Stock

The Company’s board of directors has the authority, without further action by the Company’s stockholders, to issue up to 100,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of Class A common stock. As of June 30, 2022, the Company has not issued any shares of preferred stock nor has the Company’s board of directors established the rights and privileges related to any series of preferred stock.

Note 9 Stock-Based Compensation

The Company recognized total stock compensation expense for the three and six months ended June 30, 2022 of $7.7 million and $20.4 million, respectively.  

In connection with obligations to issue Class A common stock to former holders of Award Units under the Company’s former Change in Control Bonus Plan, the Company paid approximately $1.4 million of tax withholding obligations for federal and state payroll taxes. Of that amount, $897 thousand related to employee payroll tax withholdings

15

and has accordingly been recorded as a reduction to additional paid-in capital. The Company’s stock compensation expense was recognized in the following captions within the consolidated statements of operations:

(in thousands)

   

Three Months Ended June 30, 2022

Six Months Ended June 30, 2022

Cost of revenues

$

341

$

695

General and administrative

4,969

13,907

Sales and marketing

1,491

3,484

Technology and development

867

2,264

Total stock compensation expense

$

7,668

$

20,350

Total unrecognized stock compensation expense related to unvested restricted stock units (“RSUs”) and contingently issuable shares of Class A common stock that will vest within one year of the IPO contingent upon continued employment requirements (“Contingently Issuable Shares”) was $40.6 million as of June 30, 2022, which is expected to be recognized over a weighted-average period of 2.2 years from the date of grant.

In connection with the IPO, the Company adopted the 2021 Incentive Plan (the “Plan”). The Plan provides for grants of stock options, stock appreciation rights, restricted stock, restricted stock units, bonus stock, dividend equivalents, other stock-based awards, substitute awards, annual incentive awards and performance awards intended to align the interests of participants with those of the Company’s shareholders.

During the three months ended June 30, 2022, there were 84,000 stock options granted under the Plan, at a weighted average exercise price of $9.86 per option.  As of June 30, 2022, there was approximately $523 thousand of unrecognized equity based compensation expense related to these stock options, which is expected to be recognized over a weighted-average period of approximately 3 years.  The total fair value of the stock options that vested in the three months ended June 30, 2022 was immaterial.

The assumptions used for the options granted under the Plan during the three months ended June 30, 2022 were as follows:

Assumptions

Expected volatility

64.54%

Expected term of award

6.5 years

Risk-free rate

3.39%

Dividend yield

0.00%

In connection with the IPO, the Company also adopted the 2021 Employee Stock Purchase Plan (“2021 ESPP”). Under the 2021 ESPP, eligible employees may be granted options to purchase shares of Class A common stock at the lower of 85% of the fair market value of the stock at the time of grant or 85% of the fair market value at the time of exercise. As of June 30, 2022, no options were granted to employees under the 2021 ESPP.

Note 10  Net Income (Loss) Per Class A Common Share

Basic loss per share is computed by dividing net loss attributable to Enfusion, Inc. by the weighted-average number of shares of Class A common stock outstanding during the period. Diluted loss per share is computed giving effect to all potentially dilutive shares. Diluted loss per share for all periods presented is the same as basic loss per share as the inclusion of potentially issuable shares would be antidilutive.

16

Prior to the IPO, the Enfusion, LLC membership structure included Common Units and multiple classes of Preferred Units. The Company analyzed the calculation of earnings per unit for periods prior to the IPO using the two-class method and determined that it resulted in values that would not be meaningful to the users of these Condensed Consolidated Financial Statements. Therefore, earnings per share information has not been presented for periods prior to the IPO on October 20, 2021.

A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A common stock is as follows:

Three Months

Six Months

(in thousands, except per share amounts)

    

Ended June 30, 2022

    

Ended June 30, 2022

Numerator:

Net loss

$

(4,125)

$

(16,649)

Less: Net loss attributable to non-controlling interests

1,703

6,962

Net loss attributable to Enfusion, Inc.

(2,422)

(9,687)

Adjustment to income (loss) attributable to common stockholders

(234)

(978)

Numerator for Basic Earnings per Share

$

(2,656)

$

(10,665)

Denominator:

Weighted-average shares of Class A common stock outstanding

66,287

65,935

Vested shares of Class A common stock and RSUs

18,294

18,054

Weighted-average shares of Class A common stock outstanding--basic

84,581

83,989

Net loss per share of Class A common stock--basic and diluted

$

(0.03)

$

(0.13)

The following number of potentially dilutive shares were excluded from the calculation of diluted loss per share because the effect of including such potentially dilutive shares would have been antidilutive:

Three Months

Six Months

(in thousands)

    

Ended June 30, 2022

    

Ended June 30, 2022

Class B common stock

    

46,770

    

47,121

Contingently issuable shares of Class A common stock

406

652

Restricted stock units

3,562

3,561

Stock options

84

84

50,822

51,418

Shares of Class B common stock do not share in earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been presented. Shares of Class B common stock are, however, considered potentially dilutive shares of Class A common stock. After evaluating the potential dilutive effect under both the treasury stock method and if-converted method, shares of Class B common stock were determined to be anti-dilutive and have therefore been excluded from the computation of diluted earnings per share of Class A common stock.

Note 11 Income Taxes

The Company is taxed as a corporation for income tax purposes and is subject to federal, state, and local taxes on the income allocated to it from Enfusion Ltd. LLC based upon the Company’s economic interest in Enfusion Ltd. LLC. The Company is the sole managing member of Enfusion Ltd. LLC and, as a result, consolidates the financial results of Enfusion Ltd. LLC.

Enfusion Ltd. LLC. is a limited liability company taxed as a partnership for income tax purposes. Enfusion Ltd. LLC does not pay any federal income taxes, as income or loss is included in the tax returns of the individual members. Additionally, certain wholly-owned entities taxed as corporations are subject to federal, state, and foreign income taxes in the jurisdictions in which they operate, and accruals for such taxes are included in the Condensed Consolidated Financial Statements. For periods prior to the IPO, the Company’s taxes represent those of Enfusion Ltd. LLC.

17

The Company’s effective tax rate for the three months ended June 30, 2022 and 2021 was (5.6)% and 5.5%, respectively. The Company’s effective tax rate for the six months ended June 30, 2022 and 2021 was (2.3)% and 6.2%, respectively. In the three and six months ending June 30, 2022, respectively, the Company’s effective tax rate differed from the U.S. statutory tax rate of 21% primarily due to non-controlling interest and having a full valuation allowance in the U.S. Conversely, in the three and six months ending June 30, 2021, respectively, the Company’s effective tax rate differed from the U.S. statutory tax rate of 21% primarily due to the pass-through income generated.  

Note 12  Related Party Transactions

Parties are considered to be related if one party has the ability to control or exercise significant influence over the other party in making financial or operating decisions. Since transactions with related parties may raise potential or actual conflicts of interest between the related party and the Company, upon the completion of the IPO the Company implemented a related party transaction policy that requires related party transactions to be reviewed and approved by its nominating and corporate governance committee.  

The Company used the proceeds (net of underwriting discounts) from the issuance of 5,526,608 million shares in the IPO ($87.8 million) to purchase an equivalent number of Common Units from the Company’s Pre-IPO Common Unitholders.

In connection with the IPO, the Company entered into the Tax Receivable Agreement with the Pre-IPO LLC Members, which provides for the payment by Enfusion Inc. of 85% of certain cash tax benefits that Enfusion, Inc. actually realizes, or in some cases is deemed to realize. As of June 30, 2022 and December 31, 2021, the Company has not recorded a liability under the Tax Receivable Agreement related to the tax benefits originating from the Reorganization Transactions, IPO and subsequent purchase of Enfusion Ltd. LLC units during the year ended December 31, 2021 as it is not probable that the Company will realize such tax benefits. 

On May 6, 2022, a Pre-IPO Common Unitholder delivered an exchange notice pursuant to Article XII of the LLC Operating Agreement, relating to the exchange of 1,401,818 Common Units and an equal number of shares of class B common stock for an equal number of shares of Class A common stock.

Pursuant to the terms of the LLC Operating Agreement, the Pre-IPO Common Unitholder surrendered 1,401,818 Common Units and an equal number of shares of Class B common stock. In connection therewith, the Company issued 1,401,818 shares of Class A common stock to such Pre-IPO Common Unitholder, canceled an equal number of Class B Common Stock, and received an equal number of Common Units, increasing the Company’s ownership of Common Units by 1,401,818.

18

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This discussion and analysis reflect historical results of operations and financial position. The following discussion and analysis is intended to highlight and supplement data and information presented elsewhere in this Quarterly Report on From 10-Q, including our unaudited condensed consolidated interim financial statements and related notes and other financial information, and should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission (the “SEC”) on March 30, 2022. To the extent that this discussion describes prior performance, the descriptions relate only to the periods listed, which may not be indicative of our future financial outcomes. In addition to the historical information, this discussion contains forward-looking statements that involve risks, uncertainties and assumptions that could results to differ materially from management’s expectations. Factors that could cause or contribute to such differences are discussed in the section titled “Special Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors.” We assume no obligation to update any of these forward-looking statements. All subsequent written or oral forward-looking statements attributable to us or persons acting on Enfusion’s behalf are qualified in their entirety by this paragraph.

CERTAIN DEFINITIONS

As used in this Quarterly Report on Form 10-Q, unless the context otherwise requires:

“Award Units” refers to Management Incentive Award Units issued under Enfusion Ltd. LLC’s Change in Control Bonus Plan.

“Change in Control Bonus Plan” refers to Enfusion Ltd. LLC’s former Change in Control Bonus Plan for certain members of management that provided for the payment of a cash bonus based on a specified number of Award Units in the event of a change in control transaction, as defined in Enfusion Ltd. LLC’s operating agreement.  In October 2021, Enfusion Ltd. LLC’s board of managers elected to terminate such plan (and all Award Units issued thereunder) upon effectiveness of the registration statement for our IPO.
“Common Units” refers to the new class of units of Enfusion Ltd. LLC created by the reclassification of the LLC interests of Enfusion Ltd. LLC as part of the Reorganization Transactions.
“Enfusion,” the “Company,” “we,” “us” and “our” and similar references refer: (1) following the consummation of the Reorganization Transactions, including our IPO, to Enfusion, Inc., and, unless otherwise stated, all of its direct and indirect subsidiaries, including Enfusion Ltd. LLC and (2) prior to the completion of the Reorganization Transactions, including our IPO, to Enfusion Ltd. LLC and, unless otherwise stated, all of its direct and indirect subsidiaries.
“IPO” refers to the Company’s initial public offering, completed on October 25, 2021.
“Pre-IPO Owners” refer to the equity holders who were the owners of Enfusion Ltd. LLC immediately prior to the Reorganization Transactions.
“Pre-IPO Common Unitholders” refer to Pre-IPO Owners that held Common Units following the Reorganization Transactions.
“Reorganization Transactions” refer to our IPO and certain organizational transactions that were affected in connection with our IPO, and the application of the net proceeds therefrom. See “Initial Public Offering and Reorganization Transactions” in Note 2 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021 for a description of the transactions.

Enfusion, Inc. is a holding company and, through its control over the managing member of Enfusion Ltd. LLC, operates and controls Enfusion Ltd. LLC. Enfusion, Inc.’s principal asset consists of Common Units.

19

Overview

Enfusion is a global, high-growth, software-as-a-service provider focused on transforming the investment management industry. The products and services that comprise our solution are designed to eliminate technology and information barriers, empowering investment managers to confidently make and execute better-informed investment decisions in real time. We simplify investment and operational workflows by unifying mission critical systems and coalescing data into a single dataset resulting in a single source of truth. This allows stakeholders throughout the entire client organization to interact more effectively with one another across the investment management lifecycle.

Our total revenues were approximately 98.4% and 98.7% recurring subscription-based during the three and six months ended June 30, 2022, respectively, and 98.5% and 98.4% during the three and six months ended June 30, 2021, respectively. Generally, we charge our clients fees comprised of various components such as user fees, connectivity fees, market data fees and technology-powered, managed service fees, all of which take into account client complexity and that is subject to contract minimums. The weekly enhancements and upgrades that we deliver and the dedicated client service are included in the price of the contract.

To support our growth and capitalize on our market opportunity, we continue to invest across all aspects of our business. In research and development, we are focused on developing additional system functionality that will open revenue opportunities across alternative and institutional investment managers. We have also further institutionalized and increased spend in our sales and marketing efforts, both in the United States and internationally.

We operate as a single operating and reportable segment, which reflects the way our chief operating decision maker, (“CODM”) reviews and assesses the performance of our business. Our total revenues were $36.5 million and $70.7 million for the three and six months ended June 30, 2022, respectively, compared to $26.5 million and $50.8 million for the three and six months ended June 30, 2021, respectively. Platform subscriptions and managed services revenues were $36.0 million for the three months ended June 30, 2022, up approximately 38% from $26.1 million for the three months ended June 30, 2021.  For the six months ended June 30, 2022, platform and subscriptions revenues were $69.7 million, up 39.4% compared to $50.0 million for the six months ended June 30, 2021.  We had net losses of $4.1 million and $16.7 million for the three and six months ended June 30, 2022, compared to net income of $4.3 million and $8.4 million for the three and six months ended June 30, 2021, respectively.

Components of Our Results of Operations

Revenues

Platform subscriptions

Platform subscriptions revenues consists primarily of user fees to provide our clients access to our cloud-based solution. Fees consider various components such as number of users, connectivity, trading volume, data usage and product coverage. Platform subscription clients do not have the right to take possession of the platform’s software and do not have any general return right. Platform subscription revenues are generally recognized ratably over the period of contractually enforceable rights and obligations, beginning on the date that the client gains access to the platform. Historically, our platform subscription contracts have typically had a one-year term and were cancellable with 30 days’ notice.  Beginning in the first quarter of 2021, our default platform subscription contract has had a multi-year term and did not allow termination for convenience, though each contract has and can be negotiated with varying term lengths, with or without a termination for convenience clause. Installment payments are invoiced at the end of each calendar month during the subscription term.

Managed services

Managed services revenues primarily consists of client-selected middle- and back-office, technology-powered services. We recognize revenues monthly as the managed services are performed with invoicing occurring at the end of the month. Generally, invoices have a 30-day payment period in accordance with the associated contract. There is no financing available.

20

Other

Other revenues consist of non-subscription-based revenues, such as software enhancements developed for individual, sponsoring clients, but received by all clients, and data conversion and services that integrate a client’s historical data into our solution. We recognize revenues as these services are performed with invoicing occurring at the end of each month.

Cost of Revenues

Cost of revenues consists primarily of personnel-related costs associated with the delivery of our software and services, including base salaries, bonuses, employee benefits and related costs. Additionally, cost of revenues includes amortization of capitalized software development costs, allocated overhead and certain direct data and hosting costs, and stock-based compensation. Our cost of revenues has fixed and variable components and depends on the type of revenues earned in each period. We expect our cost of revenues to increase in absolute dollars as we continue to hire personnel to provide hosting services and technical support to our growing client base. We anticipate additional expenses as a result of stock-based compensation expenses for the contingently issuable shares of our Class A common stock that will vest within one year of the IPO contingent upon continued employment requirements (the “Contingently Issuable Shares”), restricted stock units granted in connection with the IPO, and other equity awards to be issued under our equity plans.

Operating Expenses

We present stock-based compensation expense within General and administrative, Sales and marketing, and Technology and development expenses based on the individual employee’s department. We anticipate additional expenses as a result of stock-based compensation expenses for the Contingently Issuable Shares, restricted stock units granted in connection with the IPO, and other equity awards to be issued under our equity plans.

General and administrative

General and administrative expenses consist of personnel costs and related expenses for executive, finance, legal, human resources, and recruiting and administrative personnel.  These personnel costs and related expenses include salaries, benefits and bonuses, fees for external legal, accounting, recruiting and other consulting services, and stock-based compensation expense. We expect certain expenses to increase as we continue to operate as a publicly traded company and expand our client base and geographic footprint.

Sales and marketing

Sales and marketing expenses consist primarily of personnel and related costs associated with our sales and marketing staff, including base salaries, employee benefits, bonuses and commissions, and stock-based compensation expense. We expect our sales and marketing expenses to continue to increase as we implement new marketing strategies and build our professional sales organization to support our client base growth and geographic expansion.

Technology and development

Technology and development expenses consist primarily of research and development activities, non-capitalizable costs of developing content and certain overhead allocations, and stock-based compensation. These costs include employee-related costs, consulting services, expenses related to the product design, development, testing and enhancements of our subscription services. We expect that our technology and development expenses will increase as we continue to enhance our platform functionality and develop new content and features.

Income Taxes

Enfusion Ltd. LLC has historically been and is treated as a pass-through entity for U.S. federal tax purposes and most applicable state and local income tax purposes. Income tax provision represents the income tax expense or benefit associated with our foreign operations based on the tax laws of the jurisdictions in which we operate.

21

After consummation of the Reorganization Transactions, Enfusion, Inc. became subject to U.S. federal income taxes with respect to our allocable share of any U.S. taxable income of Enfusion, Ltd. LLC and is taxed at the prevailing corporate tax rates. Enfusion, Inc. is treated as a U.S. corporation for U.S. federal, state and local income tax purposes. Accordingly, a provision for income taxes is recorded for the anticipated tax consequences of our reported results of operations for federal income taxes.

Non-Controlling Interests

Non-controlling interests represent the portion of profit or loss, net assets and comprehensive loss of our consolidated subsidiary that is not allocable to the Company based on our percentage of ownership of this entity. Income or loss attributed to the non-controlling interests is based on the Common Units outstanding during the period and is presented on the consolidated statements of operations and consolidated statements of comprehensive income.

22

Results of Operations

The results of operations presented below should be reviewed in conjunction with the condensed consolidated interim financial statements and notes included elsewhere in this Quarterly Report on Form 10-Q.

Comparison of the Three Months Ended June 30, 2022 and 2021

The following table sets forth our consolidated results of operations for the periods shown:

Three Months Ended June 30, 

    

(in thousands)

    

2022

    

2021

    

Unaudited

REVENUES:

 

  

 

  

 

Platform subscriptions

$

33,560

$

24,324

Managed services

 

2,396

 

1,729

Other

 

584

 

396

Total revenues

36,540

 

26,449

COST OF REVENUES:

 

  

 

  

Platform subscriptions

 

9,065

 

5,709

Managed services

 

1,668

 

1,015

Other

 

114

 

53

Total cost of revenues

 

10,847

 

6,777

Gross profit

 

25,693

 

19,672

OPERATING EXPENSES:

 

  

 

  

General and administrative

 

18,302

 

7,457

Sales and marketing

 

7,575

 

4,264

Technology and development

 

3,722

 

2,041

Total operating expenses

 

29,599

 

13,762

(Loss) income from operations

 

(3,906)

 

5,910

NON-OPERATING INCOME (EXPENSE):

 

  

 

  

Interest expense

 

(1)

 

(1,410)

Other income (expense)

 

1

 

Total non-operating income (expense)

 

 

(1,410)

(Loss) income before income taxes

 

(3,906)

 

4,500

Income taxes

 

219

 

249

Net (loss) income

(4,125)

4,251

Net loss attributable to non-controlling interests

(1,703)

Net (loss) income attributable to Enfusion, Inc.

$

(2,422)

$

4,251

Revenues

Three Months Ended June 30, 

 

Increase (Decrease)

 

(in thousands)

    

2022

    

2021

    

Amount

    

Percent

Platform subscriptions

$

33,560

$

24,324

$

9,236

 

38.0

%

Managed services

 

2,396

 

1,729

 

667

 

38.6

%

Other

 

584

 

396

 

188

 

47.5

%

Total revenues

$

36,540

$

26,449

$

10,091

 

38.2

%

23

Total revenue was $36.5 million for the three months ended June 30, 2022 compared to $26.5 million for the three months ended June 30, 2021, representing an increase of $10.0 million, or 38.2%.

Platform subscriptions

Platform subscriptions revenue increased by $9.2 million or 38.0%, from $24.3 million for the three months ended June 30, 2021 to $33.6 million for the three months ended June 30, 2022.  The increase was primarily driven by increased revenues from new clients of approximately $4.4 million. Revenue also increased for existing clients; this increase includes sales of new services and growth from existing contracts due to new users of $5 million and the full-period impact of prior period sales of $1.6 million, partially offset by reductions in revenue due to client churn.

Managed services

Managed services revenue increased by approximately $700 thousand or 38.6%, from $1.7 million for the three months ended June 30, 2021 to $2.4 million for the three months ended June 30, 2022.  The increase was primarily driven by revenue from new clients of approximately $600 thousand and increases in revenue from existing clients of approximately $340 thousand, partially offset by reductions in revenue due to client churn.

Other

Other revenues consisting of software enhancements and data conversion services of $600 thousand remained relatively consistent for the three months ended June 30, 2022 over the comparative period.

Cost of Revenues, Gross Profit and Gross Profit Margin

Three Months Ended June 30, 

 

Increase (Decrease)

 

(in thousands)

    

2022

    

2021

    

Amount

    

Percent

Cost of revenues:

 

  

 

  

 

  

 

  

Platform subscriptions

$

9,065

$

5,709

$

3,356

 

58.8

%

Managed services

 

1,668

 

1,015

 

653

 

64.3

%

Other

 

114

 

53

 

61

 

115.1

%

Total cost of revenues

$

10,847

$

6,777

$

4,070

 

60.1

%

Gross profit

$

25,693

$

19,672

$

6,021

 

30.6

%

Gross profit margin

 

70.3

%

 

74.4

%

 

  

 

  

Cost of Revenues

Cost of revenues increased by $4.1 million or 60.1%, from $6.8 million for the three months ended June 30, 2021 to $10.9 million for the three months ended June 30, 2022. The increase was primarily driven by an increase in payroll and payroll-related costs of $2.7 million, largely resulting from headcount additions to support our continued growth. In addition, hosting costs and data fees increased by $550 thousand over the comparative period, reflective of an increased client base and increased usage.  Stock-based compensation expense of approximately $341 thousand also contributed to the increase. 

Gross profit increased by $6 million, from $19.7 million for the three months ended June 30, 2021 to $25.7 million for the three months ended June 30, 2022.  Gross profit margin as a percentage of revenue decreased by 4.1%.  The decrease in overall gross profit margin as a percentage of revenues was primarily attributable to increased personnel costs for onboarding and client services.

24

Operating Expenses

Three Months Ended June 30, 

 

Increase (Decrease)

 

(in thousands)

    

2022

    

2021

    

Amount

    

Percent

General and administrative

$

18,302

$

7,457

$

10,845

 

145.4

%

Sales and marketing

 

7,575

 

4,264

 

3,311

 

77.7

%

Technology and development

 

3,722

 

2,041

 

1,681

 

82.4

%

Total operating expenses

$

29,599

$

13,762

$

15,837

 

115.1

%

General and administrative

General and administrative expenses increased by $10.8 million, from $7.5 million for the three months ended June 30, 2021 to $18.3 million for the three months ended June 30, 2022. The increase in general and administrative expenses was primarily attributable to stock-based compensation expense of approximately $5 million.  Professional fees for accounting, consulting, legal, and tax services increased by approximately $1.1 million over the comparative period. These fees were primarily incurred to support our growth and the increased administrative complexity related to our new public company status. The remaining increase in general and administrative expenses is primarily attributable to increased corporate personnel costs and incremental public company costs such as directors and officers insurance.

Sales and marketing

Sales and marketing expenses increased by $3.3 million, from $4.3 million for the three months ended June 30, 2021 to $7.6 million for the three months ended June 30, 2022.  The increase was primarily attributable to stock-based compensation expense of $1.5 million. The increase was also attributable to higher personnel costs related to our continued focus on the growth of our professional sales organization, increased marketing spend, and increased commission expenses.  

Technology and development

Technology and development expenses increased by $1.7 million, from $2.0 million for the three months ended June 30, 2021 to $3.7 million for the three months ended June 30, 2022.  The increase in technology and development expense was primarily attributable to stock-based compensation expense of approximately $900 thousand, with the remaining increase driven by incremental personnel costs to support growth of our product development and client services groups.

Non-Operating Expense

The overall decrease of $1.4 million in non-operating expense from the three months ended June 30, 2021 to the three months ended June 30, 2022 was driven primarily by the decrease in interest expense as result of the repayment in full of the term loan in the fourth quarter of 2021 following the IPO.

25

Comparison of Six Months Ended June 30, 2022 and 2021

The following table sets forth our consolidated results of operations for the periods shown:

Six Months Ended June 30, 

(in thousands)

    

2022

    

2021

Unaudited

REVENUES:

 

  

 

  

Platform subscriptions

$

65,111

$

46,747

Managed services

 

4,626

 

3,263

Other

 

944

 

792

Total revenues

70,681

 

50,802

COST OF REVENUES:

 

  

 

  

Platform subscriptions

 

18,376

 

11,661

Managed services

 

3,283

 

1,843

Other

 

171

 

82

Total cost of revenues

 

21,830

 

13,586

Gross profit

 

48,851

 

37,216

OPERATING EXPENSES:

 

  

 

  

General and administrative

 

40,597

 

13,838

Sales and marketing

 

16,007

 

7,422

Technology and development

 

8,524

 

4,243

Total operating expenses

 

65,128

 

25,503

(Loss) income from operations

 

(16,277)

 

11,713

NON-OPERATING INCOME (EXPENSE):

 

  

 

  

Interest expense

 

(7)

 

(2,802)

Other income (expense)

 

4

 

Total non-operating income (expense)

 

(3)

 

(2,802)

(Loss) income before income taxes

 

(16,280)

 

8,911

Income taxes

 

369

 

551

Net (loss) income

(16,649)

8,360

Net loss attributable to non-controlling interests

(6,962)

Net (loss) income attributable to Enfusion, Inc.

$

(9,687)

$

8,360

Revenues

Six Months Ended June 30, 

 

Increase (Decrease)

 

(in thousands)

    

2022

    

2021

    

Amount

    

Percent

 

Platform subscriptions

$

65,111

$

46,747

$

18,364

 

39.3

%

Managed services

 

4,626

 

3,263

 

1,363

 

41.8

%

Other

 

944

 

792

 

152

 

19.2

%

Total revenues

$

70,681

$

50,802

$

19,879

 

39.1

%

Total revenue was $70.7 million for the six months ended June 30, 2022 compared to $50.8 million for the six months ended June 30, 2021, representing an increase of $19.9 million, or 39.1%.

26

Platform subscriptions

Platform subscriptions revenue increased by $18.4 million or 39.3%, from $46.7 million for the six months ended June 30, 2021 to $65.1 million for the six months ended June 30, 2022.  The increase was primarily driven by increased revenues from new clients of approximately $7.1 million. Revenue also increased for existing clients; this increase includes sales of new services and growth from existing contracts due to new users of $8.6 million and the full-period impact of prior period sales of approximately $5.5 million, partially offset by reductions in revenue due to client churn.

Managed services

Managed services revenue increased by approximately $1.3 million or 41.8%, from $3.3 million for the six months ended June 30, 2021 to $4.6 million for the six months ended June 30, 2022.  The increase was primarily driven by revenue from new clients of approximately $1 million and increases in revenue from existing clients of approximately $770 thousand, partially offset by reductions in revenue due to client churn.

Other

Other revenues consisting of software enhancements and data conversion services of approximately $900 thousand remained relatively consistent for the six months ended June 30, 2022 over the comparative period.

Cost of Revenues, Gross Profit and Gross Profit Margin

Six Months Ended June 30, 

 

Increase (Decrease)

 

(in thousands)

    

2022

    

2021

    

Amount

    

Percent

 

Cost of revenues:

 

  

 

  

 

 

  

Platform subscriptions

$

18,376

$

11,661

$

6,715

 

57.6

%

Managed services

 

3,283

 

1,843

 

1,440

 

78.1

%

Other

 

171

 

82

 

89

 

108.5

%

Total cost of revenues

$

21,830

$

13,586

$

8,244

 

60.7

%

Gross profit

$

48,851

$

37,216

$

11,635

 

31.3

%

Gross profit margin

 

69.1

%

 

73.3

%

 

  

 

  

Cost of Revenues

Cost of revenues increased by $8.2 million or 60.7%, from $13.6 million for the six months ended June 30, 2021 to $21.8 million for the six months ended June 30, 2022. The increase was primarily driven by an increase in payroll and payroll-related costs of $5.1 million, largely resulting from headcount additions to support our continued growth. In addition, hosting costs and data fees increased by $1.3 million over the comparative period, reflective of an increased client base and increased usage.  Stock-based compensation expense of approximately $695 thousand also contributed to the increase. 

Gross profit increased by approximately $11.6 million, from $37.2 million for the six months ended June 30, 2021 to $48.9 million for the six months ended June 30, 2022. Gross profit margin as a percentage of revenue decreased by 4.2%.  The decrease in gross profit margin as a percentage of revenues was primarily attributable to increased personnel costs for onboarding and client services.

27

Operating Expenses

Six Months Ended June 30, 

 

Increase (Decrease)

 

(in thousands)

    

2022

    

2021

    

Amount

    

Percent

 

General and administrative

$

40,597

$

13,838

$

26,759

 

193.4

%

Sales and marketing

 

16,007

 

7,422

 

8,585

 

115.7

%

Technology and development

 

8,524

 

4,243

 

4,281

 

100.9

%

Total operating expenses

$

65,128

$

25,503

$

39,625

 

155.4

%

General and administrative

General and administrative expenses increased by $26.8 million, from $13.8 million for the six months ended June 30, 2021 to $40.6 million for the six months ended June 30, 2022. The increase in general and administrative expenses was primarily attributable to stock-based compensation expense of $13.9 million.  Professional fees for accounting, consulting, legal, and tax services increased by approximately $4 million over the comparative period. These fees were primarily associated with our transition to a public entity and the Reorganization Transactions. The remaining increase in general and administrative expenses is primarily attributable to increased corporate personnel costs and incremental public company costs such as directors and officers insurance.

Sales and marketing

Sales and marketing expenses increased by $8.6 million, from $7.4 million for the six months ended June 30, 2021 to $16 million for the six months ended June 30, 2022.  The increase was primarily attributable to stock-based compensation expense of $3.5 million. The increase was also attributable to higher personnel costs related to our continued focus on the growth of our professional sales organization, increased marketing spend, and increased commission expenses.  

Technology and development

Technology and development expenses increased by $4.3 million, from $4.2 million for the six months ended June 30, 2021 to $8.5 million for the six months ended June 30, 2022.  The increase in technology and development expense was primarily attributable to stock-based compensation expense of $2.3 million, with the remaining increase driven by incremental personnel costs to support growth of our product development and client services groups.

Non-Operating Expense

The overall decrease of $2.8 million in non-operating expense from the six months ended June 30, 2021 to the six months ended June 30, 2022 was driven primarily by the decrease in interest expense as result of the repayment in full of the term loan in the fourth quarter of 2021 following the IPO.

Liquidity and Capital Resources

To date, we have funded our capital needs through collections from our clients and issuances of equity and debt. As of June 30, 2022, we had cash of $56.6 million and $5.0 million in available borrowing capacity under our Revolving Debt (as defined below). As of June 30, 2022, the Company was contingently obligated for a letter of credit in the amount of $0.2 million which bears interest at an annual rate of 2%. We believe that our current sources of liquidity, cash flows from operations and existing available cash, together with our other available external financing sources, will be adequate to fund our operating and capital needs for at least the next 12 months.

28

Our future capital requirements will depend on many factors, including those set forth under Item 1A. Risk Factors. As a result of the IPO, we expect that our future uses of cash will also include paying income taxes and obligations under our Tax Receivable Agreement.  Further, between October 20, 2022 and October 20, 2023, we estimate that we will issue an aggregate of approximately 18.6 million shares of Class A common stock, in one or more tranches, to former holders of Award Units and a non-executive employee, as previously disclosed in our 2021 Annual Report on Form 10-K under the risk factor entitled “Our obligations to issue Class A common stock to former holders of Award Units under our former Change in Control Bonus Plan could expose us to a variety of risks and will cause us to recognize significant stock-based compensation expense that will substantially impact our net income in the near term.”  Their related individual tax withholding obligations will be satisfied, at our discretion, through methods that may include (i) a “sell to cover” arrangement whereby a certain number of shares would be sold into the market with proceeds from such sale remitted to us in an amount that would satisfy the withholding amount, and (ii) our withholding a certain number of the shares with a value that would satisfy the withholding amount due and using our available capital resources to pay the related tax burden, which could have a material impact on our liquidity and capital resources. Refer to Part II, Section 1 A, Risk Factors for further details.

We may in the future enter into arrangements to acquire or invest in complementary businesses, services, which could decrease our cash and cash equivalents and increase our cash requirements. As a result of these and other factors, we could use our available capital resources sooner than expected and may be required to seek additional equity or debt.

Cash Flow Information

The following table presents a summary of our consolidated cash flows from operating, investing and financing activities for the periods indicated.

Six Months Ended June 30, 

 

Increase (Decrease)

 

(in thousands)

    

2022

    

2021

    

Amount

    

Percent

 

Net cash (used in) provided by operating activities

$

(1,207)

$

7,803

 

$

(9,010)

 

(115.5)

%

Net cash used in investing activities

 

(5,263)

 

(4,401)

 

 

(862)

 

(19.6)

%

Net cash used in financing activities

 

(897)

 

(2,745)

 

 

1,848

 

67.3

%

Effect of exchange rate changes on cash

 

(439)

 

(80)

 

 

(359)

 

(448.8)

%

Net decrease in cash

$

(7,806)

$

577

 

$

(8,383)

 

1,452.9

%

Operating activities

We used $1.2 million in cash flows from operating activities during the six months ended June 30, 2022, resulting from our net loss of $16.6 million, adjusted by non-cash charges of $23.8 million (of which $20.4 million is related to stock-based compensation expense), and offset by $8.4 million of cash used in working capital activities.  Cash used by working capital accounts was primarily due to increases in accounts receivable, largely related to our revenue growth.

For the six months ended June 30, 2021,  we generated $7.8 million in cash flows from operating activities, resulting from net income of $8.4 million, adjusted by non-cash charges of $2.0 million, and offset by $2.6 million of cash used in working capital activities.

Investing activities

Net cash used in investing activities in the six months ended June 30, 2022 was $5.3 million, compared to $4.4 million of net cash used in investing activities in the six months ended June 30, 2021. This increase was driven by investments in property and equipment costs to support the expansion of our business.

29

Financing activities

We used $897 thousand in cash flows from financing activities during the six months ended June 30, 2022, resulting from payment of withholding taxes on stock-based compensation.  For the six months ended June 30, 2021, we incurred $2.8 million for distributions to members.

Indebtedness

We have a revolving debt facility with Silicon Valley Bank (the “Revolving Debt”). We did not have any outstanding revolving debt as of June 30, 2022 and December 31, 2021. As of June 30, 2022 and December 31, 2021, the available unused commitment of the revolving debt was $5.0 million. The credit agreement governing the Revolving Debt contains certain covenants with which we must comply, including a fixed charge ratio covenant and a leverage ratio covenant. We were in compliance with all loan covenants and requirements as of June 30, 2022.

Contractual Obligations and Commitments and Off-Balance Sheet Arrangements

We have service agreements for the use of data processing facilities. As of June 30, 2022, these service agreements expire at various dates through 2023. We also lease office space under operating lease agreements.

As of June 30, 2022, our contractual obligations consisted of: (i) operating lease obligations of $8.6 million, of which $2.0 million is due in 2022 and $6.6 million is due thereafter, and (ii) service agreement obligations of approximately $130 thousand, a majority of which are due in 2022.

As of June 30, 2022, we did not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that may be material to investors.

Dividend Policy

Assuming Enfusion Ltd. LLC makes distributions to its members in any given year, the determination to pay dividends, if any, to our Class A common stockholders out of the portion, if any, of such distributions remaining after our payment of taxes, Tax Receivable Agreement payments and expenses will be made at the sole discretion of our board of directors. We currently intend to retain all available funds and future earnings and do not anticipate declaring or paying any cash dividends in the foreseeable future.  Our board of directors may change our dividend policy at any time.

Tax Receivable Agreement

The payment obligation under the Tax Receivable Agreement is an obligation of Enfusion, Inc. and not of Enfusion Ltd. LLC. We expect that as a result of the size of the existing tax basis and basis adjustments acquired in the IPO, the increase in existing tax basis and the anticipated tax basis adjustment of the tangible and intangible assets of Enfusion Ltd. LLC upon the purchase or exchange (or deemed exchange) of Common Units for shares of Class A common stock or distributions (or deemed distributions) with respect to Common Units and our possible utilization of certain tax attributes, the payments that we may make under the Tax Receivable Agreement will be substantial. We estimate the amount of existing tax basis and basis adjustments acquired in the IPO to be approximately $232.9 million.

There may be a material negative effect on our liquidity if, as a result of timing discrepancies or otherwise, the payments under the Tax Receivable Agreement exceed the actual cash tax benefits that Enfusion, Inc. realizes in respect of the tax attributes subject to the Tax Receivable Agreement and/or if distributions directly and/or indirectly to Enfusion, Inc. by Enfusion Ltd. LLC are not sufficient to permit Enfusion, Inc. to make payments under the Tax Receivable Agreement after it has paid taxes and other expenses. Late payments under the Tax Receivable Agreement generally will accrue interest at an uncapped rate equal to one-year LIBOR (or its successor rate) plus 100 basis points. The payments under the Tax Receivable Agreement are not conditioned upon continued ownership of us by the Pre-IPO Owners.

30

Critical Accounting Policies and Estimates

The discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated interim financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these condensed consolidated interim financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, expenses and related disclosures in the condensed consolidated interim financial statements. Our estimates are based on historical experience and on various other assumptions that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates under different assumptions or conditions and any such difference may be material. For a discussion of how these and other factors may affect our business, see “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021.

The critical accounting estimates that we believe affect our more significant judgments and estimates used in the preparation of our condensed consolidated interim financial statements presented in this Quarterly Report on Form 10-Q are described under Item 7 Management’s Discussion and Analysis of Financial Condition and Results of Operations and in the Notes to the Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2021. There have been no material changes to our critical accounting policies or estimates from those set forth in our Annual Report on Form 10-K for the year ended December 31, 2021.

Recent Accounting Pronouncements

See Note 3 to our condensed consolidated interim financial statements included elsewhere in this Quarterly Report on Form 10-Q.

Emerging Growth Company Status

We are an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act (the “JOBS Act”), and, for so long as we continue to be an emerging growth company, we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.

In addition, under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have elected to use this extended transition period to enable us to comply with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we: (i) are no longer an emerging growth company; or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

There have been no material changes to our market risk during the quarter ended June 30, 2022. For a discussion of our exposure to market risk, see Item 7A, “Quantitative and Qualitative Disclosures About Market Risk” of our Annual Report on Form 10-K for the year ended December 31, 2021.

Item 4. Controls and Procedures.

Limitations on Effectiveness of Controls and Procedures

31

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our internal controls will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of internal controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. Also, any evaluation of the effectiveness of controls in future periods are subject to the risk that those internal controls may become inadequate because of changes in business conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2022.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting identified in management’s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act during the quarter ended June 30, 2022 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

32

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

From time to time we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, operating results, financial condition or cash flows. Regardless of the outcome, legal proceedings can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

Item 1A. Risk Factors.

The following is intended to restate and supplement the risk factor entitled “Our obligations to issue Class common stock to former holders of Award Units under our former Change in Control Bonus Plan could expose us to a variety of risks and will cause us to recognize significant stock-based compensation expense that will substantially impact our net income in the near term,” as disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021. Other than the risk factor set forth below, there have been no material changes to the risk factors disclosed under the heading “1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021.

Our obligations to issue Class A common stock to former holders of Award Units under our former Change in Control Bonus Plan could expose us to a variety of risks, some of which could cause the price of our stock to decline, and will cause us to recognize significant stock-based compensation expense that will substantially impact our net income in the near term.

We previously adopted a Change in Control Bonus Plan, which provided for the payment of cash amounts to certain eligible employees upon the occurrence of a change in control of our company. The aggregate amount of payment that could have been made to all participants under the Change in Control Bonus Plan may have been as much as 18% of the gross consideration received by us or our stockholders in a change in control transaction. The board of managers of Enfusion Ltd. LLC elected to terminate the Change in Control Bonus Plan (and all Award Units issued thereunder) effective following effectiveness of the IPO registration statement. The value, based on our valuation at the IPO, of all Award Units that are vested at effectiveness of the IPO registration statement and Award Units that would have vested within one year thereafter will be paid to participants in the Change in Control Bonus Plan in the form of vested shares of Class A common stock between the first and second anniversaries of such date of effectiveness. As of June 30, 2022, we will issue approximately 14,914,206 shares of Class A common stock to former holders of vested Award Units and 1,667,852 shares of Class A common stock to former holders of Award Units that would have vested within one year after effectiveness of the of the IPO registration statement, in satisfaction of the obligations described above and subject to further required withholdings under the Federal Insurance Contributions Act. In addition, in exchange for termination of an agreement pursuant to which we were obligated to pay a percentage of our annual net profits to a non-executive employee, we will issue 2,047,064 shares of Class A common stock to such employee between the first and second anniversaries of the effectiveness of the IPO registration statement. As of the date of this report, the number of shares to be issued between the first and second anniversaries of effectiveness of the IPO registration statement in satisfaction of the obligations described above will increase the aggregate number of outstanding shares of our Class A common stock and Class B common stock outstanding by approximately 16.5%, resulting in significant dilution to holders of our capital stock. Any issuance of Class A common stock described above, or the fact of any such impending issuance, may adversely impact the market price of our Class A common stock.

The individual tax withholding obligations to be incurred in connection with the issuance of the shares described above will be satisfied, at our discretion, through methods that may include (i) a “sell to cover” arrangement whereby we would withhold from issuance a certain number of shares, which would then be sold into the market with proceeds from such sale remitted to us in an amount that would satisfy the withholding amount, and (ii) our withholding a certain number of the shares with a value that would satisfy the withholding amount due and using our available capital resources to pay the related tax burden.  If we elect to satisfy a significant component of these tax withholding obligations through a sell to cover arrangement, it could cause the sale, at one or more periods of time between October 20, 2022 and October 20, 2023,

33

of a significant number of shares relative to the current average daily trading volume of our Class A common stock. These sales, or the perception that the sales could occur, could cause the price of our stock to decline.

The issuance of shares of our Class A common stock in satisfaction of our obligations to former participants in the Change in Control Bonus Plan has and will result in significant stock-based compensation expense. At the time of the IPO, we recognized stock-based compensation expense of approximately $268.5 million (reflecting a discount for lack of marketability due to the post-vesting restriction because, although fully vested, the shares will not be issued until at least one year after the IPO) in connection with 9 future issuance of shares of Class A common stock to (i) former holders of Award Units under our former Change in Control Bonus Plan and (ii) a non-executive employee in exchange for the termination of a profit sharing agreement. We recognized approximately $16.7 million in 2021 and expect to recognize $10.1 million in 2022 in stock-based compensation expense in connection with the future issuance of shares of Class A common stock to former holders of Award Units under our former Change in Control Bonus Plan that would have vested within one year after the IPO (reflecting a discount for lack of marketability due to the post-vesting restriction because the shares will vest within the next year but will not be issued until at least one year after the IPO).  In addition, we recognized approximately $4.6 million in 2021 and expect to recognize approximately $51.0 million through 2025 in stock-based compensation related to restricted stock units granted in connection with the IPO. Further, we expect to recognize approximately $500 thousand in stock-based compensation expense related to stock options issued under the 2021 Incentive Plan.  These non-cash charges do not impact our revenues or Adjusted EBITDA; however, they will have a direct and substantial adverse impact on our net income. The impact of these equity-related matters on our net income may adversely affect the trading price of our Class A common stock.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Recent Sales of Unregistered Securities

None.

Use of Proceeds from IPO

On October 20, 2021, our Registration Statement on Form S-1 (File No. 333-259635) was declared effective by the SEC for our IPO.  There has been no material change in the use of proceeds from our IPO as described in our final prospectus filed with the SEC pursuant to Rule 424(b) of the Securities Act.

Issuer Purchases of Equity Securities

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

34

Item 6. Exhibits.

The exhibits listed below are filed or incorporated by reference in this Quarterly Report on Form 10-Q.

Exhibit Number

Description

3.1

Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-40949), filed with the Securities and Exchange Commission on December 3, 2021).

3.2

Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-40949), filed with the Securities and Exchange Commission on December 3, 2021).

10.1#*

Employment Agreement, signed on September 29, 2021, by and between Enfusion Ltd. LLC and Bronwen Bastone.

10.2#*

Offer of Employment / Appendix 1 – Scope of Employment, dated September 8, 2021, by and between Enfusion Ltd. LLC and Bronwen Bastone.

10.3#*

Amendment to Appendix 1 – Scope of Employment, dated July 1, 2022, by and between Enfusion Ltd. LLC and Bronwen Bastone.

10.4#*

Amendment to Appendix 1 – Scope of Employment, dated July 1, 2022, by and between Enfusion Ltd. LLC and Thomas Kim.

10.5#*

Amendment to Appendix 1 – Scope of Employment, dated July 1, 2022, by and between Enfusion Ltd. LLC and Stephen Dorton.

10.6#*

Amendment to Appendix 1 – Scope of Employment, dated July 1, 2022, by and between Enfusion Ltd. LLC and Steven Bachert.

10.7#*

Amendment to Appendix 1 – Scope of Employment, dated July 1, 2022, by and between Enfusion Ltd. LLC and Lorelei Skillman.

10.8#*

Amendment to Appendix 1 – Scope of Employment, dated July 1, 2022, by and between Enfusion Ltd. LLC and Daniel Groman.

31.1*

Certification of the Principal Executive Officer, pursuant to Rules 13a-14(a) and 15d-14(a) under the Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2*

Certification of the Principal Financial Officer, pursuant to Rules 13a-14(a) and 15d-14(a) under the Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1**

Certification of the Principal Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2**

Certification of the Principal Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS*

Inline XBRL Instance Document.

101.SCH*

Inline XBRL Taxonomy Extension Schema Document.

101.CAL*

Inline XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF*

Inline XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB*

Inline XBRL Taxonomy Extension Labels Linkbase Document.

101.PRE*

Inline XBRL Taxonomy Extension Presentation Linkbase Document.

104*

Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).

#

Indicates management contract or compensatory plan, contract or agreement.

*

Filed herewith.

**

Furnished herewith. The certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are deemed furnished and not filed with the SEC and are not to be incorporated by reference into any filing of the Company under the Securities Act or the Exchange Act, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.

35

Portions of this exhibit (indicated by asterisks) have been omitted in accordance with the rules of the Securities and Exchange Commission.

36

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ENFUSION, INC.

August 10, 2022

By:

/s/ Thomas Kim

Thomas Kim

Chief Executive Officer

(Principal Executive Officer)

August 10, 2022

By:

/s/ Stephen P. Dorton

Stephen P. Dorton

Chief Financial Officer

(Principal Financial and Accounting Officer)

37

EX-31.1 2 enfn-20220630xex31d1.htm EX-31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

I, Thomas Kim, certify that:

1.

I have reviewed this quarterly report on Form 10-Q of Enfusion, Inc.;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.

[Omitted];

c.

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;

d.

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 10, 2022

/s/ Thomas Kim

Thomas Kim

Chief Executive Officer

(Principal Executive Officer)


EX-31.2 3 enfn-20220630xex31d2.htm EX-31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

I, Stephen P. Dorton, certify that:

1.

I have reviewed this quarterly report on Form 10-Q of Enfusion, Inc.;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.

[Omitted];

c.

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;

d.

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 10, 2022

/s/ Stephen P. Dorton

Stephen P. Dorton

Chief Financial Officer

(Principal Financial Officer)


EX-32.1 4 enfn-20220630xex32d1.htm EX-32.1

Exhibit 32.1

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Thomas Kim, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of Enfusion, Inc. for the period ended June 30, 2022, as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Enfusion, Inc.

Date: August 10, 2022

By:

/s/ Thomas Kim

Name:

Thomas Kim

Title:

Chief Executive Officer

(Principal Executive Officer)


EX-32.2 5 enfn-20220630xex32d2.htm EX-32.2

Exhibit 32.2

CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Stephen P. Dorton, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of Enfusion, Inc. for the period ended June 30, 2022, as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Enfusion, Inc.

Date: August 10, 2022

By:

/s/ Stephen P. Dorton

Name:

Stephen P. Dorton

Title:

Chief Financial Officer

(Principal Financial Officer)


EX-10.1 6 enfn-20220630xex10d1.htm EX-10.1

Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark [***].

Exhibit 10.1

EMPLOYMENT AGREEMENT

This employment agreement, which shall include and incorporate by reference any appendix attached hereto, now or in the future (collectively Agreement), is entered into on September 1. 2021,(Effective Date), by and between ENFUSION LTD. LLC (Enfusion), with its principal place of business located at 125 SOUTH CLARK STREET, SUITE 750, CHICAGO, ILLINOIS 60603, and Bronwen Bastone, (Employee), an individual with their primary address located at: [***] (each a Party or collectively, the Parties).

WHEREAS, Enfusion is in the business of creating and providing software and related products and services to clients in the investment and financial services industry throughout the United States and Global market with offices in Chicago, IL, New York and affiliate offices in London, Dublin, Hong Kong, Singapore, São Paulo, Mumbai, and Bengaluru;

WHEREAS, Enfusion desires to hire Employee to perform certain services as described in this Agreement and any appendix attached hereto, and Employee desires to be hired by Enfusion to perform certain services described in this Agreement and any appendix attached hereto, each in accordance with the terms and conditions of this Agreement as may be amended or supplemented from time-to-time; and,

NOW THEREFORE, in exchange for good and valuable consideration, the sufficiency and receipt of which is hereby acknowledged, the Parties covenant and agree as follows:

1.

Interpretation. Unless the context of this Agreement otherwise requires: (i) a capitalized word has the meaning assigned to it by this Agreement; (ii) or will be construed such that the series may include any of the items, all of the items, or any combination of the items; (iii) words in the singular include the plural, and words in the plural include the singular; (iv) provisions apply to successive events and transactions; (v) hereof, hereunder, herein, and hereto refer to the entire Agreement and not any section or subsection; (vi) references in this Agreement to sections or annexes are references to the sections of or annexes attached to this Agreement; (vii) in writing refers to in written or printed form, facsimile transmission, or e-mail; (viii) the term include does not create an exclusive list and should be interpreted, in any variation, as includes, but is not limited to; (ix) the phrase any reason should be read as any reason or no reason; and, (x) the headings in this Agreement are for reference only and shall not limit or otherwise affect the meaning, interpretation, or construction of this Agreement.

2.

Employment. Enfusion hereby agrees to employ Employee and Employee hereby agrees to accept Enfusions employment offer, each subject to and in accordance with the terms and conditions of this Agreement.

Graphic


3.

Classification of Employment. Employees classification as Exempt or Non-Exempt under Fair Labor Standards Act (FLSA) shall be determined by Enfusion and any changes to the Employees classification shall be communicated by Enfusion to the Employee.

4.

Duties. Employees initial appointment and non-exhaustive description of duties are described on Appendix 1 (Scope of Employment) and are subject to the terms and conditions of this Agreement. Despite the duties described on Appendix 1, Employee understands and acknowledges that Enfusion, at its sole discretion, has the right to modify or redefine Employees duties or title at any time, for any reason.

5.

Work Hours. Enfusions ordinary office hours are 8:00AM to 5:00PM, Monday through Friday. Unless otherwise specified on Appendix 1, Employees regular workweek shall be forty (40) hours on a schedule of eight (8) working hours per day, Monday through Friday; however, Employee understands and agrees that from time-to-time and subject to applicable law, Employee may be required to work additional hours, including weekends and holidays, as necessary to support Enfusions business. Employee understands and agrees, Employees work hours and surrounding terms may be modified at Enfusions sole discretion to the furthest extent permitted by applicable law.

6.

Location. Employees assigned work location (the Office) will be described on Appendix 1. Subject to the terms and conditions of this Agreement and applicable law, Employee is required to be present at the Office during Work Hours (defined on Appendix 1).

7.

Performance of Duties; Exclusive Service. Employee has a duty of loyalty and care to Enfusion and agrees to perform their obligations faithfully and to the best of their ability. Similarly, Employee hereby agrees to abide by Enfusions policies and procedures (as amended from time-to-time) and agrees to devote their business time, attention, and efforts to Enfusions business (except for permitted break periods, vacation periods, and reasonable periods of illness or other incapacity). Despite the foregoing sentence, Employee may serve as a director of or otherwise participate in educational, welfare, social, religious, and civic organization, provided that Employee service or participation does not: (i) unreasonably interfere with performing their duties; and, (ii) violate any provision of this Agreement. For clarity, while employed by Enfusion, Employee is not allowed to perform duties or services for any other employer, business, or organization (including establishing or maintain their own business or organization) other than as permitted by this Agreement or with the written consent of an Enfusion authorized officer.

a)Business Ideas/Opportunities. During their employment, Employee may come up with or across potential business opportunities related to Enfusions business and services (Business Opportunity). If so, Employee agrees to promptly disclose any Business Opportunity to Enfusion so that Enfusion has an opportunity to pursue the Business Opportunity. Employee acknowledges and agrees that pursuing a Business Opportunity for Employees or anothers benefit, without first disclosing it and getting Enfusions prior written approval would be a violation of their duty of loyalty and care to Enfusion and that Employee is prohibited from pursuing a Business Opportunity, whether for Employees or anothers benefit, without Enfusions prior written approval. Enfusions reserves the right to deny Employees request to pursue a Business Opportunity in Enfusions sole discretion.

Graphic


8.

Compensation and Benefits. Employee is entitled to certain compensation and benefits, which are outlined below and described further on Appendix 1.

a)Salary. Enfusion agrees to pay Employee for services rendered under this Agreement. Employees Salary (as defined on Appendix 1) will be paid in accordance with Enfusions normal payroll policies and procedures. To be clear, although Employee is paid an annual salary, Employees employment is at-will (discussed below). Enfusion, at its sole discretion, may adjust Employees Salary after the first twelve (12) months of employment and reserves the right to adjust Employees Salary from time-to-time.

b)Benefits. During Employees employment, except as otherwise expressly provided herein, Employee will be entitled to participate in all employee health, welfare and other benefit plans and programs (Employee Benefit Plans) applicable to similarly situated employees of Enfusion, as in effect from time to time, to the extent consistent with applicable law and the terms of the applicable employee benefit plan. Enfusion reserves the right to amend or cancel any Employee Benefit Plans at any time in its sole and absolute discretion, subject to the terms of the employee benefit plan and applicable law.

c)Vacation. Employee may become entitled to paid vacation days as outlined on Appendix 1, which will be pro-rated based on Employees Commencement Date (as defined on Appendix 1). Unaccrued vacation time may not be used without prior written approval from Enfusion in accordance with its policies. Further, subject to and to the extent permitted by Enfusions ordinary paid vacation policies, Employee may be entitled rollover unused accrued paid vacation days into the following year. Employee should use their best efforts not to schedule vacation time that will conflict with their duties and when possible, agrees to provide Enfusion with at least two (2) weeks prior notice of any planned vacation. Enfusion reserves the right, in its sole discretion, to approve or deny any requested vacation time.

d)

Bonus.

i.

Discretionary Bonus. Enfusion may, from time-to-time, in its sole discretion, choose to pay Employee additional compensation as a discretionary bonus. Whether and when a bonus is awarded, and the amount (if any) of bonus awarded, will be determined in Enfusions sole discretion on whatever basis and after taking into account whatever factors it considers appropriate at the time. Any bonus is not earned until paid. Therefore, to receive any bonus, Employee must be employed by Enfusion and in good standing on the bonuss payment date and must not have indicated their intent to resign prior to or on such payment date.

ii.

Other Bonus. If the Employee is eligible to receive a non-discretionary or other type of commission-based compensation, then it will be described on Appendix 1.

e)Payments. All payments made to Employee in the course of their employment will be paid in accordance with Enfusions normal payroll policies and procedures. Further, all compensation payments made in the course of Employees employment will be subject to any applicable withholding requirements or other similar obligations.

Graphic


f)Expenses. Enfusion will reimburse Employee for out-of-pocket expenses incurred by Employee in the course of their employment pursuant to Enfusions reimbursement policy and in each case, subject to applicable law.

g)Consideration. In consideration for Employee agreeing to Sections 11 and 14 of this Agreement, the Company will provide the employee consideration, including, but not limited to, an at-will employment relationship, or continued at-will employment; training; and access to, or continued access to the Companys Confidential Information and client, customer and business relationships during Employees employment. Employee agrees the consideration outlined in this paragraph is sufficient consideration for Employees various obligations under Sections 11 and 14 of this Agreement. Employee understands that acceptance of this Agreement is a condition of employment and that the Company would not offer to employ Employee and grant Employee access to its Confidential Information and client and customer relationships, but for Employees acceptance of the terms of this Agreement and acknowledgment that the consideration outlined herein is sufficient consideration for Employees obligations under Sections 11 and 14 of this Agreement.

9.

Employment Relationship and Termination. Termination Date means the date on which Employee ceases work for Enfusion, whether voluntary or involuntary.

a)AT-WILL EMPLOYMENT. EMPLOYEE ACKNOWLEDGES AND AGREES THAT THEIR EMPLOYMENT IS AT-WILL. THIS MEANS, BOTH ENFUSION AND EMPLOYEE MAY TERMINATE EMPLOYEES EMPLOYMENT AT ANY TIME, FOR ANY REASON OR NO REASON, WITHOUT LIABILITY FOR BREACH OF CONTRACT, PROMISSORY ESTOPPEL, SEVERANCE PAY, OR OTHERWISE.

b)Voluntary Termination. Although Employee has the right to terminate their employment at any time for any reason, Employee agrees to provide Enfusion with at least fourteen (14) days prior notice to the date on which Employee intends to cease working for Enfusion.

c)Final Payment. Unless otherwise required by applicable state law, upon Employees Termination Date, Enfusion shall provide Employee with a date, no later than Enfusions next regular pay date, on which Employee will receive their final payment for all accrued Salary and vested paid vacation time through the Termination Date.

10.

Representations. Employee understands and acknowledges that the following representations and covenants are essential to Enfusions decision to enter into this Agreement. Employee represents and warrants to Enfusion as follows:

a)As of the Effective Date, Employee is not under any contractual or legal duty or obligation, engagement, understanding, restriction, or commitment with any prior employer, other entity or individual other than Enfusion or its Affiliates ("Other Employer) that would limit, prohibit, or interfere with Employees full and faithful performance of this Agreement, including but not limited to, employment, consulting, confidentiality, non-competition, or non-solicitation agreements or restrictive covenants;

Graphic


b)Employee does not have any inventions or intellectual property obligations which may affect assignment under Section 13, other than what Employee has disclosed in Appendix 2;

c)If applicable, Employee has disclosed any Other Employers existing as of the Effective Date;

d)If applicable, Employee has complied with all duties imposed on Employee by their former employer with respect to termination of their employment;

e)

Employee is free to enter this Agreement and commence employment with Enfusion;

f)Employee understands and acknowledges the offer of employment made pursuant to this Agreement is made only to Employee for their personal services, and at no time has Employee been authorized to recruit, induce, entice, or offer employment at Enfusion to any other person;

g)Employee covenants not to use, disclose, or induce the use of, any trade secret, confidential information, or proprietary information that belongs to any third party in the performance of Employees employment under this Agreement, unless Employee has prior written consent from the owner of the protected information (which, Employee agrees to provide such written consent to Enfusion); and,

h)Employee is not aware of: (i) any pending internal, criminal, civil, regulatory, or self- regulatory organization investigations involving Employee or any of Employees activities at any former employer or in relation to or arising out of Employees prior employment ; (ii) any pending customer complaints or customer arbitrations involving any of Employees activities at any former employer or in relation to or arising out of Employees prior employment; or, (iii) any circumstances that might lead to any of the matters described in this subsection. If Employee is aware of any such issues, Employee has disclosed such in writing to Enfusions Chief Human Resources Officer at least seven (7) days prior to the parties entering into this Agreement.

11.

Confidential Information and Confidentiality.

a)Employee acknowledges and agrees that through their employment, he or she will be provided, obtain, or be exposed to proprietary or non-public information relating to Enfusions business, which is confidential in nature. Such information includes, client lists or client related information, information related to or concerning Enfusions products and services; fees, costs, and pricing structures; market studies; business plans and investment analyses; designs and specifications; data and analyses; drawings, photographs, and reports; computer software, object code, source code, operating systems, applications, algorithms, and program listings; flow charts, manuals, and documentation, ideas, images, text, music, movies, concepts, video, and websites; databases; accounting and business methods; inventions, devices, new developments, methods, and processes, (whether patentable or non-patentable and whether or not reduced to practice); investor or ownership information, Client and Prospective Client information; copyrightable works; technology and trade secrets; historical financial statements, financial projections, and budgets; personnel training techniques and materials; and any other personal, business, financial, or technical information, data, patents, or ideas relating to the proprietary information observed by,

Graphic


or disclosed to, Employee, whether in oral, written documents, memoranda, reports, or correspondence in graphic or machine-readable form, or otherwise in the course of, or in connection with, Employees employment with Enfusion (individually and collectively Confidential Information).

b)Employee hereby agrees that he or she will not disclose nor use at any time; before, during, or after their employment with Enfusion; any Confidential Information of which Employee is or becomes aware of, whether or not such information is developed by Employee, except to the extent such disclosure or use is directly related to or required for Employees performance of their employment duties. Further, Employee agrees he or she will take all reasonable and appropriate steps to safeguard the Confidential Information and to protect it against disclosure, misuse, espionage, loss, or theft and will not disclose or use any Confidential Information except as reasonably necessary to perform Employee's duties for the Company, or as required by law. Employee further agrees not to otherwise transmit or download any Confidential Information to Employee's personal computer, cellular telephone, or other electronic device, or otherwise remove Confidential Information from the Company's premises or Company-owned computer, unless Employee secures the Company's specific authorization in advance and takes appropriate steps to protect such information. Employee understands and agrees that all Confidential Information, including documents, records, and electronic files, to which Employee has access as a result of Employee's employment by the Company are the exclusive property of the Company. Employee also acknowledges and agrees that all Confidential Information, and all copyrights, trademarks, patents and other rights in connection therewith, shall be the sole property of the Company and its assigns. For clarity, nothing herein in is intended to prevent Employee disclosing information that Employee has a legal right to disclose.

c)Exceptions. Confidential Information shall not include any information that: (i) was in the possession of, or demonstrably known by, (in each case without restriction on its use or disclosure) the Employee prior to their receipt of such information; (ii) any information independently known by Employee without access to or reliance upon any Confidential Information, including the general skills, knowledge and experience acquired by the Employee before and/or during employment with the Company; (iii) was lawfully disclosed to Employee following the end of their employment with Enfusion by a third party under no known obligation of confidentiality; (iv) is in the public domain at the time of disclosure, or thereafter becomes in the public domain, other than as a result of disclosure by Employee in violation of this Agreement.

d)In the event Employee is required under a subpoena, court order, statute, law, rule, regulation, or other similar requirement, (Legal Requirement) Employee shall do so only to the extent required by the Legal Requirement, must provide prompt written notice to Enfusion of the disclosure to the extent not precluded by law, and must designate the information as Confidential Information when disclosing such information. Further, when legally permissible, the Employee shall notify Enfusion of what Confidential Information was disclosed under such Legal Requirement.

e)Defend Trade Secrets Act of 2016 (DTSA) Notice. Notwithstanding any other provision of this Agreement, pursuant to Section 7 of the DTSA, the Employee cannot be held criminally or civilly liable under any federal or state trade secret law for any disclosure of a trade secret that: (1) is made: (A) in confidence to a federal, state, or local government official, either directly or indirectly,

Graphic


or to an attorney; and (B) solely for the purpose of reporting or investigating a suspected violation of law; or (2) is made in a complaint or other document that is filed under seal in a lawsuit or other proceeding. (ii) If Employee files a lawsuit for retaliation by Company for reporting a suspected violation of law, Employee may disclose Companys trade secrets to Employees attorney and use the trade secret information in the court proceeding if Employee: (1) files any document containing the trade secret under seal; and (2) does not disclose the trade secret, except pursuant to court order.

f)Violation of Law. If Employee believes Enfusion has committed or is committing a violation of law, although not required, he or she is asked to first report the possible violation to Enfusions upper-management so that Enfusion may take the proper corrective actions. Despite the foregoing, Employee is free to report possible violations, file a charge with, or participate or cooperate with any governmental agency or entity, including but not limited to the EEOC, the Department of Justice, the Securities and Exchange Commission, Congress, or any agency Inspector General, or making any other disclosures that are protected under the whistleblower, anti-discrimination or anti-retaliation provisions of federal, state or local law or regulation; provided further, the Employee does not need the prior authorization of the Company to make any such reports or disclosures, and the Employee is not required to notify the Company that the Employee has made such reports or disclosures.

g)Trading. Employee understands and agrees he or she is not permitted to use Enfusions or Clients Confidential Information on their behalf, on the behalf of others, or to assist others in trading securities. Employee further acknowledges that to use Enfusions or Clients Confidential Information for personal financial benefit or to tip others who might make an investment decision on the basis of this information is not only prohibited and unethical, but is also illegal.

12.

Company Property. Upon Enfusions request or Employees Termination Date, Employee shall, to the extent such materials are in Employees possession or under Employees control, promptly deliver to Enfusion: (i) all original and any copies of emails, employee training materials, records, agreements, manuals, books, blank forms, documents, letters, memoranda, notes, notebooks, reports, data, tables, or calculations, which are the property of Enfusion or its Affiliates and that relate, in any way, to the business, products, policies, practices, or techniques thereof, including any strategies; (ii) all other Enfusion property, including any Enfusion issued credit cards, identification, keys, computers, cell phone, or other equipment; (iii) all Confidential Information of Enfusion or its Affiliates, including all documents that, in whole or in part, contain any Confidential Information of Enfusion or its Affiliates or their respective clients or licensors; and

(iv) all proprietary information, intellectual property and trade secrets of Enfusion or its Affiliates or their respective clients or licensors. In addition, if applicable, Employee shall promptly cancel or transfer to himself or herself any telecommunications services for which Enfusion was directly paying. Nothing in this Section shall prohibit Employee from retaining papers or materials that are solely of a personal nature, including copies of documents showing their compensation or reimbursable expenses and a copy of this Employment Agreement.

13.

Intellectual Property. (Intellectual Property) means any and all intellectual property in any form or stage of development, including any innovation, discovery, idea, concept, design, prototype, product configuration, invention, improvement, modification, patentable subject matter,

Graphic


method, process, technique, procedure, system, plan, model, program, software or code, source code, algorithms, data, specification, drawing, images, text, music, movies, video, websites, diagram, flow chart, documentation, know-how, work of authorship, copyrightable subject matter, derivative work, trademark or trade name, and any other subject matter, material, or information that qualifies or is considered by Employer to qualify for patent, copyright, trademark, trade dress, trade secret, or any other protection under any law providing or creating intellectual property rights, including the Uniform Trade Secrets Act. Intellectual Property also includes Confidential Information learned, obtained, or developed in connection with Employees employment, such as specifications, financial data, personnel information, market information, business arrangements, and other non-public information of Employer described in Section [11] of this Agreement. EMPLOYEE AGREES THAT ANY INTELLECTUAL PROPERTY CONCEIVED OR MADE BY EMPLOYEE, WHETHER ALONE OR WITH OTHER, DURING THE TERM OF EMPLOYEES EMPLOYMENT WITH ENFUSION RELATING IN ANY MANNER TO THE BUSINESS, BUSINESS PLANS, OR STRATEGIES OF ENFUSION OR ITS AFFILIATES, SHALL BE THE EXCLUSIVE PROPERTY OF ENFUSION OR SUCH AFFILIATE. WITHOUT LIMITING THE FOREGOING, TO THE EXTENT ANY COPYRIGHTABLE WORK IS INCLUDED IN THE FOREGOING, IT WILL BE DEEMED A WORK MADE FOR HIRE FOR THE BENEFIT OF ENFUSION OR SUCH AFFILIATE UNDER SECTION 201(b) OF THE 1976 U.S. COPYRIGHT ACT, AS AMENDED, OR OTHER SIMILAR APPLICABLE STATE OR FOREIGN OR INTERNATIONAL LAWS. FURTHER, EMPLOYEE AGREES THAT ALL INVENTIONS, HE OR SHE DEVELOPS OR DEVISES (WHETHER INDIVIDUALLY OR IN CONCERT WITH OTHERS): (i) USING ENFUSIONS EQUIPMENT, SUPPLIES, RESOURCES, OR CONFIDENTIAL INFORMATION; (ii) RESULTING FROM WORK HE OR SHE PERFORMS OR PERFORMED FOR ENFUSION; OR, (iii) RELATING TO ENFUSIONS CURRENT OR PLANNED RESEARCH OR DEVELOPMENT WILL BE ENFUSIONS SOLE AND EXCLUSIVE PROPERTY. ACCORDINGLY, EMPLOYEE HEREBY ASSIGNS ALL INTELLECTUAL PROPERTY RIGHTS, TITLE, AND INTERESTES TO ENFUSION AND WAIVES ANY MOREAL RIGHTS IN THE INTELLECTUAL PROPERTY TO THE FURTHEST EXTENT PERMITED BY LAW.

14.

Restrictive Covenants. Employee understands and recognizes that Enfusion is engaged in a highly competitive business and has spent a considerable amount of time, effort, and resources building its business, products, client base (domestically and internationally), and training its employees. Further, Employee through their employment will receive training regarding and have access to Enfusions (and its clients and licensors) Confidential Information (as defined above), trade secrets, and sensitive proprietary business methods or data, customer lists, and other valuable business information. Employee acknowledges and agrees that Enfusion has a legitimate business interest in protecting its goodwill, client and employee base, Confidential Information, trade secrets, and other proprietary information. Accordingly, Employee agrees to be bound by the following restrictive covenants (Restrictive Covenants), which are reasonably tailored to protect Enfusions legitimate interests from improper and unfair competition, and will not unreasonably impair or infringe on Employees right to work or earn a living after Employees Termination Date:

a)

Definitions: For purposes of this section, the following terms are defined as follows:

i.

(Client) means a person or organization who has retained, in writing or otherwise, Enfusion or any of its Affiliates to perform a service for compensation, which is, is

Graphic


related to, or is an extension of Enfusions or its Affiliates normal line of business and which Employee was involved; and,

ii.(Prospective Client) means a person or entity that has not yet retained, in writing or otherwise, Enfusion or any of its Affiliates to perform a service for compensation as described above when defining Clients, but instead, is a person or entity that Enfusion or any of its Affiliates reasonably expect to do so by virtue of Prospective Clients solicitation of Enfusion or its Affiliates or Enfusions or its Affiliates targeted, direct solicitation of that person or entity within a six (6) month period immediately prior to Employees Termination Date.

b)Non-solicitation of Enfusions Employees. Throughout Employees employment with Enfusion and for a period of one (1) year, to commence on Employees Termination Date, Employee agrees not to: directly or indirectly, through any person or entity, or as an agent for any person or entity, or authorize, encourage, suggest, or approve any person or entity to employ or cause to be employed, entice, induce, or solicit employment or engagement, in any capacity, any person that Employee had contact with and who is employed by Enfusion or any of its Affiliates or was employed or engaged by Enfusion or its Affiliates within three (3) months of the solicitation. While there is no geographic restraint, Employee understands and acknowledges that the restriction prohibiting solicitation of Enfusion employees is necessary and reasonable based upon Enfusions global presence and to protect Enfusions legitimate interest in its employee base and the resources utilized in training and maintaining such employee base.

c)Non-solicitation of Enfusions Clients. Throughout Employees employment with Enfusion and for a period of one (1) year, to commence on Employees Termination Date, Employee agrees not to: directly or indirectly, through any person or entity, or as an agent for any person or entity, or authorize, encourage, suggest, or approve any person or entity to directly or indirectly, through any person or entity, or as an agent for any person or entity, or authorize, encourage, suggest, or knowingly approve any person or entity to, induce, attempt to induce, or entice any Client (as defined above) or Prospective Client (as defined above), in whole or in part, from doing business with Enfusion or any such Affiliate, regardless of which party initiates the contact or communication; or directly or indirectly, or through any person or entity, or authorize, encourage, suggest, or knowingly approve any person or entity to, solicit, communicate with, contact, sell or render assistance, services or products to any Client or Prospective Client that would interfere with, take away, divert, or urge any Client or Prospective Client to discontinue, in whole or in part, business with Enfusion or any of its Affiliates. While there is no geographic restraint, Employee understands and acknowledges that the restriction prohibiting solicitation of any Enfusion Client or Prospective Client is limited to those Clients or Prospective Clients with whom Employee worked, to whom Employee marketed or sold services or products, or about whom Employee received Confidential Information, as such would give Employee an unfair competitive advantage. Employee agrees this restriction is necessary and reasonable, without regard to geographic constraint, based upon the Employees knowledge and/or interaction with the Client or Prospective Client and to protect Enfusions legitimate interest in protecting its business relationships.

d)Non-compete. Employee understands and recognizes that: (i) Enfusion has spent a considerable amount of time and resources into training Employee; and, (ii) Employee will gain

Graphic


access to or knowledge of confidential and proprietary information and of practices, successes, and failures during the course of their employment; and, (iii) Employee will build relationships with Enfusion clients or prospective clients through their employment with Enfusion, made possible through Enfusions brand and resources, each of which Enfusion has a legitimate interest in protecting and Enfusions competitors or prospective competitors will gain an unfair advantage by obtaining the benefit of such foregoing investments made into and interests obtained by Employee. Therefore, throughout Employees employment with Enfusion and throughout the Restricted Period (as defined below), Employee agrees not to, directly or indirectly, alone or in association with or on behalf of any other person or entity, engage in any Competitive Activity (as defined below) (Restricted Employment).

i.

Restricted Period. (Restricted Period) means a period of twelve (12) months to commence on Employees Termination Date.

ii.Competitive Activity. (Competitive Activity) means:

1.

Engaging in a Competitive Business (as defined below) directly or indirectly, on Employees own behalf or on the behalf of another;

2.

Providing services, similar or related to any services Employee provided to Enfusion while employed by Enfusion, to any person engaged in a Competitive Business, whether as an employee, consultant, officer, director, manager, partner, principal, agent, representative, or in any other capacity; or,

3.

Controlling (by contract, equity ownership, or otherwise), investing in (except as the owner of up to 3% of the securities of a publicly-traded entity), or providing other financial support to any person engaged in a Competitive Business.

iii.Competitive Business. (Competitive Business) means:

1.

Asset Management Software, including (a) portfolio management system;

(b) order management system; (c) execution management system; (d) fund accounting system; or (e) fund risk management system, or any combination of the foregoing or any software substantially similar to any new software offering Enfusion offers or proposes to offer during Employees employment at Enfusion and in which Employee was involved in or received Confidential Information or trade secrets regarding; or

2.

Any middle- or back-office services or servicing tied to Enfusions software that Enfusion offers or proposes to offer during Employees employment at Enfusion and in which Employee was involved in or received Confidential Information or trade secrets regarding, or any other similar software that is an alternative to or competes with Enfusions managed services offering, whether in whole or in part; or

Graphic


3.

Any other business or extension of a line of business in which Enfusion was engaged at any time during Employees employment, or in which Enfusion plans to engage or is considering plans to engage at the time of the Termination Date (as evidenced in writing) and in which Employee was involved or about which Employee received Confidential Information or trade secrets.

e)Notice. During the Restricted Period, Employee shall notify any other employers or prospective employers of their obligations under this Agreement before Employee begins working for such employer and further, agrees to simultaneously deliver a copy of such notice to Enfusion in accordance with Section 19 (Notices). Further, Employee agrees that Enfusion may also notify such other employers or prospective employers of Employees obligations under this Agreement. Employee agrees to inform Enfusion of the name, address, and telephone number of Employees supervisor at each subsequent employer to whom Employee reports this Agreement during the Restricted Period.

f)Undue Hardship. If Employee believes in good faith that the provisions in this Section will prevent him or her from obtaining a new job due to its categorization as Restricted Employment, Employee may notify Enfusion in writing, providing reasonable details about the proposed responsibilities of the new job (without disclosing another persons Confidential Information). The Parties agree to discuss whether appropriate accommodations can be made to balance the protection of Enfusions business interests and Employees desire to engage in Restricted Employment, and any appropriate adjustments to the payments described above. Except to the extent required by applicable law, Enfusion is under no obligation to modify the restrictions in this Section but may do so in its sole and absolute discretion.

g)General. For the avoidance of doubt, the Restrictive Covenants contained in this Agreement are in addition to, and not in lieu of, any other restrictive covenants or similar covenants or agreements between the Employee and Enfusion. The above-described restrictions are narrowly tailored to protect Enfusions legitimate business interests. The restrictions shall only apply to competitive employment in a capacity that is related to or requires the same or similar skills or knowledge necessary to have performed Employees duties at Enfusion or any role similar or related to any role held by Employee while employed at Enfusion.

h)Client Competition. Enfusion will spend a considerable amount of time and resources making Employee an expert of Enfusions products and service offerings and has a legitimate interest in protecting such investment in Employee. To protect its legitimate interest and to prevent clients from circumventing and eliminating the need for Enfusions services, (whether explicitly or under the guise of reverse engineering) through hiring Employee, Employee agrees that for a period of six (6) months to commence on Employees Termination Date, Employee will not, directly or indirectly, accept employment or perform services or duties, paid or unpaid, from any of Enfusions Clients or Prospective Clients, provided that Employee had contact with during their employment and to the extent such employment would be in a capacity substantially similar the capacity in which the Employee worked for Enfusion. Employee further acknowledges the employment opportunities that Employee could get without violating this Agreement, including the immense number of hedge funds, asset managers, fund administrators, fund of funds, and other financial

Graphic


services or investment companies, and that as such he or she will be able to earn a livelihood without violating this Agreement.

i)Extension of Restricted Period. In the event of any violation of any Restrictive Covenant, the restricted period of the covenant that was violated shall be extended by a period of time equal to the period beginning when such violation commenced and ending when the activities constituting such violation have ceased, such that Enfusion gets the full benefit of the bargain with respect to the agreed upon period of restriction.

15.

Remedies. Employee acknowledges and agrees that due to the unique nature of Enfusions business, Employees breach of any obligation may result in irreparable and continuing harm to Enfusion, for which monetary damages may be inadequate to compensate or make Enfusion whole. Therefore, Employee agrees Enfusion is entitled to seek injunctive relief or specific performance to enforce the terms of this Agreement without the necessity of posting a bond. Employee further agrees Enfusion shall also have any other right or remedy available to it under law or in equity including the right to seek and recover monetary damages for lost profits and other compensable damages. Should any court of competent jurisdiction determine that Employee has breached any of the provisions as contained in this Agreement, Enfusion shall have a right to collect, in addition to any monetary damages awarded to it, all of its reasonable attorneys fees and costs incurred in connection with its efforts to enforce this Agreement, including pre-litigation efforts. Employee agrees that, if Enfusion seeks preliminary or emergency injunctive relief, and obtains same in whole or in part, the Company shall be entitled to an award of its attorney fees, expenses, and costs incurred in connection therewith upon the entry of the Order granting said preliminary or emergency injunctive relief, in addition to any such fees and costs that may be incurred and awarded with respect to any subsequent proceedings in said action.

16.

Voluntary Agreement. Employee represents that Employee has carefully read, considered and understands the scope and effect of the provisions of this Agreement and that Employee is fully aware of the legal and binding effect of this Agreement. This Agreement is executed voluntarily by Employee and without any duress or undue influence on the part or behalf of the Company. Employee further acknowledges and agrees that Employee has been provided sufficient time to review the Agreement and consult with an attorney or legal representative regarding the Employees rights and obligations under this Agreement. In doing so, Employee acknowledges and agrees, the restrictions set forth in this Agreement impose a fair and reasonable restriction on Employee, reasonably necessary to protect Enfusions and its officers directors, members, and employees interests, business, and goodwill.

17.

Severability. If any provision of this Agreement is found to be unenforceable or contrary to law; including if any provision concerning time, scope, or geographic restrictions are deemed by a court with competent jurisdiction to be overly broad; the provision in question should be reformed to the minimum extent necessary to correct any invalidity while preserving to the maximum extent, the rights and commercial expectations of the Parties. The remaining portions of this Agreement will remain in full force and effect. Further, every provision of this Agreement shall be construed as independent agreements between Enfusion and Employee. Therefore, any claim or cause of

Graphic


action Employee may have against Enfusion, whether predicated on this Agreement or otherwise, shall not constitute a defense to prohibit the enforcement of any other provision or covenant.

18.

Counterparts. This Agreement, and any amendment thereto, may be executed in one or more counterparts and by the Parties hereto in separate counterparts, each of which when executed shall be deemed to be an original, but all of which taken together, shall constitute one and the same Agreement. Facsimile, PDF, and any other digital or electronic signatures to this Agreement shall have the same effect as original or wet signatures. If executed in counterparts, this Agreement or any amendment, will not be effective or enforceable until signed by both Employee and an authorized representative of Enfusion.

19.

Notices. All notices, requests, claims, demands, and other communications under this Agreement, (collectively Notices), must be in writing and sent to the person and address designated in this Section. Any Notices must be hand-delivered, sent by an internationally recognized overnight courier service, sent via e-mail, or sent via registered or certified mail with postage pre-paid and return receipt requested. Notices will be considered given or made upon receipt.

Notices to Enfusion:

Notices to Employee:

Enfusion, LLC

125 S. Clark Street, Suite 750

Chicago, IL 60603

Attn: Human Resources Phone: 312.253.9800

E-mail: HR@enfusion.com

See Appendix 1 (Scope of Employment)

Employee agrees to provide an updated address to Enfusion at the time of termination and if that address changes during the any period of restriction following the Employees termination to provide Enfusion the updated address. In the event Enfusion is unable to locate Employee at their last known residence, Employee agrees Enfusion may seek injunctive relief or specific performance without personal service on Employee, so long as Enfusion uses reasonable efforts to first locate Employee.

20.

Entire Agreement. This Agreement constitute the entire agreement between the Parties with respect to its subject matter and (to the extent permissible by law) supersedes all prior agreements, proposals, communications, representations, writings, negotiations, or understandings with respect to that subject matter. All terms, conditions, and warranties not stated expressly in this Agreement, and which would in the absence of this provision be implied into this Agreement by statute, common law, equity, trade, custom or usage or otherwise, are excluded to the maximum extent permitted by law.

21.

Governing Law. The legal relations between the Parties hereto and any dispute arising under or in connection with this Agreement, or breach thereof, whether sounding in contract, tort, or

Graphic


otherwise, shall be governed by and construed in accordance with the laws of the United States of America and the State in which the employees assigned Office is located (provided in Appendix 1) , regardless of any laws that might otherwise govern under applicable choice-of-law principles. Any claim, legal proceeding, or litigation arising out of or in connection with this Agreement or the relationship between Enfusion and Employee will be brought solely in the jurisdiction in which the Office is located, regardless of any laws or rules that might otherwise govern under applicable forum non conveniens principles. Any claim brought in any other jurisdiction or forum is precluded. ACCORDING, BOTH PARTIES HEREBY CONSENT TO THE EXCLUSIVE JURISDICTION OF THE FEDERAL AND STATE COURTS LOCATED WITHIN THE JURISDICTION IN WHICH THE OFFICE IS LOCATED.

22.

No Waiver. No waiver, of any of the terms of this Agreement, will be valid unless in writing, explicitly stated as such, and signed by the party waiving its rights. Any forbearance or delay by either party to enforce any of its rights under this Agreement will not be construed as a waiver to enforce any such rights pertaining to the occurrence in question or any other occurrence. The waiver, by any Party, of any breach of covenant will not be construed as a waiver of any succeeding breach of the same or any other covenant.

23.

Assignment. Enfusion may assign this Agreement or its rights under this Agreement to - and Employee may be employed by - any affiliate or subsidiary of Enfusion, or entity that acquires all or substantially all of Enfusions assets or acquires a department or line of business of Enfusion that Employee works within, or that is otherwise a successor in interest to Enfusion. This Agreement may not be assigned by Employee, except that Employees rights to compensation and benefits hereunder, subject to the limitations of this Agreement, may be transferred by will, by operation of law or as required by the law or a court order.

24.

Compliance with Section 409A. This Employment Agreement is intended to comply with, (or be exempt from), Section 409A of the Internal Revenue Code of 1986, as amended, to the extent applicable, and shall be administered and interpreted accordingly. To further clarify, this Section is in no way intended to change that bonuses, if any, are earned upon payment.

25.

Binding Agreement. This Agreement shall be binding upon and shall inure to the benefit of both Enfusion and Employee and their respective successors, assigns, heirs, and legal representatives.

26.

Terms of Acceptance. This Agreement is conditioned upon and subject to: (i) confirmation that Employee is not a subject to any contractual or other legal restrictions that would prevent or impair their ability to perform the duties of the position offered under this Agreement; (ii) Enfusions satisfactory completion of a background investigation, credit check, and reference check (where appropriate); and, (iii) Enfusions receipt of Employees acceptance of the terms and conditions of this Employment Agreement on or before the close of business on September 10, 2021

[Signature Page to Follow]

Graphic


Signature Page to the Employment Agreement between Enfusion Ltd. LLC and Bronwen Bastone made effective on September 1, 2021

IN WITNESS WHEREOF, the undersigned have caused this Agreement to be executed as of the Effective Date written above.

Enfusion Ltd. LLC

Employee

Signature:                  /s/ Steve Dorton

Signature:

/s/ Bronwen Bastone

Name: Steve Dorton

Name:

Bronwen Bastone

Title: Chief Financial Officer

Date: September 1, 2021

Date:

September 29, 2021

Graphic


EX-10.2 7 enfn-20220630xex10d2.htm EX-10.2

Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”.

Exhibit 10.2

Graphic

Offer of Employment /

APPENDIX 1 (to Employment Agreement) - Scope of Employment

Offer Letter

Please note that: (1) upon your acceptance of these terms set forth herein, as acknowledged by your signature below, (2) upon your acceptance of the terms contained in the employment agreement (a copy of which is set forth below), as set forth therein and as acknowledged by both your and Enfusion’s signature of that document, and (3) provided all other conditions precedent to employment are satisfied, this Offer of Employment will become a Scope of Employment appendix to your employment agreement.

Benefits

As a full-time employee, you will be able to participate in Enfusion’s generally offered benefits program, which includes, being eligible to participate in Enfusion’s health benefit programs the first day of the first full month following your hire date. Similarly, you will be able to participate in Enfusion’s 401(k) plan following thirty (30) days of employment. Further details on your benefits will be provided to you on your first day.

“At-Will” Employ m ent

Please note, if you choose to accept this offer of employment, your employment will be on an “at-will” basis. Your “at-will” status will be further detailed in the employment agreement; however, for the purposes of this document, “at-will” employment means that both employee and Enfusion will be free to terminate your employment at any time, with or without cause, and with or without notice.

Immigration Reform and Control Act of 1986

In compliance with the Immigration Reform and Control Act of 1986, each new employee, as a condition of employment, must complete an Employment Verification Form I9 and present proof of identity and employment eligibility. If you accept this offer and we enter into an employment agreement (in accordance will all terms set forth herein), you will be required to bring the following necessary documentation on your first day of work:

1.

Social Security card for payroll and benefit purposes.

Graphic


Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”.

Exhibit 10.2

Graphic

2.

Proof that you are presently eligible to work in the United States for I-9 purposes. This includes (1) a driver’s license or state issued ID card with a photograph and either your Social Security card or an original birth certificate or (2) your U.S. passport.

Graphic


Graphic

Conditional Offer

In addition to and not limiting the conditions described in this letter, your offer of employment (as well as continued employment) is subject to final reference checking and satisfactory completion of Enfusion's pre-employment screening process. This Offer of Employment is not binding upon Enfusion until such time that: (i) all conditions precedent have been met to Enfusion’s satisfaction and (2) both employee and Enfusion have executed a valid and binding employment agreement. The starting date may be delayed if all results of the pre-employment screening process have not been received. Further, it is important to note that, despite being an “at-will” employee, your employment will be conditioned on you entering into an employment agreement. Your employment agreement will include customary protections such as confidentiality and intellectual property protections and restrictive covenants.

Scope of Employment

APPENDIX 1 to Employment Agreement

Reference is made to the “Employment Agreement” entered into by and between Enfusion Ltd. LLC (“Enfusion”) and Bronwen Bastone (“Employee”) on September 1, 2021 (as may be amended from time-to- time, the “Agreement”). The Parties hereby agree that this Appendix 1 shall be subject to and controlled by the terms and conditions of the Agreement, which shall be incorporated by reference into this Appendix 1. If there is any inconsistency between the terms of the Agreement and this Appendix 1, the terms of the Agreement shall prevail. Further, all capitalized terms used but not defined in this Appendix 1 shall be construed in accordance with the Agreement.

1.

Commencement Date of Employment. The Employee’s first day of work will be on October 4, 2021 (“Commencement Date”) unless otherwise agreed to by Enfusion and Employee in writing pursuant to the terms of the Employment Agreement.

2.

Appointment & Duties. Employee shall initially be a member of the Corporate Executive department, serve as Chief People Officer and report to Thomas Kim, Chief Executive Officer.

3.

Work Hours. During an ordinary work week, Employee shall be present at the Office during Enfusion’s ordinary office hours described under Section 5 of the Agreement (“Work Hours”).

4.

Office. Employee is initially assigned to Enfusion’s office located in New York, New York.

5.

Status. Employee will be classified as an Exempt employee, which means Employee will not be eligible for overtime pay for hours worked in excess of forty (40) hours in any given week.

6.

Pay Cycle. As an exempt employee, Employee will ordinarily receive payment for services rendered once per month, in accordance with Enfusion’s ordinary payroll policies and procedures.

Graphic


Graphic

7.

Salary. Employee agrees to accept, a base salary to be paid at an annualized rate of $450,000 US Dollars (“Salary”). The Salary is paid less applicable deductions and withholdings. Employee’s Salary will be paid in accordance with Enfusion’s normal payroll policies and procedures.

8.

Other.

Discretionary Bonus

In addition to Salary, Enfusion may reward exemplary performance through a bonus (less applicable deductions and withholdings). A bonus is not guaranteed; however, when determining if a bonus is warranted, Enfusion may consider a multitude of factors, including, but not limited to, the level of your performance and Enfusion’s performance, as determined by Enfusion at its sole discretion. By way of example only, if all conditions and goals are satisfied a target annual bonus would be $150,000. For 2021, your prorated bonus would be $37,500. In order to be eligible for a bonus, you must be in “active working status” at the time of the bonus payment. “Active working status” means that you have not resigned (or have given notice of your resignation) or been terminated (or been given notice of your termination).

Sign-On Bonus

Following the Commencement Date, Employee will receive a one-time sign-on bonus of $25,000 US Dollars (“Sign-On Bonus”), which shall be subject to deductions for taxes and other withholdings as required by law or the standard and lawful policies of the Company.

Enfusion’s payment of the Sign-On Bonus is conditioned on agreeing to the restrictive covenants in the Employment Agreement and Employee’s continuous employment with Enfusion for a period of one (1) year, beginning on the Commencement Date. If employment is terminated either by Employee or Enfusion, for any reason within the one (1) year period, Employee agrees to repay Enfusion seventy-five percent (75%) the Sign-On Bonus within thirty (30) days of Employee’s Termination Date or such other date as agreed upon by Enfusion in its sole discretion.

Equity Eligibility

In addition to the annual compensation described above and subject to Enfusion’s Board approval, you will be given an opportunity to participate in Enfusion’s shadow equity plan (the “Plan”). Your award will be broken into four components:

(i)

three tenths (0.3) of a unit with a Strike Value at one billion, five hundred million ($1,500,000,000 USD) US Dollars and a Knock-in Value at the same value of one billion, five hundred million ($1,500,000,000 USD) US Dollars that will, subject to the Plan, vest annually in four equal portions of zero tenths, seven hundredths and five thousandths of a point (0.075) unit each year on the anniversary of your Start Date to be fully vested on the fourth (4th) anniversary of your Start Date;

(ii)

one tenth (0.1) of a unit with a Strike Value at one billion, five hundred million ($1,500,000,000 USD) US Dollars and a Knock-in Value that will vest if Enfusion achieves the equity value in a

Graphic


Graphic

change-in-control event (Liquidity Event as defined under the Plan) is equal to or greater than three billion ($3,000,000,000 USD) US Dollars;

(iii)

one tenth (0.1) of a unit with a Strike Value at one billion, five hundred million ($1,500,000,000 USD) US Dollars and a Knock-in Value that will vest if Enfusion achieves the equity value in a change-in-control event (Liquidity Event as defined under the Plan) is equal to or greater than four billion ($4,000,000,000 USD) US Dollars;

(iv)

one tenth (0.1) of a unit with a Strike Value at one billion, five hundred million ($1,500,000,000 USD) US Dollars and a Knock-in Value that will vest if Enfusion achieves the equity value in a change-in-control event (Liquidity Event as defined under the Plan) is equal to or greater than five billion ($5,000,000,000 USD) US Dollars. Each component of your award will be subject to a cliff and acceleration.

Severance

Although Employee’s employment is “at-will”, in the event Employee's employment is terminated without cause during Employee's first year of employment, Enfusion will offer Employee the opportunity to enter into a separate severance agreement describing the parties' post-termination rights and obligations. The severance agreement will at minimum provide for severance pay (i.e. consideration for entering into the severance agreement) in accordance with the following scenario: if the employee is terminated without cause in the first year of employment, Employee will be entitled to nine (9) months' base salary as severance pay, which will be payable in regular installments in accordance with Enfusion’s regular payroll practices and subject to customary withholding. Subject to the foregoing, should Employee obtain subsequent or alternative employment within nine (9) months following the effective date of a severance agreement, Enfusion shall have the unilateral right to cease any remaining severance payments owed to Employee under the severance agreement.

9.

Vacation.

In accordance with Enfusion’s current vacation policy, which may be amended time to time, Employee is entitled to 20 paid vacation days per calendar year, which will be accrued at a rate of 1.67 days per month. Time off granted in the first calendar year of employment will be on a pro-rata basis.

10.

Notices to Employee.

Bronwen Bastone

[***]

Graphic


Graphic

Acknowledged and Accepted:

By Employee

Signature:

/s/ Bronwen Bastone

Name:

BRONWEN BASTONE

Date:

9 - 8 - 21

Graphic


EX-10.3 8 enfn-20220630xex10d3.htm EX-10.3

Exhibit 10.3

Amendment to Appendix 1 – Scope of Employment

This document serves as an amendment to the vacation paragraph within your most recent employment agreement appendix. The below paragraph replaces the paragraph related to vacation in its entirety. This amendment does not constitute a new employment agreement or alter any other terms of your employment with Enfusion.

In accordance with Enfusion’s Flexible Time Off policy effective July 1, 2022, which may be amended from time to time, Employee is entitled to flexible time off as needed each calendar year. Flexible Time Off will not accrue or vest and therefore will not be paid out at the time of separation of employment. Any unused and unexpired accrued vacation days that Employee earned under the previous policy will expire on December 31, 2022 if unused by the Employee. If the Employee’s Termination Date is on or before December 31, 2022, the Employee will receive a final payment for all vested paid vacation time through their Termination Date. If the Employee’s Termination Date is on or after January 1, 2023, in accordance with Enfusion’s vacation policy, Employee will not be paid out for any expired accrued vacation days. Any employee beginning employment after July 1, 2022 will not accrue vacation days.

/s/ Bronwen Bastone

Bronwen Bastone

Chief People Officer

July 01, 2022

/s/ Bronwen Bastone

Bronwen Bastone


EX-10.4 9 enfn-20220630xex10d4.htm EX-10.4

Exhibit 10.4

Amendment to Appendix 1 – Scope of Employment

This document serves as an amendment to the vacation paragraph within your most recent employment agreement appendix. The below paragraph replaces the paragraph related to vacation in its entirety. This amendment does not constitute a new employment agreement or alter any other terms of your employment with Enfusion.

In accordance with Enfusion’s Flexible Time Off policy effective July 1, 2022, which may be amended from time to time, Employee is entitled to flexible time off as needed each calendar year. Flexible Time Off will not accrue or vest and therefore will not be paid out at the time of separation of employment. Any unused and unexpired accrued vacation days that Employee earned under the previous policy will expire on December 31, 2022 if unused by the Employee. If the Employee’s Termination Date is on or before December 31, 2022, the Employee will receive a final payment for all vested paid vacation time through their Termination Date. If the Employee’s Termination Date is on or after January 1, 2023, in accordance with Enfusion’s vacation policy, Employee will not be paid out for any expired accrued vacation days. Any employee beginning employment after July 1, 2022 will not accrue vacation days.

/s/ Bronwen Bastone

Bronwen Bastone

Chief People Officer

July 01, 2022

/s/ Thomas Kim

Thomas Kim


EX-10.5 10 enfn-20220630xex10d5.htm EX-10.5

Exhibit 10.5

Amendment to Appendix 1 – Scope of Employment

This document serves as an amendment to the vacation paragraph within your most recent employment agreement appendix. The below paragraph replaces the paragraph related to vacation in its entirety. This amendment does not constitute a new employment agreement or alter any other terms of your employment with Enfusion.

In accordance with Enfusion’s Flexible Time Off policy effective July 1, 2022, which may be amended from time to time, Employee is entitled to flexible time off as needed each calendar year. Flexible Time Off will not accrue or vest and therefore will not be paid out at the time of separation of employment. Any unused and unexpired accrued vacation days that Employee earned under the previous policy will expire on December 31, 2022 if unused by the Employee. If the Employee’s Termination Date is on or before December 31, 2022, the Employee will receive a final payment for all vested paid vacation time through their Termination Date. If the Employee’s Termination Date is on or after January 1, 2023, in accordance with Enfusion’s vacation policy, Employee will not be paid out for any expired accrued vacation days. Any employee beginning employment after July 1, 2022 will not accrue vacation days.

/s/ Bronwen Bastone

Bronwen Bastone

Chief People Officer

July 01, 2022

/s/ Steve Dorton

Stephen (Steve) Dorton


EX-10.6 11 enfn-20220630xex10d6.htm EX-10.6

Exhibit 10.6

Amendment to Appendix 1 – Scope of Employment

This document serves as an amendment to the vacation paragraph within your most recent employment agreement appendix. The below paragraph replaces the paragraph related to vacation in its entirety. This amendment does not constitute a new employment agreement or alter any other terms of your employment with Enfusion.

In accordance with Enfusion’s Flexible Time Off policy effective July 1, 2022, which may be amended from time to time, Employee is entitled to flexible time off as needed each calendar year. Flexible Time Off will not accrue or vest and therefore will not be paid out at the time of separation of employment. Any unused and unexpired accrued vacation days that Employee earned under the previous policy will expire on December 31, 2022 if unused by the Employee. If the Employee’s Termination Date is on or before December 31, 2022, the Employee will receive a final payment for all vested paid vacation time through their Termination Date. If the Employee’s Termination Date is on or after January 1, 2023, in accordance with Enfusion’s vacation policy, Employee will not be paid out for any expired accrued vacation days. Any employee beginning employment after July 1, 2022 will not accrue vacation days.

/s/ Bronwen Bastone

Bronwen Bastone

Chief People Officer

July 01, 2022

/s/ Steve Bachert

Steven (Steve) Bachert


EX-10.7 12 enfn-20220630xex10d7.htm EX-10.7

Exhibit 10.7

Amendment to Appendix 1 – Scope of Employment

This document serves as an amendment to the vacation paragraph within your most recent employment agreement appendix. The below paragraph replaces the paragraph related to vacation in its entirety. This amendment does not constitute a new employment agreement or alter any other terms of your employment with Enfusion.

In accordance with Enfusion’s Flexible Time Off policy effective July 1, 2022, which may be amended from time to time, Employee is entitled to flexible time off as needed each calendar year. Flexible Time Off will not accrue or vest and therefore will not be paid out at the time of separation of employment. Any unused and unexpired accrued vacation days that Employee earned under the previous policy will expire on December 31, 2022 if unused by the Employee. If the Employee’s Termination Date is on or before December 31, 2022, the Employee will receive a final payment for all vested paid vacation time through their Termination Date. If the Employee’s Termination Date is on or after January 1, 2023, in accordance with Enfusion’s vacation policy, Employee will not be paid out for any expired accrued vacation days. Any employee beginning employment after July 1, 2022 will not accrue vacation days.

/s/ Bronwen Bastone

Bronwen Bastone

Chief People Officer

July 01, 2022

/s/ Lorelei Skillman

Lorelei Skillman


EX-10.8 13 enfn-20220630xex10d8.htm EX-10.8

Exhibit 10.8

Amendment to Appendix 1 – Scope of Employment

This document serves as an amendment to the vacation paragraph within your most recent employment agreement appendix. The below paragraph replaces the paragraph related to vacation in its entirety. This amendment does not constitute a new employment agreement or alter any other terms of your employment with Enfusion.

In accordance with Enfusion’s Flexible Time Off policy effective July 1, 2022, which may be amended from time to time, Employee is entitled to flexible time off as needed each calendar year. Flexible Time Off will not accrue or vest and therefore will not be paid out at the time of separation of employment. Any unused and unexpired accrued vacation days that Employee earned under the previous policy will expire on December 31, 2022 if unused by the Employee. If the Employee’s Termination Date is on or before December 31, 2022, the Employee will receive a final payment for all vested paid vacation time through their Termination Date. If the Employee’s Termination Date is on or after January 1, 2023, in accordance with Enfusion’s vacation policy, Employee will not be paid out for any expired accrued vacation days. Any employee beginning employment after July 1, 2022 will not accrue vacation days.

/s/ Bronwen Bastone

Bronwen Bastone
Chief People Officer
July 01, 2022

/s/ Dan Groman

Daniel (Dan) Groman


GRAPHIC 14 enfn-20220630xex10d1001.jpg GRAPHIC begin 644 enfn-20220630xex10d1001.jpg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enfn-20220630xex10d2002.jpg GRAPHIC begin 644 enfn-20220630xex10d2002.jpg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end GRAPHIC 16 enfn-20220630xex10d2001.jpg GRAPHIC begin 644 enfn-20220630xex10d2001.jpg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enfn-20220630.xsd EX-101.SCH 00100 - Statement - Condensed Consolidated Interim Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Condensed Consolidated Interim Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Condensed Consolidated Interim Statements of Comprehensive (Loss) Income link:presentationLink link:calculationLink link:definitionLink 00500 - Statement - Condensed Consolidated Interim Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Property and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Accrued Expenses and Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Operating Leases and Service Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Net Income (Loss) Per Class A Common Share - Diluted net loss per common unit (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - Condensed Consolidated Interim Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Condensed Consolidated Interim Statements of Preferred Units, Stockholders' Equity and Members' Deficit link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Organization and Description of Business link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Property and Equipment, Net link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Accrued Expenses and Other Current Liabilities link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Preferred Units, Stockholders' Equity and Members' Deficit link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 20302 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Property and Equipment, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Organization and Description of Business - IPO and reorganization (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Summary of Significant Accounting Policies - Narrative Default (Details) link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - Summary of Significant Accounting Policies - Disaggregation of revenue (Details) link:presentationLink link:calculationLink link:definitionLink 40402 - Disclosure - Property and Equipment, Net - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Preferred Units Stockholders' Equity and Members' Deficit (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Stock-Based Compensation- Narratives (Details) link:presentationLink link:calculationLink link:definitionLink 40902 - Disclosure - Stock-Based Compensation- Equity-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 40903 - Disclosure - Stock-based compensation - Assumptions for Performance-based shares (Details) link:presentationLink link:calculationLink link:definitionLink 41002 - Disclosure - Net Income (Loss) Per Class A Common Share - Dilutive shares (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Income taxes - Narratives (Details) link:presentationLink link:calculationLink link:definitionLink 41201 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Operating Leases and Service Agreements link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Net Income (Loss) Per Class A Common Share link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Operating Leases and Service Agreements (Tables) link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 31003 - Disclosure - Net Income (Loss) Per Class A Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 18 enfn-20220630_cal.xml EX-101.CAL EX-101.DEF 19 enfn-20220630_def.xml EX-101.DEF EX-101.LAB 20 enfn-20220630_lab.xml EX-101.LAB EX-101.PRE 21 enfn-20220630_pre.xml EX-101.PRE XML 22 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Document and Entity Information - shares
6 Months Ended
Jun. 30, 2022
Aug. 09, 2022
Document Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jun. 30, 2022  
Document Transition Report false  
Entity File Number 001-40949  
Entity Registrant Name Enfusion, Inc  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 87-1268462  
Entity Address State Or Province IL  
Entity Address, Address Line One 125 South Clark Street  
Entity Address, Address Line Two Suite 750  
Entity Address, City or Town Chicago  
Entity Address, Postal Zip Code 60603  
City Area Code 312  
Local Phone Number 253-9800  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Shell Company false  
Title of 12(b) Security Class A common stock, par value $0.001per share  
Trading Symbol ENFN  
Security Exchange Name NYSE  
Entity Central Index Key 0001868912  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q2  
Amendment Flag false  
Common Stock    
Document Information [Line Items]    
Entity Common Stock, Shares Outstanding   113,070,805
Common Class A    
Document Information [Line Items]    
Entity Common Stock, Shares Outstanding   67,001,652
Common Class B    
Document Information [Line Items]    
Entity Common Stock, Shares Outstanding   46,069,153
XML 23 R2.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Interim Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Current Assets:    
Cash $ 56,559 $ 64,365
Accounts receivable, net 28,771 18,223
Prepaid expenses 3,634 6,030
Other current assets 1,287 1,060
Total current assets 90,251 89,678
Property and equipment, net 16,093 13,051
Other assets 3,783 3,356
Total assets 110,127 106,085
Current liabilities:    
Accounts payable 879 2,528
Accrued expenses and other current liabilities 8,963 5,578
Total current liabilities 9,842 8,106
Other liabilities 479 538
Total liabilities 10,321 8,644
Stockholders' Equity:    
Additional paid-in capital 240,501 226,717
Accumulated deficit (180,896) (171,209)
Accumulated other comprehensive loss (582) (325)
Total stockholders' equity attributable to Enfusion, Inc. 59,136 55,296
Non-controlling interests 40,670 42,145
Total stockholders' equity 99,806 97,441
Total liabilities and stockholders' equity 110,127 106,085
Common Class A    
Stockholders' Equity:    
Common stock 67 66
Common Class B    
Stockholders' Equity:    
Common stock $ 46 $ 47
XML 24 R3.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Interim Balance Sheets (Parenthetical) - $ / shares
Jun. 30, 2022
Dec. 31, 2021
Common Class A    
Common stock par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized 1,000,000,000 1,000,000,000
Common stock, shares issued 67,001,652 65,583,289
Common stock, shares outstanding 67,001,652 65,583,289
Common Class B    
Common stock par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized 150,000,000 150,000,000
Common stock, shares issued 46,069,153 47,470,971
Common stock, shares outstanding 46,069,153 47,470,971
XML 25 R4.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Interim Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
REVENUES:        
Total revenues $ 36,540 $ 26,449 $ 70,681 $ 50,802
COST OF REVENUES:        
Total cost of revenues 10,847 6,777 21,830 13,586
Gross profit 25,693 19,672 48,851 37,216
OPERATING EXPENSES:        
General and administrative 18,302 7,457 40,597 13,838
Sales and marketing 7,575 4,264 16,007 7,422
Technology and development 3,722 2,041 8,524 4,243
Total operating expenses 29,599 13,762 65,128 25,503
(Loss) income from operations (3,906) 5,910 (16,277) 11,713
NON-OPERATING INCOME (EXPENSE):        
Interest expense (1) (1,410) (7) (2,802)
Other income (expense) 1   4  
Total non-operating income (expense)   (1,410) (3) (2,802)
(Loss) income before income taxes (3,906) 4,500 (16,280) 8,911
Income taxes 219 249 369 551
Net (loss) income (4,125) 4,251 (16,649) 8,360
Net loss attributable to non-controlling interests (1,703)   (6,962)  
Net (loss) income attributable to Enfusion, Inc. $ (2,422) 4,251 $ (9,687) 8,360
Net loss per Class A common shares attributable to Enfusion, Inc.:        
Net loss per Class A common shares attributable to Enfusion, Inc., Basic $ (0.03)   $ (0.13)  
Net loss per Class A common shares attributable to Enfusion, Inc., Diluted $ (0.03)   $ (0.13)  
Weighted Average number of Class A common shares outstanding:        
Weighted Average number of Class A common shares outstanding, Basic 84,581   83,989  
Weighted Average number of Class A common shares outstanding, Diluted 84,581   83,989  
Platform subscriptions        
REVENUES:        
Total revenues $ 33,560 24,324 $ 65,111 46,747
COST OF REVENUES:        
Total cost of revenues 9,065 5,709 18,376 11,661
Managed services        
REVENUES:        
Total revenues 2,396 1,729 4,626 3,263
COST OF REVENUES:        
Total cost of revenues 1,668 1,015 3,283 1,843
Other        
REVENUES:        
Total revenues 584 396 944 792
COST OF REVENUES:        
Total cost of revenues $ 114 $ 53 $ 171 $ 82
XML 26 R5.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Interim Statements of Comprehensive (Loss) Income - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Condensed Consolidated Interim Statements of Comprehensive (Loss) Income        
Net (loss) income $ (4,125) $ 4,251 $ (16,649) $ 8,360
Other comprehensive loss, net of income tax:        
Foreign currency translation loss (353) (16) (439) (77)
Total other comprehensive (loss) income (4,478) 4,235 (17,088) 8,283
Comprehensive loss attributable to non-controlling interests (1,849)   (7,144)  
Total comprehensive (loss) income attributable to Enfusion, Inc. $ (2,629) $ 4,235 $ (9,944) $ 8,283
XML 27 R6.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Interim Statements of Preferred Units, Stockholders' Equity and Members' Deficit - USD ($)
Preferred Units
Members' Equity
Common Stock
Common Class A
Common Stock
Common Class B
Additional Paid-in Capital
Accumulated Deficit/Retained Earnings
Accumulated Other Comprehensive Loss
Noncontrolling Interest
Total
Balance at Beginning of period at Dec. 31, 2020   $ (233,347,000)         $ (212,000)   $ (233,559,000)
Balance at Beginning of period (in shares) at Dec. 31, 2020   47.968              
Members' Equity (Deficit)                  
Net Income (Loss)   $ 3,941,000             3,941,000
Distributions to members   (1,188,000)             (1,188,000)
Foreign currency translation loss             (77,000)   (77,000)
Balance at end of period at Jun. 30, 2021 $ 53.774 $ (230,594,000)         (289,000)   (230,883,000)
Balance at end of period (in shares) at Jun. 30, 2021   47.968              
Balance at Beginning of period at Dec. 31, 2020 $ 165,515,000                
Balance at Beginning of period (in shares) at Dec. 31, 2020 53.774                
Preferred Units                  
Net income $ 4,419,000                
Distributions to members (1,565,000)                
Balance at end of period at Jun. 30, 2021 $ 168,369,000                
Balance at end of period (in shares) at Jun. 30, 2021 53.774                
Balance at Beginning of period at Mar. 31, 2021   $ (231,410,000)         (273,000)   (231,683,000)
Balance at Beginning of period (in shares) at Mar. 31, 2021   47.968              
Members' Equity (Deficit)                  
Net Income (Loss)   $ 2,004,000             2,004,000
Distributions to members   (1,188,000)             (1,188,000)
Foreign currency translation loss             (16,000)   (16,000)
Balance at end of period at Jun. 30, 2021 $ 53.774 $ (230,594,000)         (289,000)   (230,883,000)
Balance at end of period (in shares) at Jun. 30, 2021   47.968              
Balance at Beginning of period at Mar. 31, 2021 $ 167,523,000                
Balance at Beginning of period (in shares) at Mar. 31, 2021 53.774                
Preferred Units                  
Net income $ 2,247,000                
Distributions to members (1,401,000)                
Balance at end of period at Jun. 30, 2021 $ 168,369,000                
Balance at end of period (in shares) at Jun. 30, 2021 53.774                
Balance at Beginning of period at Dec. 31, 2021     $ 66,000 $ 47,000 $ 226,717,000 $ (171,209,000) (325,000) $ 42,145,000 97,441,000
Balance at Beginning of period (in shares) at Dec. 31, 2021     65,583,289 47,470,971          
Members' Equity (Deficit)                  
Net Income (Loss)           (9,687,000)   (6,962,000) (16,649,000)
Share-based compensation, net of taxes paid         11,331,000     8,122,000 19,453,000
Share exchange     $ 1,000 $ (1,000) 2,453,000     (2,453,000)  
Share exchange (in shares)     1,401,818 (1,401,818)          
Issuance of restricted shares (in Shares)     16,545            
Foreign currency translation loss             (257,000) (182,000) (439,000)
Balance at end of period at Jun. 30, 2022     $ 67,000 $ 46,000 240,501,000 (180,896,000) (582,000) 40,670,000 99,806,000
Balance at end of period (in shares) at Jun. 30, 2022     67,001,652 46,069,153          
Balance at Beginning of period at Mar. 31, 2022     $ 66,000 $ 47,000 233,607,000 (178,474,000) (375,000) 41,837,000 96,708,000
Balance at Beginning of period (in shares) at Mar. 31, 2022     65,583,289 47,470,971          
Members' Equity (Deficit)                  
Net Income (Loss)           (2,422,000)   (1,703,000) (4,125,000)
Share-based compensation, net of taxes paid         4,441,000     3,135,000 7,576,000
Share exchange     $ 1,000 $ (1,000) 2,453,000     (2,453,000)  
Share exchange (in shares)     1,401,818 (1,401,818)          
Issuance of restricted shares (in Shares)     16,545            
Foreign currency translation loss             (207,000) (146,000) (353,000)
Balance at end of period at Jun. 30, 2022     $ 67,000 $ 46,000 $ 240,501,000 $ (180,896,000) $ (582,000) $ 40,670,000 $ 99,806,000
Balance at end of period (in shares) at Jun. 30, 2022     67,001,652 46,069,153          
XML 28 R7.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Interim Statements of Cash Flows - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Cash flows from operating activities:    
Net (loss) income $ (16,649) $ 8,360
Adjustments to reconcile net (loss) income to net cash provided by operating activities:    
Depreciation and amortization 2,955 1,672
Provision for bad debts 459 174
Amortization of debt-related costs 13 148
Stock-based compensation expense 20,350  
Change in operating assets and liabilities:    
Accounts receivable (11,007) (3,466)
Prepaid expenses and other current assets 1,316 (1,481)
Accounts payable (1,970) 763
Accrued expenses and other liabilities 3,326 1,633
Net cash (used) provided by operating activities (1,207) 7,803
Cash flows from investing activities:    
Purchases of property and equipment (5,263) (4,401)
Net cash used in investing activities (5,263) (4,401)
Cash flows from financing activities:    
Payment of Member distributions   (2,745)
Payment of withholding taxes on stock-based compensation (897)  
Net cash used in financing activities (897) (2,745)
Effect of exchange rate changes on cash (439) (80)
Net decrease in cash (7,806) 577
Cash, beginning of period 64,365 13,938
Cash, end of period 56,559 14,515
Supplemental disclosure of non-cash investing activities:    
Accrued Property, Plant and Equipment 321  
Supplemental disclosure of cash flow information:    
Interest paid in cash   $ 2,712
Income taxes paid in cash $ 333  
XML 29 R8.htm IDEA: XBRL DOCUMENT v3.22.2
Organization and Description of Business
6 Months Ended
Jun. 30, 2022
Organization and Description of Business  
Organization and Description of Business

Note 1   Organization and Description of Business

Enfusion, Inc. (“Enfusion” or the “Company”) is a leading provider of cloud-based order and execution management, portfolio management and risk systems. Enfusion’s clients include large global hedge fund managers, institutional asset managers, family offices and other institutional investors. Enfusion provides its clients with innovative real-time performance, risk calculations, and accounting capabilities for some of the most sophisticated financial products. The Company is headquartered in Chicago, Illinois and has offices in Chicago, New York, London, Dublin, Hong Kong, Singapore, São Paulo, Mumbai, Bengaluru, and Sydney.

Enfusion, Inc. was incorporated in Delaware on June 11, 2021 for the purpose of facilitating an initial public offering (“IPO”), which was completed on October 25, 2021, and other related transactions in order to carry on the business of Enfusion Ltd. LLC.

Enfusion, Inc. has three wholly-owned subsidiaries: Enfusion US 1, Inc., Enfusion US 2, Inc. and Enfusion US 3, Inc.; as well as a substantial financial interest in Enfusion Ltd. LLC and its majority-owned subsidiary, Enfusion Softech India Private Limited, as well as the wholly-owned subsidiaries of Enfusion Ltd. LLC: Enfusion Systems UK Ltd, Enfusion HK Limited, Enfusion Software Limited, Enfusion (Singapore) Pte. Ltd., Enfusion do Brasil Tecnologia da Informacao Ltda, Enfusion (Australia) Pty. Ltd. and Enfusion (Shanghai) Co., Ltd. Enfusion, Inc., through its control over the managing member of Enfusion Ltd. LLC, manages and operates Enfusion Ltd. LLC’s business and controls its strategic decisions and day-to-day operations. As such, Enfusion, Inc. consolidates the financial results of Enfusion Ltd. LLC, and a portion of Enfusion, Inc.’s net income will be allocated to non-controlling interests to reflect the entitlement to a portion of Enfusion Ltd. LLC’s net income by the unitholders that held Enfusion Ltd. LLC’s common units prior to the Company’s IPO and following the reorganization transactions (the “Pre-IPO Common Unitholders”). As of June 30, 2022, Enfusion, Inc. owned approximately 59% of Enfusion Ltd. LLC.

XML 30 R9.htm IDEA: XBRL DOCUMENT v3.22.2
Basis of Presentation
6 Months Ended
Jun. 30, 2022
Basis of Presentation  
Basis of Presentation

Note 2    Basis of Presentation

Principles of Consolidation

These statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and in accordance with rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Accordingly, the financial statements do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments necessary for a fair presentation of the Company’s financial position and results of operations, and all adjustments are of a normal recurring nature. The operating results for the three and six months ended June 30, 2022 are not necessarily indicative of the results expected for the full year ending December 31, 2022. The condensed consolidated interim financial information should be read in conjunction with the consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021. The unaudited condensed consolidated interim financial statements include the accounts of Enfusion, Inc. and its wholly or majority-owned subsidiaries.  All intercompany balances and transactions are eliminated in consolidation.

Use of Estimates

The preparation of condensed consolidated interim financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated interim financial statements and accompanying notes. Actual results could differ from those estimates. The effect of the change in the estimates will be recognized in the current period of the change.

In order to better align with industry standards, the Company revised the presentation of its condensed  consolidated interim statement of operations for the three and six months ended June 30, 2021 to reclassify certain

immaterial expenses to cost of sales for Platform subscriptions.  These expenses were previously classified in cost of sales for Managed services and Other revenues.  This change in presentation has no effect on our gross profit or other consolidated results.  In addition, the Company revised the presentation of certain credit charges that were previously recorded in Other revenues to reclassify these charges to Platform subscription and Managed services revenues, respectively.  This change in presentation has no effect on the Company’s total revenues or other consolidated results.  

XML 31 R10.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of Significant Accounting Policies
6 Months Ended
Jun. 30, 2022
Summary of Significant Accounting Policies  
Summary of Significant Accounting Policies

Note 3   Summary of Significant Accounting Policies

A description of the Company’s significant accounting policies is included in the audited financial statements within its Annual Report on Form 10-K for the year ended December 31, 2021. There have been no material changes in the Company’s significant accounting policies during the three and six months ended June 30, 2022.

Revenue Recognition

The Company recognizes revenue in accordance with Accounting Standards Codification 606 (“ASC 606”), Revenue from Contracts with Customers. The Company derives its revenues primarily from fees for platform subscription and managed services provided to clients. Revenues are recognized when control of these services are transferred to the Company’s clients in an amount that reflects the consideration the Company expects to be entitled to in exchange for these services. Revenues are recognized net of taxes that will be remitted to governmental agencies applicable to service contacts.

Historically, platform subscription contracts have typically had a one-year term and were cancellable with 30 days’ notice.  Beginning in the first quarter of 2021, our default platform subscription contract has had a multi-year term and did not allow termination for convenience, though each contract has and can be negotiated with varying term lengths, with or without a termination for convenience clause.  Clients are invoiced each month for the services provided in accordance with the stated terms of their service contracts. Fees for partial term service contracts are prorated, as applicable. Payment of fees are due from clients within 30 days of the invoice date. The Company does not provide financing to clients. The Company determines revenue recognition through the following five-step framework:

Identification of the contract, or contracts, with a client;
Identification of the performance obligation in the contract;
Determination of transaction price;
Allocation of the transaction price to the performance obligations in the contract; and
Recognition of revenue when, or as, performance obligations are satisfied.

Platform subscription revenues

Platform subscription revenues consist primarily of fees for providing clients with access to the Company’s cloud-based platform. Platform subscription clients do not have the right to take possession of the platform’s software, and do not have any general return rights. Platform subscription revenues are generally recognized ratably over the period of contractually enforceable rights and obligations, beginning on the date that the client gains access to the platform. Installment payments are invoiced at the end of each calendar month during the subscription term.

Managed services revenues

Managed services revenues primarily consist of client-selected middle and back-office services provided on our clients’ behalf using the Company’s platform. Revenue is recognized monthly as the managed services are performed, with invoicing occurring at the end of the calendar month.

Other revenues

Other revenues consists of non-subscription-based revenues, such as software enhancements developed for individual, sponsoring clients, but received by all clients, and data conversion and services that integrate a client’s historical data into our solution. The Company recognizes revenues as these services are performed with invoicing occurring at the end of each month.

Service contracts with multiple performance obligations

Our service contracts with clients can include multiple performance obligations. For these contracts, we account for individual performance obligations separately if they are distinct. However, all distinct performance obligations within a contract are satisfied over a similar period of time with the same measure of progress. Accordingly, each distinct performance obligation within a contract has the same pattern of revenue recognition. The Company has determined that implementation services are not distinct from the ongoing platform subscription services due to the highly specialized knowledge required to execute on our solution. Such services are recognized with the platform subscription services revenue over time.

Remaining performance obligations

For the Company’s contracts that exceed one year and do not include a termination for convenience clause, the amount of the transaction price allocated to remaining performance obligations as of June 30, 2022 and December 31, 2021 was $28.5 million and $23.4 million, respectively. The Company expects to recognize this amount over the next one to five years.

Disaggregation of revenue

The Company’s total revenues by geographic region, based on the client’s physical location is presented in the following tables (in thousands):

    

Three Months Ended June 30, 

 

2022

2021

 

Geographic Region

Amount

    

Percent

    

Amount

    

Percent

 

Americas*

$

23,339

 

63.9

%  

$

17,141

 

64.8

%

Europe, Middle East and Africa (EMEA)

 

4,639

 

12.7

%  

 

3,263

 

12.3

%

Asia Pacific (APAC)

 

8,562

 

23.4

%  

 

6,045

 

22.9

%

Total revenues

$

36,540

 

100.0

%  

$

26,449

 

100.0

%

*

The Company’s total revenues in the United States were $22.8 million and $16.6 million for the three months ended June 30, 2022 and 2021, respectively.

    

Six Months Ended June 30, 

 

2022

2021

 

Geographic Region

Amount

    

Percent

    

Amount

    

Percent

 

Americas*

$

45,277

 

64.1

%  

$

33,399

 

65.7

%

Europe, Middle East and Africa (EMEA)

 

8,949

 

12.6

%  

 

5,976

 

11.8

%

Asia Pacific (APAC)

 

16,455

 

23.3

%  

 

11,427

 

22.5

%

Total revenues

$

70,681

 

100.0

%  

$

50,802

 

100.0

%

*   The Company’s total revenues in the United States were $44.3 million and $32.6 million or the six months ended June 30, 2022 and 2021, respectively.

Accounts Receivable

As of June 30, 2022 and December 31, 2021, no individual client represented more than 10% of accounts receivable. For the three and six months ended June 30, 2022 and 2021, respectively, no individual client represented more than 10% of the Company’s total revenues.

Recent Accounting Pronouncements Not Yet Adopted

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes the guidance in former ASC 840, Leases, to increase transparency and comparability among organizations by requiring recognition of right-of-use assets and lease liabilities on the balance sheet and disclosure of key information about leasing arrangements (with the exception of short-term leases). In July 2018, the FASB issued ASU 2018-10, Codification Improvements to Topic 842, Leases, to clarify how to apply certain aspects of the new Leases (Topic 842) standard. ASU 2016-02, as subsequently amended for various technical issues, is effective for private companies and emerging growth companies in fiscal years beginning after December 15, 2021, and interim periods within annual periods beginning after December 15, 2022, and early adoption is permitted. For leases existing at, or entered into after, the beginning of the earliest comparative period presented in the consolidated financial statements, lessees and lessors must apply a modified retrospective transition approach. While the Company expects the adoption of this standard to result in an increase to the reported assets and liabilities, it has not yet determined the full impact the adoption of this standard will have on its consolidated financial statements and related disclosures.  However, the Company expects the adjustment to retained earnings to be immaterial.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which changes the impairment model for most financial assets. The new model uses a forward-looking expected loss method, which will generally result in earlier recognition of allowances for losses. ASU 2016-13, as subsequently amended for various technical issues is effective for annual reporting periods beginning after December 15, 2022, for private entities and emerging growth companies. The Company is evaluating the impact of this standard on its consolidated financial statements.

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for private entities and emerging growth companies in fiscal years beginning after December 15, 2021, and interim periods within annual periods beginning after December 15, 2022, with early adoption permitted, including adoption in an interim period. The Company is evaluating the effect of adopting this new accounting guidance but does not expect adoption will have a material impact on its consolidated financial statements.

XML 32 R11.htm IDEA: XBRL DOCUMENT v3.22.2
Property and Equipment, Net
6 Months Ended
Jun. 30, 2022
Property and Equipment, Net  
Property and Equipment, Net

Note 4   Property and Equipment, Net

Property and equipment, net consists of the following (in thousands):

    

June 30, 2022

    

December 31, 2021

Computer equipment and software

$

17,195

$

14,163

Software development costs

 

7,423

 

4,866

Leasehold improvements

 

1,897

 

1,947

Furniture and fixtures

 

542

 

540

Total property and equipment, cost

 

27,057

 

21,516

Less accumulated depreciation and amortization

 

(10,964)

 

(8,465)

Total property and equipment, net

$

16,093

$

13,051

As of June 30, 2022 and December 31, 2021, property and equipment, net located in the United States was $13.7 million and $10.4 million, respectively. The remainder was located in our various international locations. Included in property and equipment are the capitalized costs of software development. Software development costs capitalized during the three months ended June 30, 2022 and 2021 were $1.4 million and $501 thousand, respectively.  Software development costs capitalized during the six months ended June 30, 2022 and 2021 were $2.6 million and $1.0 million, respectively.  

Depreciation and amortization expense related to property and equipment, excluding software development costs, was $849 thousand and $516 thousand for the three months ended June 30, 2022 and 2021, respectively. Depreciation and amortization expense related to property and equipment, excluding software development costs, was $1.6 million and $1.0 million for the six months ended June 30, 2022 and 2021, respectively. Amortization expense related to software development costs was $507 thousand and $305 thousand for the three months ended June 30, 2022 and 2021, respectively. Amortization expense related to software development costs was $915 thousand and $577 thousand for the six months ended June 30, 2022 and 2021, respectively.

XML 33 R12.htm IDEA: XBRL DOCUMENT v3.22.2
Accrued Expenses and Other Current Liabilities
6 Months Ended
Jun. 30, 2022
Accrued Expenses and Other Current Liabilities  
Accrued Expenses and Other Current Liabilities

Note 5   Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):

    

June 30, 2022

    

December 31, 2021

Accrued compensation

$

7,041

$

3,180

Accrued expenses

 

1,354

 

1,182

Accrued taxes

 

568

 

1,216

Total accrued expenses and other current liabilities

$

8,963

$

5,578

XML 34 R13.htm IDEA: XBRL DOCUMENT v3.22.2
Operating Leases and Service Agreements
6 Months Ended
Jun. 30, 2022
Operating Leases and Service Agreements  
Operating Leases and Service Agreements

Note 6   Operating Leases and Service Agreements

Operating Leases and Service Agreements

The Company leases office space in various locations under operating lease agreements in the normal course of business, which expire at various dates through 2025. Certain operating leases are secured with cash security deposits or letters of credit.

The Company has service agreements for the use of data processing facilities. These service agreements expire at various dates through 2023. Monthly base payments as of June 30, 2022 range from $6 thousand to $16 thousand.

Future aggregate minimum rental payments under the noncancelable operating leases and service agreements noted above, excluding the Company’s share of real estate taxes and other operating costs, are as follows (in thousands):

    

Amount

2022 (remaining six months)

$

2,111

2023

 

3,344

2024

 

2,385

2025

 

901

Total

$

8,741

Total expense related to these lease agreements, which is included in Cost of revenues and Operating expenses, was $1.2 million and $2.2 million for the three and six months ended June 30, 2022, respectively, and $1.0 million and $1.9 million for the three and six months ended June 30, 2021, respectively.

XML 35 R14.htm IDEA: XBRL DOCUMENT v3.22.2
Commitments and Contingencies
6 Months Ended
Jun. 30, 2022
Commitments and Contingencies  
Commitments and Contingencies

Note 7   Commitments and Contingencies

The Company records accruals for contingencies when it is probable that a liability will be incurred, and the amount of loss can be reasonably estimated based on historical claim activity and loss development factors. No accruals for contingencies were recorded as of June 30, 2022 and December 31, 2021, respectively.

XML 36 R15.htm IDEA: XBRL DOCUMENT v3.22.2
Preferred Units, Stockholders' Equity and Members' Deficit
6 Months Ended
Jun. 30, 2022
Preferred Units, Stockholders' Equity and Members' Deficit  
Preferred Units, Stockholders' Equity and Members' Deficit

Note 8   Preferred Units, Stockholders’ Equity and Members’ Deficit

Prior to the organizational restructuring consummated in connection with the Company’s IPO and the application of the net proceeds therefrom (the “Reorganization Transactions”), Enfusion Ltd. LLC was organized as a limited liability company owned by its members, each of whose membership interests consisted of an equal number of: (i) “Economic

Units”, which represented a Member’s economic interest in Enfusion Ltd. LLC; and (ii) “Participation Units”, which represented a Member’s right to participate (vote) in the affairs of Enfusion Ltd. LLC.

As a limited liability company, the Enfusion Ltd. LLC issued more than one class of Units. The Class A Units were considered to be Members’ Equity, whereas all of the other Unit classes were considered to be Preferred Units because of provisions in the Company’s former Operating Agreement that conferred certain rights and privileges to the members owning these Units, such as voting rights, redemption rights and liquidation preferences.

Holders of the Class C-1, C-2 and D Preferred Units had the option to require the Company to redeem their Units. In accordance with the guidance in ASC 480, Distinguishing Liabilities from Equity, outstanding Class C-1, C-2 and D Preferred Units were classified outside of permanent equity and within temporary equity due to their optional redemption features and liquidation preferences.

In connection with the Reorganization Transactions, the Amended and Restated Operating Agreement of Enfusion Ltd. LLC (the “LLC Operating Agreement”) was amended and restated to, among other things, modify its capital structure by reclassifying each of the outstanding Class A Units and C-1, C-2 and D Preferred Units into a new class of LLC interests (or “Common Units”) through a stock split on a 1,000,000 to 1 basis. The number of Common Units outstanding following the Reorganization Transaction reflect the 1,000,000 to 1 stock split. Pursuant to the adoption of the LLC Operating Agreement, Enfusion US 1, Inc., a newly-formed wholly owned subsidiary of Enfusion, Inc., was appointed the sole managing member of Enfusion Ltd. LLC.

Amendment and Restatement of Certificate of Incorporation

In October 2021, the Company amended its certificate of incorporation. The amended and restated certificate of incorporation of Enfusion, Inc. provides for 1,000,000,000 authorized shares of Class A common stock, 150,000,000 authorized shares of Class B common stock and 100,000,000 shares of preferred stock. Each share of the Company’s Class A common stock is entitled to one vote per share and is not convertible into any other shares of the Company’s capital stock. Holders of shares of the Company’s Class A common stock are entitled to receive dividends when, as and if declared by the Company’s board of directors. Upon the Company’s liquidation, dissolution or winding up and after payment in full of all amounts required to be paid to creditors, and subject to the rights of the holders of one or more outstanding series of preferred stock, as applicable, having liquidation preferences, the holders of shares of the Company’s Class A common stock will be entitled to receive pro rata the Company’s remaining assets available for distribution. Each share of the Company’s Class B common stock is entitled to one vote per share and is not convertible or exchangeable for a share of Class A common stock or any other security. Holders of the Company’s Class B common stock do not have any right to receive dividends or to receive a distribution upon a liquidation, dissolution or winding up of Enfusion, Inc.

Preferred Stock

The Company’s board of directors has the authority, without further action by the Company’s stockholders, to issue up to 100,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of Class A common stock. As of June 30, 2022, the Company has not issued any shares of preferred stock nor has the Company’s board of directors established the rights and privileges related to any series of preferred stock.

XML 37 R16.htm IDEA: XBRL DOCUMENT v3.22.2
Stock-Based Compensation
6 Months Ended
Jun. 30, 2022
Stock-Based Compensation  
Stock-Based Compensation

Note 9 Stock-Based Compensation

The Company recognized total stock compensation expense for the three and six months ended June 30, 2022 of $7.7 million and $20.4 million, respectively.  

In connection with obligations to issue Class A common stock to former holders of Award Units under the Company’s former Change in Control Bonus Plan, the Company paid approximately $1.4 million of tax withholding obligations for federal and state payroll taxes. Of that amount, $897 thousand related to employee payroll tax withholdings

and has accordingly been recorded as a reduction to additional paid-in capital. The Company’s stock compensation expense was recognized in the following captions within the consolidated statements of operations:

(in thousands)

   

Three Months Ended June 30, 2022

Six Months Ended June 30, 2022

Cost of revenues

$

341

$

695

General and administrative

4,969

13,907

Sales and marketing

1,491

3,484

Technology and development

867

2,264

Total stock compensation expense

$

7,668

$

20,350

Total unrecognized stock compensation expense related to unvested restricted stock units (“RSUs”) and contingently issuable shares of Class A common stock that will vest within one year of the IPO contingent upon continued employment requirements (“Contingently Issuable Shares”) was $40.6 million as of June 30, 2022, which is expected to be recognized over a weighted-average period of 2.2 years from the date of grant.

In connection with the IPO, the Company adopted the 2021 Incentive Plan (the “Plan”). The Plan provides for grants of stock options, stock appreciation rights, restricted stock, restricted stock units, bonus stock, dividend equivalents, other stock-based awards, substitute awards, annual incentive awards and performance awards intended to align the interests of participants with those of the Company’s shareholders.

During the three months ended June 30, 2022, there were 84,000 stock options granted under the Plan, at a weighted average exercise price of $9.86 per option.  As of June 30, 2022, there was approximately $523 thousand of unrecognized equity based compensation expense related to these stock options, which is expected to be recognized over a weighted-average period of approximately 3 years.  The total fair value of the stock options that vested in the three months ended June 30, 2022 was immaterial.

The assumptions used for the options granted under the Plan during the three months ended June 30, 2022 were as follows:

Assumptions

Expected volatility

64.54%

Expected term of award

6.5 years

Risk-free rate

3.39%

Dividend yield

0.00%

In connection with the IPO, the Company also adopted the 2021 Employee Stock Purchase Plan (“2021 ESPP”). Under the 2021 ESPP, eligible employees may be granted options to purchase shares of Class A common stock at the lower of 85% of the fair market value of the stock at the time of grant or 85% of the fair market value at the time of exercise. As of June 30, 2022, no options were granted to employees under the 2021 ESPP.

XML 38 R17.htm IDEA: XBRL DOCUMENT v3.22.2
Net Income (Loss) Per Class A Common Share
6 Months Ended
Jun. 30, 2022
Net Income (Loss) Per Class A Common Share  
Net Income (Loss) Per Class A Common Share

Note 10  Net Income (Loss) Per Class A Common Share

Basic loss per share is computed by dividing net loss attributable to Enfusion, Inc. by the weighted-average number of shares of Class A common stock outstanding during the period. Diluted loss per share is computed giving effect to all potentially dilutive shares. Diluted loss per share for all periods presented is the same as basic loss per share as the inclusion of potentially issuable shares would be antidilutive.

Prior to the IPO, the Enfusion, LLC membership structure included Common Units and multiple classes of Preferred Units. The Company analyzed the calculation of earnings per unit for periods prior to the IPO using the two-class method and determined that it resulted in values that would not be meaningful to the users of these Condensed Consolidated Financial Statements. Therefore, earnings per share information has not been presented for periods prior to the IPO on October 20, 2021.

A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A common stock is as follows:

Three Months

Six Months

(in thousands, except per share amounts)

    

Ended June 30, 2022

    

Ended June 30, 2022

Numerator:

Net loss

$

(4,125)

$

(16,649)

Less: Net loss attributable to non-controlling interests

1,703

6,962

Net loss attributable to Enfusion, Inc.

(2,422)

(9,687)

Adjustment to income (loss) attributable to common stockholders

(234)

(978)

Numerator for Basic Earnings per Share

$

(2,656)

$

(10,665)

Denominator:

Weighted-average shares of Class A common stock outstanding

66,287

65,935

Vested shares of Class A common stock and RSUs

18,294

18,054

Weighted-average shares of Class A common stock outstanding--basic

84,581

83,989

Net loss per share of Class A common stock--basic and diluted

$

(0.03)

$

(0.13)

The following number of potentially dilutive shares were excluded from the calculation of diluted loss per share because the effect of including such potentially dilutive shares would have been antidilutive:

Three Months

Six Months

(in thousands)

    

Ended June 30, 2022

    

Ended June 30, 2022

Class B common stock

    

46,770

    

47,121

Contingently issuable shares of Class A common stock

406

652

Restricted stock units

3,562

3,561

Stock options

84

84

50,822

51,418

Shares of Class B common stock do not share in earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been presented. Shares of Class B common stock are, however, considered potentially dilutive shares of Class A common stock. After evaluating the potential dilutive effect under both the treasury stock method and if-converted method, shares of Class B common stock were determined to be anti-dilutive and have therefore been excluded from the computation of diluted earnings per share of Class A common stock.

XML 39 R18.htm IDEA: XBRL DOCUMENT v3.22.2
Income Taxes
6 Months Ended
Jun. 30, 2022
Income Taxes  
Income Taxes

Note 11 Income Taxes

The Company is taxed as a corporation for income tax purposes and is subject to federal, state, and local taxes on the income allocated to it from Enfusion Ltd. LLC based upon the Company’s economic interest in Enfusion Ltd. LLC. The Company is the sole managing member of Enfusion Ltd. LLC and, as a result, consolidates the financial results of Enfusion Ltd. LLC.

Enfusion Ltd. LLC. is a limited liability company taxed as a partnership for income tax purposes. Enfusion Ltd. LLC does not pay any federal income taxes, as income or loss is included in the tax returns of the individual members. Additionally, certain wholly-owned entities taxed as corporations are subject to federal, state, and foreign income taxes in the jurisdictions in which they operate, and accruals for such taxes are included in the Condensed Consolidated Financial Statements. For periods prior to the IPO, the Company’s taxes represent those of Enfusion Ltd. LLC.

The Company’s effective tax rate for the three months ended June 30, 2022 and 2021 was (5.6)% and 5.5%, respectively. The Company’s effective tax rate for the six months ended June 30, 2022 and 2021 was (2.3)% and 6.2%, respectively. In the three and six months ending June 30, 2022, respectively, the Company’s effective tax rate differed from the U.S. statutory tax rate of 21% primarily due to non-controlling interest and having a full valuation allowance in the U.S. Conversely, in the three and six months ending June 30, 2021, respectively, the Company’s effective tax rate differed from the U.S. statutory tax rate of 21% primarily due to the pass-through income generated.  

XML 40 R19.htm IDEA: XBRL DOCUMENT v3.22.2
Related Party Transactions
6 Months Ended
Jun. 30, 2022
Related Party Transactions  
Related Party Transactions

Note 12  Related Party Transactions

Parties are considered to be related if one party has the ability to control or exercise significant influence over the other party in making financial or operating decisions. Since transactions with related parties may raise potential or actual conflicts of interest between the related party and the Company, upon the completion of the IPO the Company implemented a related party transaction policy that requires related party transactions to be reviewed and approved by its nominating and corporate governance committee.  

The Company used the proceeds (net of underwriting discounts) from the issuance of 5,526,608 million shares in the IPO ($87.8 million) to purchase an equivalent number of Common Units from the Company’s Pre-IPO Common Unitholders.

In connection with the IPO, the Company entered into the Tax Receivable Agreement with the Pre-IPO LLC Members, which provides for the payment by Enfusion Inc. of 85% of certain cash tax benefits that Enfusion, Inc. actually realizes, or in some cases is deemed to realize. As of June 30, 2022 and December 31, 2021, the Company has not recorded a liability under the Tax Receivable Agreement related to the tax benefits originating from the Reorganization Transactions, IPO and subsequent purchase of Enfusion Ltd. LLC units during the year ended December 31, 2021 as it is not probable that the Company will realize such tax benefits. 

On May 6, 2022, a Pre-IPO Common Unitholder delivered an exchange notice pursuant to Article XII of the LLC Operating Agreement, relating to the exchange of 1,401,818 Common Units and an equal number of shares of class B common stock for an equal number of shares of Class A common stock.

Pursuant to the terms of the LLC Operating Agreement, the Pre-IPO Common Unitholder surrendered 1,401,818 Common Units and an equal number of shares of Class B common stock. In connection therewith, the Company issued 1,401,818 shares of Class A common stock to such Pre-IPO Common Unitholder, canceled an equal number of Class B Common Stock, and received an equal number of Common Units, increasing the Company’s ownership of Common Units by 1,401,818.

XML 41 R20.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of Significant Accounting Policies (Policies)
6 Months Ended
Jun. 30, 2022
Summary of Significant Accounting Policies  
Principles of Consolidation

Principles of Consolidation

These statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and in accordance with rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Accordingly, the financial statements do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments necessary for a fair presentation of the Company’s financial position and results of operations, and all adjustments are of a normal recurring nature. The operating results for the three and six months ended June 30, 2022 are not necessarily indicative of the results expected for the full year ending December 31, 2022. The condensed consolidated interim financial information should be read in conjunction with the consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021. The unaudited condensed consolidated interim financial statements include the accounts of Enfusion, Inc. and its wholly or majority-owned subsidiaries.  All intercompany balances and transactions are eliminated in consolidation.

Use of Estimates

Use of Estimates

The preparation of condensed consolidated interim financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated interim financial statements and accompanying notes. Actual results could differ from those estimates. The effect of the change in the estimates will be recognized in the current period of the change.

In order to better align with industry standards, the Company revised the presentation of its condensed  consolidated interim statement of operations for the three and six months ended June 30, 2021 to reclassify certain

immaterial expenses to cost of sales for Platform subscriptions.  These expenses were previously classified in cost of sales for Managed services and Other revenues.  This change in presentation has no effect on our gross profit or other consolidated results.  In addition, the Company revised the presentation of certain credit charges that were previously recorded in Other revenues to reclassify these charges to Platform subscription and Managed services revenues, respectively.  This change in presentation has no effect on the Company’s total revenues or other consolidated results.  

Revenue Recognition

Revenue Recognition

The Company recognizes revenue in accordance with Accounting Standards Codification 606 (“ASC 606”), Revenue from Contracts with Customers. The Company derives its revenues primarily from fees for platform subscription and managed services provided to clients. Revenues are recognized when control of these services are transferred to the Company’s clients in an amount that reflects the consideration the Company expects to be entitled to in exchange for these services. Revenues are recognized net of taxes that will be remitted to governmental agencies applicable to service contacts.

Historically, platform subscription contracts have typically had a one-year term and were cancellable with 30 days’ notice.  Beginning in the first quarter of 2021, our default platform subscription contract has had a multi-year term and did not allow termination for convenience, though each contract has and can be negotiated with varying term lengths, with or without a termination for convenience clause.  Clients are invoiced each month for the services provided in accordance with the stated terms of their service contracts. Fees for partial term service contracts are prorated, as applicable. Payment of fees are due from clients within 30 days of the invoice date. The Company does not provide financing to clients. The Company determines revenue recognition through the following five-step framework:

Identification of the contract, or contracts, with a client;
Identification of the performance obligation in the contract;
Determination of transaction price;
Allocation of the transaction price to the performance obligations in the contract; and
Recognition of revenue when, or as, performance obligations are satisfied.

Platform subscription revenues

Platform subscription revenues consist primarily of fees for providing clients with access to the Company’s cloud-based platform. Platform subscription clients do not have the right to take possession of the platform’s software, and do not have any general return rights. Platform subscription revenues are generally recognized ratably over the period of contractually enforceable rights and obligations, beginning on the date that the client gains access to the platform. Installment payments are invoiced at the end of each calendar month during the subscription term.

Managed services revenues

Managed services revenues primarily consist of client-selected middle and back-office services provided on our clients’ behalf using the Company’s platform. Revenue is recognized monthly as the managed services are performed, with invoicing occurring at the end of the calendar month.

Other revenues

Other revenues consists of non-subscription-based revenues, such as software enhancements developed for individual, sponsoring clients, but received by all clients, and data conversion and services that integrate a client’s historical data into our solution. The Company recognizes revenues as these services are performed with invoicing occurring at the end of each month.

Service contracts with multiple performance obligations

Our service contracts with clients can include multiple performance obligations. For these contracts, we account for individual performance obligations separately if they are distinct. However, all distinct performance obligations within a contract are satisfied over a similar period of time with the same measure of progress. Accordingly, each distinct performance obligation within a contract has the same pattern of revenue recognition. The Company has determined that implementation services are not distinct from the ongoing platform subscription services due to the highly specialized knowledge required to execute on our solution. Such services are recognized with the platform subscription services revenue over time.

Remaining performance obligations

For the Company’s contracts that exceed one year and do not include a termination for convenience clause, the amount of the transaction price allocated to remaining performance obligations as of June 30, 2022 and December 31, 2021 was $28.5 million and $23.4 million, respectively. The Company expects to recognize this amount over the next one to five years.

Disaggregation of revenue

The Company’s total revenues by geographic region, based on the client’s physical location is presented in the following tables (in thousands):

    

Three Months Ended June 30, 

 

2022

2021

 

Geographic Region

Amount

    

Percent

    

Amount

    

Percent

 

Americas*

$

23,339

 

63.9

%  

$

17,141

 

64.8

%

Europe, Middle East and Africa (EMEA)

 

4,639

 

12.7

%  

 

3,263

 

12.3

%

Asia Pacific (APAC)

 

8,562

 

23.4

%  

 

6,045

 

22.9

%

Total revenues

$

36,540

 

100.0

%  

$

26,449

 

100.0

%

*

The Company’s total revenues in the United States were $22.8 million and $16.6 million for the three months ended June 30, 2022 and 2021, respectively.

    

Six Months Ended June 30, 

 

2022

2021

 

Geographic Region

Amount

    

Percent

    

Amount

    

Percent

 

Americas*

$

45,277

 

64.1

%  

$

33,399

 

65.7

%

Europe, Middle East and Africa (EMEA)

 

8,949

 

12.6

%  

 

5,976

 

11.8

%

Asia Pacific (APAC)

 

16,455

 

23.3

%  

 

11,427

 

22.5

%

Total revenues

$

70,681

 

100.0

%  

$

50,802

 

100.0

%

*   The Company’s total revenues in the United States were $44.3 million and $32.6 million or the six months ended June 30, 2022 and 2021, respectively.

Accounts Receivable

Accounts Receivable

As of June 30, 2022 and December 31, 2021, no individual client represented more than 10% of accounts receivable. For the three and six months ended June 30, 2022 and 2021, respectively, no individual client represented more than 10% of the Company’s total revenues.

Recent Accounting Pronouncements Not Yet Adopted

Recent Accounting Pronouncements Not Yet Adopted

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes the guidance in former ASC 840, Leases, to increase transparency and comparability among organizations by requiring recognition of right-of-use assets and lease liabilities on the balance sheet and disclosure of key information about leasing arrangements (with the exception of short-term leases). In July 2018, the FASB issued ASU 2018-10, Codification Improvements to Topic 842, Leases, to clarify how to apply certain aspects of the new Leases (Topic 842) standard. ASU 2016-02, as subsequently amended for various technical issues, is effective for private companies and emerging growth companies in fiscal years beginning after December 15, 2021, and interim periods within annual periods beginning after December 15, 2022, and early adoption is permitted. For leases existing at, or entered into after, the beginning of the earliest comparative period presented in the consolidated financial statements, lessees and lessors must apply a modified retrospective transition approach. While the Company expects the adoption of this standard to result in an increase to the reported assets and liabilities, it has not yet determined the full impact the adoption of this standard will have on its consolidated financial statements and related disclosures.  However, the Company expects the adjustment to retained earnings to be immaterial.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which changes the impairment model for most financial assets. The new model uses a forward-looking expected loss method, which will generally result in earlier recognition of allowances for losses. ASU 2016-13, as subsequently amended for various technical issues is effective for annual reporting periods beginning after December 15, 2022, for private entities and emerging growth companies. The Company is evaluating the impact of this standard on its consolidated financial statements.

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for private entities and emerging growth companies in fiscal years beginning after December 15, 2021, and interim periods within annual periods beginning after December 15, 2022, with early adoption permitted, including adoption in an interim period. The Company is evaluating the effect of adopting this new accounting guidance but does not expect adoption will have a material impact on its consolidated financial statements.

XML 42 R21.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of Significant Accounting Policies (Tables)
6 Months Ended
Jun. 30, 2022
Summary of Significant Accounting Policies  
Schedule of total net revenues by geographic region

The Company’s total revenues by geographic region, based on the client’s physical location is presented in the following tables (in thousands):

    

Three Months Ended June 30, 

 

2022

2021

 

Geographic Region

Amount

    

Percent

    

Amount

    

Percent

 

Americas*

$

23,339

 

63.9

%  

$

17,141

 

64.8

%

Europe, Middle East and Africa (EMEA)

 

4,639

 

12.7

%  

 

3,263

 

12.3

%

Asia Pacific (APAC)

 

8,562

 

23.4

%  

 

6,045

 

22.9

%

Total revenues

$

36,540

 

100.0

%  

$

26,449

 

100.0

%

*

The Company’s total revenues in the United States were $22.8 million and $16.6 million for the three months ended June 30, 2022 and 2021, respectively.

    

Six Months Ended June 30, 

 

2022

2021

 

Geographic Region

Amount

    

Percent

    

Amount

    

Percent

 

Americas*

$

45,277

 

64.1

%  

$

33,399

 

65.7

%

Europe, Middle East and Africa (EMEA)

 

8,949

 

12.6

%  

 

5,976

 

11.8

%

Asia Pacific (APAC)

 

16,455

 

23.3

%  

 

11,427

 

22.5

%

Total revenues

$

70,681

 

100.0

%  

$

50,802

 

100.0

%

*   The Company’s total revenues in the United States were $44.3 million and $32.6 million or the six months ended June 30, 2022 and 2021, respectively.

XML 43 R22.htm IDEA: XBRL DOCUMENT v3.22.2
Property and Equipment, Net (Tables)
6 Months Ended
Jun. 30, 2022
Property and Equipment, Net  
Schedule of Property and equipment, net

Property and equipment, net consists of the following (in thousands):

    

June 30, 2022

    

December 31, 2021

Computer equipment and software

$

17,195

$

14,163

Software development costs

 

7,423

 

4,866

Leasehold improvements

 

1,897

 

1,947

Furniture and fixtures

 

542

 

540

Total property and equipment, cost

 

27,057

 

21,516

Less accumulated depreciation and amortization

 

(10,964)

 

(8,465)

Total property and equipment, net

$

16,093

$

13,051

XML 44 R23.htm IDEA: XBRL DOCUMENT v3.22.2
Accrued Expenses and Other Current Liabilities (Tables)
6 Months Ended
Jun. 30, 2022
Accrued Expenses and Other Current Liabilities  
Schedule of accrued expenses and other current liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):

    

June 30, 2022

    

December 31, 2021

Accrued compensation

$

7,041

$

3,180

Accrued expenses

 

1,354

 

1,182

Accrued taxes

 

568

 

1,216

Total accrued expenses and other current liabilities

$

8,963

$

5,578

XML 45 R24.htm IDEA: XBRL DOCUMENT v3.22.2
Operating Leases and Service Agreements (Tables)
6 Months Ended
Jun. 30, 2022
Operating Leases and Service Agreements  
Schedule of future aggregate minimum rental payments

Future aggregate minimum rental payments under the noncancelable operating leases and service agreements noted above, excluding the Company’s share of real estate taxes and other operating costs, are as follows (in thousands):

    

Amount

2022 (remaining six months)

$

2,111

2023

 

3,344

2024

 

2,385

2025

 

901

Total

$

8,741

XML 46 R25.htm IDEA: XBRL DOCUMENT v3.22.2
Stock-Based Compensation (Tables)
6 Months Ended
Jun. 30, 2022
Stock-Based Compensation  
Schedule of stock compensation expense

(in thousands)

   

Three Months Ended June 30, 2022

Six Months Ended June 30, 2022

Cost of revenues

$

341

$

695

General and administrative

4,969

13,907

Sales and marketing

1,491

3,484

Technology and development

867

2,264

Total stock compensation expense

$

7,668

$

20,350

Schedule of assumptions

Assumptions

Expected volatility

64.54%

Expected term of award

6.5 years

Risk-free rate

3.39%

Dividend yield

0.00%

XML 47 R26.htm IDEA: XBRL DOCUMENT v3.22.2
Net Income (Loss) Per Class A Common Share (Tables)
6 Months Ended
Jun. 30, 2022
Net Income (Loss) Per Class A Common Share  
Schedule of reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share

Three Months

Six Months

(in thousands, except per share amounts)

    

Ended June 30, 2022

    

Ended June 30, 2022

Numerator:

Net loss

$

(4,125)

$

(16,649)

Less: Net loss attributable to non-controlling interests

1,703

6,962

Net loss attributable to Enfusion, Inc.

(2,422)

(9,687)

Adjustment to income (loss) attributable to common stockholders

(234)

(978)

Numerator for Basic Earnings per Share

$

(2,656)

$

(10,665)

Denominator:

Weighted-average shares of Class A common stock outstanding

66,287

65,935

Vested shares of Class A common stock and RSUs

18,294

18,054

Weighted-average shares of Class A common stock outstanding--basic

84,581

83,989

Net loss per share of Class A common stock--basic and diluted

$

(0.03)

$

(0.13)

Schedule of effect of dilutive shares antidilutive

Three Months

Six Months

(in thousands)

    

Ended June 30, 2022

    

Ended June 30, 2022

Class B common stock

    

46,770

    

47,121

Contingently issuable shares of Class A common stock

406

652

Restricted stock units

3,562

3,561

Stock options

84

84

50,822

51,418

XML 48 R27.htm IDEA: XBRL DOCUMENT v3.22.2
Organization and Description of Business - IPO and reorganization (Details)
6 Months Ended
Jun. 30, 2022
subsidiary
Number of wholly-owned subsidiaries. 3
Enfusion LLC  
Ownership Percentage 59.00%
XML 49 R28.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of Significant Accounting Policies - Narrative (Details)
$ in Millions
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2022
USD ($)
customer
Jun. 30, 2021
customer
Jun. 30, 2022
USD ($)
customer
Jun. 30, 2021
customer
Dec. 31, 2021
USD ($)
customer
Revenue remaining performance obligation | $         $ 23.4
Major Customer | Revenues | Customer Concentration Risk          
Number of customers | customer 0 0 0 0  
Major Customer | Accounts Receivable | Customer Concentration Risk          
Number of customers | customer     0   0
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-07-01          
Revenue remaining performance obligation | $ $ 28.5   $ 28.5    
Minimum | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-07-01          
Remaining performance obligation satisfaction period 1 year   1 year    
Maximum | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01          
Remaining performance obligation satisfaction period 5 years   5 years    
XML 50 R29.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of Significant Accounting Policies - Disaggregation of revenue (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Disaggregation of Revenue [Line Items]        
Total revenues $ 36,540 $ 26,449 $ 70,681 $ 50,802
Revenues | Geographic Region        
Disaggregation of Revenue [Line Items]        
Total revenues $ 36,540 $ 26,449 $ 70,681 $ 50,802
Total net revenues percent 100.00% 100.00% 100.00% 100.00%
Americas | Revenues | Geographic Region        
Disaggregation of Revenue [Line Items]        
Total revenues $ 23,339 $ 17,141 $ 45,277 $ 33,399
Total net revenues percent 63.90% 64.80% 64.10% 65.70%
Europe, Middle East and Africa (EMEA) | Revenues | Geographic Region        
Disaggregation of Revenue [Line Items]        
Total revenues $ 4,639 $ 3,263 $ 8,949 $ 5,976
Total net revenues percent 12.70% 12.30% 12.60% 11.80%
Asia Pacific (APAC) | Revenues | Geographic Region        
Disaggregation of Revenue [Line Items]        
Total revenues $ 8,562 $ 6,045 $ 16,455 $ 11,427
Total net revenues percent 23.40% 22.90% 23.30% 22.50%
United States        
Disaggregation of Revenue [Line Items]        
Total revenues $ 22,800 $ 16,600 $ 44,300 $ 32,600
XML 51 R30.htm IDEA: XBRL DOCUMENT v3.22.2
Property and Equipment, Net (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Property and Equipment, Net    
Total property and equipment, cost $ 27,057 $ 21,516
Less accumulated depreciation and amortization (10,964) (8,465)
Total property and equipment, net 16,093 13,051
Computer equipment and software    
Property and Equipment, Net    
Total property and equipment, cost 17,195 14,163
Software development costs    
Property and Equipment, Net    
Total property and equipment, cost 7,423 4,866
Leasehold improvements    
Property and Equipment, Net    
Total property and equipment, cost 1,897 1,947
Furniture and fixtures    
Property and Equipment, Net    
Total property and equipment, cost $ 542 $ 540
XML 52 R31.htm IDEA: XBRL DOCUMENT v3.22.2
Property and Equipment, Net - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Property and Equipment, Net          
Property and equipment, net $ 16,093   $ 16,093   $ 13,051
Capitalized software development costs 1,400 $ 501 2,600 $ 1,000  
Depreciation and amortization expense 849 516 1,600 1,000  
Amortization expense related to software development costs 507 $ 305 915 $ 577  
United States          
Property and Equipment, Net          
Property and equipment, net $ 13,700   $ 13,700   $ 10,400
XML 53 R32.htm IDEA: XBRL DOCUMENT v3.22.2
Accrued Expenses and Other Current Liabilities (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Accrued Expenses and Other Current Liabilities    
Accrued compensation $ 7,041 $ 3,180
Accrued expenses 1,354 1,182
Accrued taxes 568 1,216
Total accrued expenses and other current liabilities $ 8,963 $ 5,578
XML 54 R33.htm IDEA: XBRL DOCUMENT v3.22.2
Operating Leases and Service Agreements (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Total        
2022 (remaining six months) $ 2,111   $ 2,111  
2023 3,344   3,344  
2024 2,385   2,385  
2025 901   901  
Total 8,741   8,741  
Expense related to lease agreements $ 1,200 $ 1,000 2,200 $ 1,900
Minimum        
Operating Leases and Service Agreements        
Monthly base payments     6  
Maximum        
Operating Leases and Service Agreements        
Monthly base payments     $ 16  
XML 55 R34.htm IDEA: XBRL DOCUMENT v3.22.2
Commitments and Contingencies (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Commitments and Contingencies    
Accruals for contingencies $ 0 $ 0
XML 56 R35.htm IDEA: XBRL DOCUMENT v3.22.2
Preferred Units Stockholders' Equity and Members' Deficit (Details)
1 Months Ended
Oct. 31, 2021
Vote
shares
Jun. 30, 2022
shares
Dec. 31, 2021
shares
Class of Stock [Line Items]      
Preferred stock authorized 100,000,000    
Common Class A      
Class of Stock [Line Items]      
Common stock, shares authorized 1,000,000,000 1,000,000,000 1,000,000,000
Number of Voting Rights | Vote 1    
Common Class B      
Class of Stock [Line Items]      
Common stock, shares authorized 150,000,000 150,000,000 150,000,000
Number of Voting Rights | Vote 1    
Capital Units      
Class of Stock [Line Items]      
Stock exchange ratio 1,000,000    
XML 57 R36.htm IDEA: XBRL DOCUMENT v3.22.2
Stock-Based Compensation- Narratives (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Oct. 31, 2021
Jun. 30, 2022
Jun. 30, 2022
Management Incentive Plans      
Total stock compensation expense   $ 7,668 $ 20,350
Payment of tax withholding obligations for federal payroll taxes     1,400
Payment for employee payroll tax withholding obligations on stock-based compensation     $ 897
Options granted to employees     0
Employee stock option      
Management Incentive Plans      
Options granted to employees   84,000  
Weighted average grants in period   $ 9.86  
Nonvested award option   $ 523 $ 523
Stock based compensation recognition period     3 years
Common Class A | 2021 ESPP      
Management Incentive Plans      
Purchase price of common stock, percent 85.00%    
XML 58 R37.htm IDEA: XBRL DOCUMENT v3.22.2
Stock-Based Compensation- Equity-Based Compensation (Details)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
USD ($)
Jun. 30, 2022
USD ($)
Management Incentive Plans    
Total stock compensation expense $ 7,668 $ 20,350
Restricted Stock Units And Class A Common Stock Vested    
Management Incentive Plans    
Unrecognized stock compensation expense 40,600 $ 40,600
Stock based compensation recognition period   2 years 2 months 12 days
Vested (in years)   1 year
Cost of revenues    
Management Incentive Plans    
Total stock compensation expense 341 $ 695
General and administrative    
Management Incentive Plans    
Total stock compensation expense 4,969 13,907
Sales and marketing    
Management Incentive Plans    
Total stock compensation expense 1,491 3,484
Technology and development    
Management Incentive Plans    
Total stock compensation expense $ 867 $ 2,264
XML 59 R38.htm IDEA: XBRL DOCUMENT v3.22.2
Stock-based compensation - Assumptions for Performance-based shares (Details) - Employee stock option
6 Months Ended
Jun. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Expected volatility 64.54%
Expected term of award 6 years 6 months
Risk-free interest rate 3.39%
Expected dividend yield 0.00%
XML 60 R39.htm IDEA: XBRL DOCUMENT v3.22.2
Net Income (Loss) Per Class A Common Share - Diluted net loss per common unit (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Numerator:        
Net loss $ (4,125) $ 4,251 $ (16,649) $ 8,360
Less: Net loss attributable to non-controlling interests 1,703   6,962  
Net (loss) income attributable to Enfusion, Inc. (2,422) $ 4,251 (9,687) $ 8,360
Adjustment to income (loss) attributable to common stockholders (234)   (978)  
Numerator for Basic Earnings per Share $ (2,656)   $ (10,665)  
Denominator:        
Weighted-average shares of Class A common stock outstanding 66,287   65,935  
Vested shares of Class A common stock and RSUs 18,294   18,054  
Weighted-average shares of Class A common stock outstanding--basic 84,581   83,989  
Net loss per share of Class A common stock-basic $ (0.03)   $ (0.13)  
Net loss per share of Class A common stock- diluted $ (0.03)   $ (0.13)  
XML 61 R40.htm IDEA: XBRL DOCUMENT v3.22.2
Net Income (Loss) Per Class A Common Share - Dilutive shares (Details) - shares
shares in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2022
Antidilutive securities amount 50,822 51,418
Common Class B    
Antidilutive securities amount 46,770 47,121
Contingently issuable shares of Class A common stock    
Antidilutive securities amount 406 652
Restricted Stock Units    
Antidilutive securities amount 3,562 3,561
Employee stock option    
Antidilutive securities amount 84 84
XML 62 R41.htm IDEA: XBRL DOCUMENT v3.22.2
Income taxes - Narratives (Details)
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Income Taxes        
Effective tax rate (as a percent) (5.60%) 5.50% (2.30%) 6.20%
U.S. statutory tax rate (as a percent) 21.00% 21.00% 21.00% 21.00%
XML 63 R42.htm IDEA: XBRL DOCUMENT v3.22.2
Related Party Transactions (Details) - USD ($)
$ in Millions
May 06, 2022
Oct. 20, 2021
Related Party Transaction [Line Items]    
Percentage of Entity's Share of Tax Benefits Under Tax Receivable Agreement   85.00%
Common units exchanged (in shares) 1,401,818  
Common units surrendered (in shares) 1,401,818  
Increase in common units (in shares) 1,401,818  
Common Class A    
Related Party Transaction [Line Items]    
Stock issued (in shares) 1,401,818  
IPO    
Related Party Transaction [Line Items]    
Purchase of Common Units   5,526,608
Payments to acquire newly issued common units   $ 87.8
XML 64 enfn-20220630x10q_htm.xml IDEA: XBRL DOCUMENT 0001868912 enfn:PreferredUnitsMember 2021-03-31 0001868912 enfn:PreferredUnitsMember 2020-12-31 0001868912 us-gaap:CommonClassAMember 2022-05-06 2022-05-06 0001868912 us-gaap:CapitalUnitsMember 2021-10-01 2021-10-31 0001868912 us-gaap:RetainedEarningsMember 2022-06-30 0001868912 us-gaap:NoncontrollingInterestMember 2022-06-30 0001868912 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001868912 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001868912 us-gaap:RetainedEarningsMember 2022-03-31 0001868912 us-gaap:NoncontrollingInterestMember 2022-03-31 0001868912 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001868912 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001868912 2022-03-31 0001868912 us-gaap:RetainedEarningsMember 2021-12-31 0001868912 us-gaap:NoncontrollingInterestMember 2021-12-31 0001868912 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001868912 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001868912 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001868912 enfn:PreferredUnitsMember 2021-06-30 0001868912 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001868912 2021-03-31 0001868912 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001868912 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-06-30 0001868912 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-06-30 0001868912 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-03-31 0001868912 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-03-31 0001868912 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-12-31 0001868912 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-12-31 0001868912 us-gaap:MemberUnitsMember 2021-06-30 0001868912 us-gaap:MemberUnitsMember 2021-03-31 0001868912 us-gaap:MemberUnitsMember 2020-12-31 0001868912 enfn:EmployeeStockPurchasePlan2021Member us-gaap:CommonClassAMember 2021-10-01 2021-10-31 0001868912 us-gaap:EmployeeStockOptionMember 2022-04-01 2022-06-30 0001868912 srt:MinimumMember 2022-07-01 2022-06-30 0001868912 srt:MaximumMember 2026-01-01 2022-06-30 0001868912 2022-07-01 2022-06-30 0001868912 country:US 2022-04-01 2022-06-30 0001868912 country:US 2022-01-01 2022-06-30 0001868912 country:US 2021-04-01 2021-06-30 0001868912 country:US 2021-01-01 2021-06-30 0001868912 country:US 2022-06-30 0001868912 country:US 2021-12-31 0001868912 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2022-06-30 0001868912 us-gaap:LeaseholdImprovementsMember 2022-06-30 0001868912 us-gaap:FurnitureAndFixturesMember 2022-06-30 0001868912 us-gaap:ComputerEquipmentMember 2022-06-30 0001868912 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2021-12-31 0001868912 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001868912 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001868912 us-gaap:ComputerEquipmentMember 2021-12-31 0001868912 2021-10-31 0001868912 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001868912 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-06-30 0001868912 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001868912 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-06-30 0001868912 enfn:EnfusionLtd.LlcMember 2022-06-30 0001868912 us-gaap:EmployeeStockOptionMember 2022-06-30 0001868912 enfn:RestrictedStockAndClassaCommonStockVestedMember 2022-06-30 0001868912 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-06-30 0001868912 enfn:RestrictedStockAndClassaCommonStockVestedMember 2022-01-01 2022-06-30 0001868912 enfn:PlatformSubscriptionsMember 2022-04-01 2022-06-30 0001868912 enfn:OtherServicesMember 2022-04-01 2022-06-30 0001868912 enfn:ManagedServicesMember 2022-04-01 2022-06-30 0001868912 enfn:PlatformSubscriptionsMember 2022-01-01 2022-06-30 0001868912 enfn:OtherServicesMember 2022-01-01 2022-06-30 0001868912 enfn:ManagedServicesMember 2022-01-01 2022-06-30 0001868912 enfn:PlatformSubscriptionsMember 2021-04-01 2021-06-30 0001868912 enfn:OtherServicesMember 2021-04-01 2021-06-30 0001868912 enfn:ManagedServicesMember 2021-04-01 2021-06-30 0001868912 enfn:PlatformSubscriptionsMember 2021-01-01 2021-06-30 0001868912 enfn:OtherServicesMember 2021-01-01 2021-06-30 0001868912 enfn:ManagedServicesMember 2021-01-01 2021-06-30 0001868912 us-gaap:EMEAMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2022-04-01 2022-06-30 0001868912 srt:AsiaPacificMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2022-04-01 2022-06-30 0001868912 srt:AmericasMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2022-04-01 2022-06-30 0001868912 us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2022-04-01 2022-06-30 0001868912 us-gaap:EMEAMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-06-30 0001868912 srt:AsiaPacificMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-06-30 0001868912 srt:AmericasMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-06-30 0001868912 us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-06-30 0001868912 us-gaap:EMEAMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2021-04-01 2021-06-30 0001868912 srt:AsiaPacificMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2021-04-01 2021-06-30 0001868912 srt:AmericasMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2021-04-01 2021-06-30 0001868912 us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2021-04-01 2021-06-30 0001868912 us-gaap:EMEAMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-06-30 0001868912 srt:AsiaPacificMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-06-30 0001868912 srt:AmericasMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-06-30 0001868912 us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-06-30 0001868912 us-gaap:CommonClassBMember 2022-06-30 0001868912 us-gaap:CommonClassAMember 2022-06-30 0001868912 us-gaap:CommonClassBMember 2021-12-31 0001868912 us-gaap:CommonClassAMember 2021-12-31 0001868912 2021-06-30 0001868912 2020-12-31 0001868912 us-gaap:RestrictedStockUnitsRSUMember 2022-04-01 2022-06-30 0001868912 us-gaap:EmployeeStockOptionMember 2022-04-01 2022-06-30 0001868912 us-gaap:CommonClassBMember 2022-04-01 2022-06-30 0001868912 enfn:ContingentlyIssuableClassCommonStockMember 2022-04-01 2022-06-30 0001868912 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-06-30 0001868912 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-06-30 0001868912 us-gaap:CommonClassBMember 2022-01-01 2022-06-30 0001868912 enfn:ContingentlyIssuableClassCommonStockMember 2022-01-01 2022-06-30 0001868912 us-gaap:SellingAndMarketingExpenseMember 2022-04-01 2022-06-30 0001868912 us-gaap:ResearchAndDevelopmentExpenseMember 2022-04-01 2022-06-30 0001868912 us-gaap:GeneralAndAdministrativeExpenseMember 2022-04-01 2022-06-30 0001868912 us-gaap:CostOfSalesMember 2022-04-01 2022-06-30 0001868912 us-gaap:SellingAndMarketingExpenseMember 2022-01-01 2022-06-30 0001868912 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-06-30 0001868912 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-06-30 0001868912 us-gaap:CostOfSalesMember 2022-01-01 2022-06-30 0001868912 enfn:PreferredUnitsMember 2021-04-01 2021-06-30 0001868912 enfn:PreferredUnitsMember 2021-01-01 2021-06-30 0001868912 srt:MinimumMember 2022-01-01 2022-06-30 0001868912 srt:MaximumMember 2022-01-01 2022-06-30 0001868912 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001868912 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-06-30 0001868912 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001868912 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001868912 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-01-01 2022-06-30 0001868912 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-01-01 2022-06-30 0001868912 2021-10-20 2021-10-20 0001868912 us-gaap:IPOMember 2021-10-20 2021-10-20 0001868912 us-gaap:CommonClassBMember 2021-10-31 0001868912 us-gaap:CommonClassAMember 2021-10-31 0001868912 enfn:MajorCustomerMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-04-01 2022-06-30 0001868912 enfn:MajorCustomerMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-06-30 0001868912 enfn:MajorCustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-06-30 0001868912 enfn:MajorCustomerMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0001868912 enfn:MajorCustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001868912 enfn:MajorCustomerMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0001868912 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001868912 us-gaap:NoncontrollingInterestMember 2022-04-01 2022-06-30 0001868912 us-gaap:RetainedEarningsMember 2022-01-01 2022-06-30 0001868912 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-06-30 0001868912 us-gaap:MemberUnitsMember 2021-04-01 2021-06-30 0001868912 2021-04-01 2021-06-30 0001868912 us-gaap:MemberUnitsMember 2021-01-01 2021-06-30 0001868912 2021-01-01 2021-06-30 0001868912 2022-05-06 2022-05-06 0001868912 2022-04-01 2022-06-30 0001868912 2022-06-30 0001868912 2021-12-31 0001868912 us-gaap:CommonStockMember 2022-08-09 0001868912 us-gaap:CommonClassBMember 2022-08-09 0001868912 us-gaap:CommonClassAMember 2022-08-09 0001868912 2022-01-01 2022-06-30 shares iso4217:USD enfn:customer enfn:subsidiary enfn:Vote pure iso4217:USD shares -0.03 -0.13 84581000 83989000 0001868912 --12-31 2022 Q2 false -0.03 -0.13 65583289 47470971 P1Y 46069153 67001652 10-Q true 2022-06-30 false 001-40949 Enfusion, Inc DE 87-1268462 125 South Clark Street Suite 750 Chicago IL 60603 312 253-9800 Class A common stock, par value $0.001per share ENFN NYSE Yes Yes Non-accelerated Filer false true false false 113070805 67001652 46069153 56559000 64365000 28771000 18223000 3634000 6030000 1287000 1060000 90251000 89678000 16093000 13051000 3783000 3356000 110127000 106085000 879000 2528000 8963000 5578000 9842000 8106000 479000 538000 10321000 8644000 0.001 0.001 1000000000 1000000000 67001652 65583289 67000 66000 0.001 0.001 150000000 150000000 46069153 47470971 46000 47000 240501000 226717000 -180896000 -171209000 -582000 -325000 59136000 55296000 40670000 42145000 99806000 97441000 110127000 106085000 33560000 24324000 65111000 46747000 2396000 1729000 4626000 3263000 584000 396000 944000 792000 36540000 26449000 70681000 50802000 9065000 5709000 18376000 11661000 1668000 1015000 3283000 1843000 114000 53000 171000 82000 10847000 6777000 21830000 13586000 25693000 19672000 48851000 37216000 18302000 7457000 40597000 13838000 7575000 4264000 16007000 7422000 3722000 2041000 8524000 4243000 29599000 13762000 65128000 25503000 -3906000 5910000 -16277000 11713000 1000 1410000 7000 2802000 1000 4000 -1410000 -3000 -2802000 -3906000 4500000 -16280000 8911000 219000 249000 369000 551000 -4125000 4251000 -16649000 8360000 -1703000 -6962000 -2422000 4251000 -9687000 8360000 -0.03 -0.13 84581000 83989000 -4125000 4251000 -16649000 8360000 -353000 -16000 -439000 -77000 -4478000 4235000 -17088000 8283000 -1849000 -7144000 -2629000 4235000 -9944000 8283000 65583289 66000 47470971 47000 233607000 -178474000 -375000 41837000 96708000 -2422000 -1703000 -4125000 4441000 3135000 7576000 1401818 1000 -1401818 -1000 2453000 -2453000 16545 -207000 -146000 -353000 67001652 67000 46069153 46000 240501000 -180896000 -582000 40670000 99806000 65583289 66000 47470971 47000 226717000 -171209000 -325000 42145000 97441000 -9687000 -6962000 -16649000 11331000 8122000 19453000 1401818 1000 -1401818 -1000 2453000 -2453000 16545 -257000 -182000 -439000 67001652 67000 46069153 46000 240501000 -180896000 -582000 40670000 99806000 53.774 167523000 47.968 -231410000 -273000 -231683000 2247000 2004000 2004000 -16000 -16000 1401000 1188000 1188000 53.774 168369000 47.968 -230594000 -289000 -230883000 53.774 165515000 47.968 -233347000 -212000 -233559000 4419000 3941000 3941000 -77000 -77000 1565000 1188000 1188000 53.774 168369000 47.968 -230594000 -289000 -230883000 -16649000 8360000 2955000 1672000 459000 174000 13000 148000 20350000 11007000 3466000 -1316000 1481000 -1970000 763000 3326000 1633000 -1207000 7803000 5263000 4401000 -5263000 -4401000 2745000 897000 -897000 -2745000 -439000 -80000 -7806000 577000 64365000 13938000 56559000 14515000 321000 2712000 333000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 1   Organization and Description of Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Enfusion, Inc. (“Enfusion” or the “Company”) is a leading provider of cloud-based order and execution management, portfolio management and risk systems. Enfusion’s clients include large global hedge fund managers, institutional asset managers, family offices and other institutional investors. Enfusion provides its clients with innovative real-time performance, risk calculations, and accounting capabilities for some of the most sophisticated financial products. The Company is headquartered in Chicago, Illinois and has offices in Chicago, New York, London, Dublin, Hong Kong, Singapore, São Paulo, Mumbai, Bengaluru, and Sydney.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Enfusion, Inc. was incorporated in Delaware on June 11, 2021 for the purpose of facilitating an initial public offering (“IPO”), which was completed on October 25, 2021, and other related transactions in order to carry on the business of Enfusion Ltd. LLC. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Enfusion, Inc. has three wholly-owned subsidiaries: Enfusion US 1, Inc., Enfusion US 2, Inc. and Enfusion US 3, Inc.; as well as a substantial financial interest in Enfusion Ltd. LLC and its majority-owned subsidiary, Enfusion Softech India Private Limited, as well as the wholly-owned subsidiaries of Enfusion Ltd. LLC: Enfusion Systems UK Ltd, Enfusion HK Limited, Enfusion Software Limited, Enfusion (Singapore) Pte. Ltd., Enfusion do Brasil Tecnologia da Informacao Ltda, Enfusion (Australia) Pty. Ltd. and Enfusion (Shanghai) Co., Ltd. Enfusion, Inc., through its control over the managing member of Enfusion Ltd. LLC, manages and operates Enfusion Ltd. LLC’s business and controls its strategic decisions and day-to-day operations. As such, Enfusion, Inc. consolidates the financial results of Enfusion Ltd. LLC, and a portion of Enfusion, Inc.’s net income will be allocated to non-controlling interests to reflect the entitlement to a portion of Enfusion Ltd. LLC’s net income by the unitholders that held Enfusion Ltd. LLC’s common units prior to the Company’s IPO and following the reorganization transactions (the “Pre-IPO Common Unitholders”). As of June 30, 2022, Enfusion, Inc. owned approximately 59% of Enfusion Ltd. LLC. </p> 3 0.59 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 2    Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Principles of Consolidation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and in accordance with rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Accordingly, the financial statements do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments necessary for a fair presentation of the Company’s financial position and results of operations, and all adjustments are of a normal recurring nature. The operating results for the three and six months ended June 30, 2022 are not necessarily indicative of the results expected for the full year ending December 31, 2022. The condensed consolidated interim financial information should be read in conjunction with the consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021. The unaudited condensed consolidated interim financial statements include the accounts of Enfusion, Inc. and its wholly or majority-owned subsidiaries.  All intercompany balances and transactions are eliminated in consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">The preparation of condensed consolidated interim financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated interim financial statements and accompanying notes. Actual results could differ from those estimates. The effect of the change in the estimates will be recognized in the current period of the change. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">In order to better align with industry standards, the Company revised the presentation of its condensed  consolidated interim statement of operations for the three and six months ended June 30, 2021 to reclassify certain </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="background:#ffffff;">immaterial expenses to cost of sales for Platform subscriptions.  These expenses were previously classified in cost of sales for Managed services and Other revenues.  This change in presentation has no effect on our gross profit or other consolidated results.  In addition, the Company revised the presentation of certain credit charges that were previously recorded in Other revenues to reclassify these charges to Platform subscription and Managed services revenues, respectively.  This change in presentation has no effect on the Company’s total revenues or other consolidated results.</span><span style="background:#ffffff;">   </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Principles of Consolidation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and in accordance with rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Accordingly, the financial statements do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments necessary for a fair presentation of the Company’s financial position and results of operations, and all adjustments are of a normal recurring nature. The operating results for the three and six months ended June 30, 2022 are not necessarily indicative of the results expected for the full year ending December 31, 2022. The condensed consolidated interim financial information should be read in conjunction with the consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021. The unaudited condensed consolidated interim financial statements include the accounts of Enfusion, Inc. and its wholly or majority-owned subsidiaries.  All intercompany balances and transactions are eliminated in consolidation.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">The preparation of condensed consolidated interim financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated interim financial statements and accompanying notes. Actual results could differ from those estimates. The effect of the change in the estimates will be recognized in the current period of the change. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">In order to better align with industry standards, the Company revised the presentation of its condensed  consolidated interim statement of operations for the three and six months ended June 30, 2021 to reclassify certain </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="background:#ffffff;">immaterial expenses to cost of sales for Platform subscriptions.  These expenses were previously classified in cost of sales for Managed services and Other revenues.  This change in presentation has no effect on our gross profit or other consolidated results.  In addition, the Company revised the presentation of certain credit charges that were previously recorded in Other revenues to reclassify these charges to Platform subscription and Managed services revenues, respectively.  This change in presentation has no effect on the Company’s total revenues or other consolidated results.</span><span style="background:#ffffff;">   </span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 3   Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">A description of the Company’s significant accounting policies is included in the audited financial statements within its Annual Report on Form 10-K for the year ended December 31, 2021. There have been no material changes in the Company’s significant accounting policies during the three and six months ended June 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Revenue Recognition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue in accordance with Accounting Standards Codification 606 (“ASC 606”), Revenue from Contracts with Customers. The Company derives its revenues primarily from fees for platform subscription and managed services provided to clients. Revenues are recognized when control of these services are transferred to the Company’s clients in an amount that reflects the consideration the Company expects to be entitled to in exchange for these services. Revenues are recognized net of taxes that will be remitted to governmental agencies applicable to service contacts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Historically, platform subscription contracts have typically had a one-year term and were cancellable with 30 days’ notice.  Beginning in the first quarter of 2021, our default platform subscription contract has had a multi-year term and did not allow termination for convenience, though each contract has and can be negotiated with varying term lengths, with or without a termination for convenience clause.  Clients are invoiced each month for the services provided in accordance with the stated terms of their service contracts. Fees for partial term service contracts are prorated, as applicable. Payment of fees are due from clients within 30 days of the invoice date. The Company does not provide financing to clients. The Company determines revenue recognition through the following five-step framework:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Identification of the contract, or contracts, with a client;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Identification of the performance obligation in the contract;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Determination of transaction price;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Allocation of the transaction price to the performance obligations in the contract; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Recognition of revenue when, or as, performance obligations are satisfied.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Platform subscription revenues</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Platform subscription revenues consist primarily of fees for providing clients with access to the Company’s cloud-based platform. Platform subscription clients do not have the right to take possession of the platform’s software, and do not have any general return rights. Platform subscription revenues are generally recognized ratably over the period of contractually enforceable rights and obligations, beginning on the date that the client gains access to the platform. Installment payments are invoiced at the end of each calendar month during the subscription term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Managed services revenues</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Managed services revenues primarily consist of client-selected middle and back-office services provided on our clients’ behalf using the Company’s platform. Revenue is recognized monthly as the managed services are performed, with invoicing occurring at the end of the calendar month.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Other revenues</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other revenues consists of non-subscription-based revenues, such as software enhancements developed for individual, sponsoring clients, but received by all clients, and data conversion and services that integrate a client’s historical data into our solution. The Company recognizes revenues as these services are performed with invoicing occurring at the end of each month.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Service contracts with multiple performance obligations</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our service contracts with clients can include multiple performance obligations. For these contracts, we account for individual performance obligations separately if they are distinct. However, all distinct performance obligations within a contract are satisfied over a similar period of time with the same measure of progress. Accordingly, each distinct performance obligation within a contract has the same pattern of revenue recognition. The Company has determined that implementation services are not distinct from the ongoing platform subscription services due to the highly specialized knowledge required to execute on our solution. Such services are recognized with the platform subscription services revenue over time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Remaining performance obligations</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the Company’s contracts that exceed one year and do not include a termination for convenience clause, the amount of the transaction price allocated to remaining performance obligations as of June 30, 2022 and December 31, 2021 was $28.5 million and $23.4 million, respectively. The Company expects to recognize this amount over the next <span style="-sec-ix-hidden:Hidden_P_IodeFWgEO065sDudsvLw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> to five years. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Disaggregation of revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company’s total revenues by geographic region, based on the client’s physical location is presented in the following tables (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:60.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:35.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:60.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:60.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Geographic Region</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:top;width:60.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Americas*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 23,339</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 63.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 17,141</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 64.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:60.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Europe, Middle East and Africa (EMEA)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,639</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 12.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 12.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:60.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Asia Pacific (APAC)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8,562</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 23.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6,045</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 22.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:60.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 36,540</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 26,449</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The Company’s total revenues in the United States were $22.8 million and $16.6 million for the three months ended June 30, 2022 and 2021, respectively.</p></td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:60.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:35.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:60.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:60.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Geographic Region</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:top;width:60.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Americas*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 45,277</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 64.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 33,399</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 65.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:60.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Europe, Middle East and Africa (EMEA)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8,949</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 12.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:60.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Asia Pacific (APAC)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 16,455</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 23.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11,427</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 22.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:60.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 70,681</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 50,802</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">*   The Company’s total revenues in the United States were $44.3 million and $32.6 million or the six months ended June 30, 2022 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Accounts Receivable</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">As of June 30, 2022 and December 31, 2021, no individual client represented more than 10% of accounts receivable. For the three and six months ended June 30, 2022 and 2021, respectively, no individual client represented more than 10% of the Company’s total revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 3pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Recent Accounting Pronouncements Not Yet Adopted</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:9pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2016, the FASB issued ASU 2016-02<i style="font-style:italic;">, Leases</i> (Topic 842), which supersedes the guidance in former ASC 840, <i style="font-style:italic;">Leases</i>, to increase transparency and comparability among organizations by requiring recognition of right-of-use assets and lease liabilities on the balance sheet and disclosure of key information about leasing arrangements (with the exception of short-term leases). In July 2018, the FASB issued ASU 2018-10, <i style="font-style:italic;">Codification Improvements to Topic 842, Leases</i>, to clarify how to apply certain aspects of the new <i style="font-style:italic;">Leases</i> (Topic 842) standard. ASU 2016-02, as subsequently amended for various technical issues, is effective for private companies and emerging growth companies in fiscal years beginning after December 15, 2021, and interim periods within annual periods beginning after December 15, 2022, and early adoption is permitted. For leases existing at, or entered into after, the beginning of the earliest comparative period presented in the consolidated financial statements, lessees and lessors must apply a modified retrospective transition approach. While the Company expects the adoption of this standard to result in an increase to the reported assets and liabilities, it has not yet determined the full impact the adoption of this standard will have on its consolidated financial statements and related disclosures.  However, the Company expects the adjustment to retained earnings to be immaterial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 12pt 0pt;">In June 2016, the FASB issued ASU No. 2016-13, <i style="font-style:italic;">Financial Instruments – Credit Losses</i> (Topic 326): <i style="font-style:italic;">Measurement of Credit Losses on Financial Instruments</i>, which changes the impairment model for most financial assets. The new model uses a forward-looking expected loss method, which will generally result in earlier recognition of allowances for losses. ASU 2016-13, as subsequently amended for various technical issues is effective for annual reporting periods beginning after December 15, 2022, for private entities and emerging growth companies. The Company is evaluating the impact of this standard on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">In December 2019, the FASB issued ASU 2019-12, <i style="font-style:italic;">Income Taxes</i> (Topic 740): <i style="font-style:italic;">Simplifying the Accounting for Income Taxes</i>, which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for private entities and emerging growth companies in fiscal years beginning after December 15, 2021, and interim periods within annual periods beginning after December 15, 2022, with early adoption permitted, including adoption in an interim period. The Company is evaluating the effect of adopting this new accounting guidance but does not expect adoption will have a material impact on its consolidated financial statements.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Revenue Recognition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue in accordance with Accounting Standards Codification 606 (“ASC 606”), Revenue from Contracts with Customers. The Company derives its revenues primarily from fees for platform subscription and managed services provided to clients. Revenues are recognized when control of these services are transferred to the Company’s clients in an amount that reflects the consideration the Company expects to be entitled to in exchange for these services. Revenues are recognized net of taxes that will be remitted to governmental agencies applicable to service contacts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Historically, platform subscription contracts have typically had a one-year term and were cancellable with 30 days’ notice.  Beginning in the first quarter of 2021, our default platform subscription contract has had a multi-year term and did not allow termination for convenience, though each contract has and can be negotiated with varying term lengths, with or without a termination for convenience clause.  Clients are invoiced each month for the services provided in accordance with the stated terms of their service contracts. Fees for partial term service contracts are prorated, as applicable. Payment of fees are due from clients within 30 days of the invoice date. The Company does not provide financing to clients. The Company determines revenue recognition through the following five-step framework:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Identification of the contract, or contracts, with a client;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Identification of the performance obligation in the contract;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Determination of transaction price;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Allocation of the transaction price to the performance obligations in the contract; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Recognition of revenue when, or as, performance obligations are satisfied.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Platform subscription revenues</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Platform subscription revenues consist primarily of fees for providing clients with access to the Company’s cloud-based platform. Platform subscription clients do not have the right to take possession of the platform’s software, and do not have any general return rights. Platform subscription revenues are generally recognized ratably over the period of contractually enforceable rights and obligations, beginning on the date that the client gains access to the platform. Installment payments are invoiced at the end of each calendar month during the subscription term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Managed services revenues</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Managed services revenues primarily consist of client-selected middle and back-office services provided on our clients’ behalf using the Company’s platform. Revenue is recognized monthly as the managed services are performed, with invoicing occurring at the end of the calendar month.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Other revenues</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other revenues consists of non-subscription-based revenues, such as software enhancements developed for individual, sponsoring clients, but received by all clients, and data conversion and services that integrate a client’s historical data into our solution. The Company recognizes revenues as these services are performed with invoicing occurring at the end of each month.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Service contracts with multiple performance obligations</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our service contracts with clients can include multiple performance obligations. For these contracts, we account for individual performance obligations separately if they are distinct. However, all distinct performance obligations within a contract are satisfied over a similar period of time with the same measure of progress. Accordingly, each distinct performance obligation within a contract has the same pattern of revenue recognition. The Company has determined that implementation services are not distinct from the ongoing platform subscription services due to the highly specialized knowledge required to execute on our solution. Such services are recognized with the platform subscription services revenue over time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Remaining performance obligations</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the Company’s contracts that exceed one year and do not include a termination for convenience clause, the amount of the transaction price allocated to remaining performance obligations as of June 30, 2022 and December 31, 2021 was $28.5 million and $23.4 million, respectively. The Company expects to recognize this amount over the next <span style="-sec-ix-hidden:Hidden_P_IodeFWgEO065sDudsvLw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> to five years. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Disaggregation of revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company’s total revenues by geographic region, based on the client’s physical location is presented in the following tables (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:60.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:35.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:60.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:60.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Geographic Region</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:top;width:60.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Americas*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 23,339</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 63.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 17,141</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 64.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:60.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Europe, Middle East and Africa (EMEA)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,639</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 12.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 12.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:60.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Asia Pacific (APAC)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8,562</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 23.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6,045</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 22.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:60.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 36,540</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 26,449</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The Company’s total revenues in the United States were $22.8 million and $16.6 million for the three months ended June 30, 2022 and 2021, respectively.</p></td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:60.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:35.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:60.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:60.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Geographic Region</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:top;width:60.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Americas*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 45,277</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 64.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 33,399</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 65.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:60.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Europe, Middle East and Africa (EMEA)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8,949</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 12.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:60.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Asia Pacific (APAC)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 16,455</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 23.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11,427</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 22.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:60.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 70,681</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 50,802</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">*   The Company’s total revenues in the United States were $44.3 million and $32.6 million or the six months ended June 30, 2022 and 2021, respectively.</p> 28500000 23400000 P5Y <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company’s total revenues by geographic region, based on the client’s physical location is presented in the following tables (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:60.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:35.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:60.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:60.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Geographic Region</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:top;width:60.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Americas*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 23,339</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 63.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 17,141</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 64.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:60.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Europe, Middle East and Africa (EMEA)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,639</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 12.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 12.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:60.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Asia Pacific (APAC)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8,562</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 23.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6,045</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 22.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:60.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 36,540</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 26,449</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The Company’s total revenues in the United States were $22.8 million and $16.6 million for the three months ended June 30, 2022 and 2021, respectively.</p></td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:60.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:35.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:60.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:60.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Geographic Region</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:top;width:60.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Americas*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 45,277</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 64.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 33,399</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 65.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:60.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Europe, Middle East and Africa (EMEA)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8,949</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 12.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:60.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Asia Pacific (APAC)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 16,455</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 23.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11,427</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 22.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:60.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 70,681</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 50,802</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">*   The Company’s total revenues in the United States were $44.3 million and $32.6 million or the six months ended June 30, 2022 and 2021, respectively.</p> 23339000 0.639 17141000 0.648 4639000 0.127 3263000 0.123 8562000 0.234 6045000 0.229 36540000 1.000 26449000 1.000 22800000 16600000 45277000 0.641 33399000 0.657 8949000 0.126 5976000 0.118 16455000 0.233 11427000 0.225 70681000 1.000 50802000 1.000 44300000 32600000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Accounts Receivable</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">As of June 30, 2022 and December 31, 2021, no individual client represented more than 10% of accounts receivable. For the three and six months ended June 30, 2022 and 2021, respectively, no individual client represented more than 10% of the Company’s total revenues.</p> 0 0 0 0 0 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 3pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Recent Accounting Pronouncements Not Yet Adopted</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:9pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2016, the FASB issued ASU 2016-02<i style="font-style:italic;">, Leases</i> (Topic 842), which supersedes the guidance in former ASC 840, <i style="font-style:italic;">Leases</i>, to increase transparency and comparability among organizations by requiring recognition of right-of-use assets and lease liabilities on the balance sheet and disclosure of key information about leasing arrangements (with the exception of short-term leases). In July 2018, the FASB issued ASU 2018-10, <i style="font-style:italic;">Codification Improvements to Topic 842, Leases</i>, to clarify how to apply certain aspects of the new <i style="font-style:italic;">Leases</i> (Topic 842) standard. ASU 2016-02, as subsequently amended for various technical issues, is effective for private companies and emerging growth companies in fiscal years beginning after December 15, 2021, and interim periods within annual periods beginning after December 15, 2022, and early adoption is permitted. For leases existing at, or entered into after, the beginning of the earliest comparative period presented in the consolidated financial statements, lessees and lessors must apply a modified retrospective transition approach. While the Company expects the adoption of this standard to result in an increase to the reported assets and liabilities, it has not yet determined the full impact the adoption of this standard will have on its consolidated financial statements and related disclosures.  However, the Company expects the adjustment to retained earnings to be immaterial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 12pt 0pt;">In June 2016, the FASB issued ASU No. 2016-13, <i style="font-style:italic;">Financial Instruments – Credit Losses</i> (Topic 326): <i style="font-style:italic;">Measurement of Credit Losses on Financial Instruments</i>, which changes the impairment model for most financial assets. The new model uses a forward-looking expected loss method, which will generally result in earlier recognition of allowances for losses. ASU 2016-13, as subsequently amended for various technical issues is effective for annual reporting periods beginning after December 15, 2022, for private entities and emerging growth companies. The Company is evaluating the impact of this standard on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">In December 2019, the FASB issued ASU 2019-12, <i style="font-style:italic;">Income Taxes</i> (Topic 740): <i style="font-style:italic;">Simplifying the Accounting for Income Taxes</i>, which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for private entities and emerging growth companies in fiscal years beginning after December 15, 2021, and interim periods within annual periods beginning after December 15, 2022, with early adoption permitted, including adoption in an interim period. The Company is evaluating the effect of adopting this new accounting guidance but does not expect adoption will have a material impact on its consolidated financial statements.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Note 4   Property and Equipment, Net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Property and equipment, net consists of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 17,195</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 14,163</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Software development costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 7,423</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,866</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,897</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,947</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 542</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 540</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total property and equipment, cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 27,057</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 21,516</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,964)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,465)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 16,093</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 13,051</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2022 and December 31, 2021, property and equipment, net located in the United States was $13.7 million and $10.4 million, respectively. The remainder was located in our various international locations. Included in property and equipment are the capitalized costs of software development. Software development costs capitalized during the three months ended June 30, 2022 and 2021 were $1.4 million and $501 thousand, respectively.  Software development costs capitalized during the six months ended June 30, 2022 and 2021 were $2.6 million and $1.0 million, respectively.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Depreciation and amortization expense related to property and equipment, excluding software development costs, was $849 thousand and $516 thousand for the three months ended June 30, 2022 and 2021, respectively. Depreciation and amortization expense related to property and equipment, excluding software development costs, was $1.6 million and $1.0 million for the six months ended June 30, 2022 and 2021, respectively. Amortization expense related to software development costs was $507 thousand and $305 thousand for the three months ended June 30, 2022 and 2021, respectively. Amortization expense related to software development costs was $915 thousand and $577 thousand for the six months ended June 30, 2022 and 2021, respectively.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Property and equipment, net consists of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 17,195</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 14,163</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Software development costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 7,423</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,866</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,897</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,947</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 542</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 540</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total property and equipment, cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 27,057</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 21,516</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,964)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,465)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 16,093</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 13,051</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p> 17195000 14163000 7423000 4866000 1897000 1947000 542000 540000 27057000 21516000 10964000 8465000 16093000 13051000 13700000 10400000 1400000 501000 2600000 1000000.0 849000 516000 1600000 1000000.0 507000 305000 915000 577000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 5   Accrued Expenses and Other Current Liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Accrued expenses and other current liabilities consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 7,041</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,180</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,354</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,182</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued taxes </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 568</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,216</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8,963</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,578</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Accrued expenses and other current liabilities consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 7,041</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,180</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,354</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,182</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued taxes </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 568</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,216</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8,963</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,578</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 7041000 3180000 1354000 1182000 568000 1216000 8963000 5578000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 6   Operating Leases and Service Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Operating Leases and Service Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company leases office space in various locations under operating lease agreements in the normal course of business, which expire at various dates through 2025. Certain operating leases are secured with cash security deposits or letters of credit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company has service agreements for the use of data processing facilities. These service agreements expire at various dates through 2023. Monthly base payments as of June 30, 2022 range from $6 thousand to $16 thousand. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Future aggregate minimum rental payments under the noncancelable operating leases and service agreements noted above, excluding the Company’s share of real estate taxes and other operating costs, are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022 (remaining six months)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,111</p></td></tr><tr><td style="vertical-align:bottom;width:85.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,344</p></td></tr><tr><td style="vertical-align:bottom;width:85.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,385</p></td></tr><tr><td style="vertical-align:bottom;width:85.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 901</p></td></tr><tr><td style="vertical-align:bottom;width:85.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8,741</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Total expense related to these lease agreements, which is included in Cost of revenues and Operating expenses, was $1.2 million and $2.2 million for the three and six months ended June 30, 2022, respectively, and $1.0 million and $1.9 million for the three and six months ended June 30, 2021, respectively.</p> 6000 16000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Future aggregate minimum rental payments under the noncancelable operating leases and service agreements noted above, excluding the Company’s share of real estate taxes and other operating costs, are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022 (remaining six months)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,111</p></td></tr><tr><td style="vertical-align:bottom;width:85.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,344</p></td></tr><tr><td style="vertical-align:bottom;width:85.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,385</p></td></tr><tr><td style="vertical-align:bottom;width:85.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 901</p></td></tr><tr><td style="vertical-align:bottom;width:85.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8,741</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">​</span></p> 2111000 3344000 2385000 901000 8741000 1200000 2200000 1000000.0 1900000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 7   Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company records accruals for contingencies when it is probable that a liability will be incurred, and the amount of loss can be reasonably estimated based on historical claim activity and loss development factors. No accruals for contingencies were recorded as of June 30, 2022 and December 31, 2021, respectively.</p> 0 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 8   Preferred Units, Stockholders’ Equity and Members’ Deficit</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Prior to the organizational restructuring consummated in connection with the Company’s IPO and the application of the net proceeds therefrom (the “Reorganization Transactions”), Enfusion Ltd. LLC was organized as a limited liability company owned by its members, each of whose membership interests consisted of an equal number of: (i) “Economic </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Units”, which represented a Member’s economic interest in Enfusion Ltd. LLC; and (ii) “Participation Units”, which represented a Member’s right to participate (vote) in the affairs of Enfusion Ltd. LLC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a limited liability company, the Enfusion Ltd. LLC issued more than one class of Units. The Class A Units were considered to be Members’ Equity, whereas all of the other Unit classes were considered to be Preferred Units because of provisions in the Company’s former Operating Agreement that conferred certain rights and privileges to the members owning these Units, such as voting rights, redemption rights and liquidation preferences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Holders of the Class C-1, C-2 and D Preferred Units had the option to require the Company to redeem their Units. In accordance with the guidance in ASC 480, <i style="font-style:italic;">Distinguishing Liabilities from Equity</i>, outstanding Class C-1, C-2 and D Preferred Units were classified outside of permanent equity and within temporary equity due to their optional redemption features and liquidation preferences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the Reorganization Transactions, the Amended and Restated Operating Agreement of Enfusion Ltd. LLC (the “LLC Operating Agreement”) was amended and restated to, among other things, modify its capital structure by reclassifying each of the outstanding Class A Units and C-1, C-2 and D Preferred Units into a new class of LLC interests (or “Common Units”) through a stock split on a 1,000,000 to 1 basis. The number of Common Units outstanding following the Reorganization Transaction reflect the 1,000,000 to 1 stock split. Pursuant to the adoption of the LLC Operating Agreement, Enfusion US 1, Inc., a newly-formed wholly owned subsidiary of Enfusion, Inc., was appointed the sole managing member of Enfusion Ltd. LLC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment and Restatement of Certificate of Incorporation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2021, the Company amended its certificate of incorporation. The amended and restated certificate of incorporation of Enfusion, Inc. provides for 1,000,000,000 authorized shares of Class A common stock, 150,000,000 authorized shares of Class B common stock and 100,000,000 shares of preferred stock. Each share of the Company’s Class A common stock is entitled to one vote per share and is not convertible into any other shares of the Company’s capital stock. Holders of shares of the Company’s Class A common stock are entitled to receive dividends when, as and if declared by the Company’s board of directors. Upon the Company’s liquidation, dissolution or winding up and after payment in full of all amounts required to be paid to creditors, and subject to the rights of the holders of one or more outstanding series of preferred stock, as applicable, having liquidation preferences, the holders of shares of the Company’s Class A common stock will be entitled to receive pro rata the Company’s remaining assets available for distribution. Each share of the Company’s Class B common stock is entitled to one vote per share and is not convertible or exchangeable for a share of Class A common stock or any other security. Holders of the Company’s Class B common stock do not have any right to receive dividends or to receive a distribution upon a liquidation, dissolution or winding up of Enfusion, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company’s board of directors has the authority, without further action by the Company’s stockholders, to issue up to 100,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of Class A common stock. As of June 30, 2022, the Company has not issued any shares of preferred stock nor has the Company’s board of directors established the rights and privileges related to any series of preferred stock.</p> 1000000 1000000 1000000000 150000000 100000000 1 1 100000000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note <b style="font-weight:bold;white-space:pre-wrap;">9 </b>Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company recognized total stock compensation expense for the three and six months ended June 30, 2022 of $7.7 million and $20.4 million, respectively.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In connection with obligations to issue Class A common stock to former holders of Award Units under the Company’s former Change in Control Bonus Plan, the Company paid approximately $1.4 million of tax withholding obligations for federal and state payroll taxes. Of that amount, $897 thousand related to employee payroll tax withholdings </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">and has accordingly been recorded as a reduction to additional paid-in capital. The Company’s stock compensation expense was recognized in the following captions within the consolidated statements of operations:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:59.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:16.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:16.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(in thousands)</p></td><td style="vertical-align:bottom;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">   </b></p></td><td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended June 30, 2022</b></p></td><td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended June 30, 2022</b></p></td></tr><tr><td style="vertical-align:top;width:59.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of revenues</p></td><td style="vertical-align:middle;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 341</p></td><td style="vertical-align:middle;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 695</p></td></tr><tr><td style="vertical-align:top;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,969</p></td><td style="vertical-align:middle;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 13,907</p></td></tr><tr><td style="vertical-align:top;width:59.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sales and marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,491</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,484</p></td></tr><tr><td style="vertical-align:top;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Technology and development</p></td><td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 867</p></td><td style="vertical-align:middle;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,264</p></td></tr><tr><td style="vertical-align:top;width:59.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total stock compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:16.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,668</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:16.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 20,350</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Total unrecognized stock compensation expense related to unvested restricted stock units (“RSUs”) and contingently issuable shares of Class A common stock that will vest within one year of the IPO contingent upon continued employment requirements (“Contingently Issuable Shares”) was $40.6 million as of June 30, 2022, which is expected to be recognized over a weighted-average period of 2.2 years from the date of grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the IPO, the Company adopted the 2021 Incentive Plan (the “Plan”). The Plan provides for grants of stock options, stock appreciation rights, restricted stock, restricted stock units, bonus stock, dividend equivalents, other stock-based awards, substitute awards, annual incentive awards and performance awards intended to align the interests of participants with those of the Company’s shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">During the three months ended June 30, 2022, there were 84,000 stock options granted under the Plan, at a weighted average exercise price of $9.86 per option.  As of June 30, 2022, there was approximately $523 thousand of unrecognized equity based compensation expense related to these stock options, which is expected to be recognized over a weighted-average period of approximately 3 years.  The total fair value of the stock options that vested in the three months ended June 30, 2022 was immaterial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The assumptions used for the options granted under the Plan during the three months ended June 30, 2022 were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:80.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:3.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:80.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assumptions</b></p></td><td style="vertical-align:middle;width:3.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:80.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:middle;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:16.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">64.54%</p></td></tr><tr><td style="vertical-align:middle;width:80.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term of award</p></td><td style="vertical-align:middle;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:16.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.5 years</p></td></tr><tr><td style="vertical-align:middle;width:80.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free rate</p></td><td style="vertical-align:middle;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:16.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.39%</p></td></tr><tr><td style="vertical-align:middle;width:80.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield </p></td><td style="vertical-align:middle;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:16.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0.00%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">In connection with the IPO, the Company also adopted the 2021 Employee Stock Purchase Plan (“2021 ESPP”). Under the 2021 ESPP, eligible employees may be granted options to purchase shares of Class A common stock at the lower of </span><span style="background:#ffffff;">85%</span><span style="background:#ffffff;"> of the fair market value of the stock at the time of grant or </span><span style="background:#ffffff;">85%</span><span style="background:#ffffff;"> of the fair market value at the time of exercise. As of June 30, 2022, </span><span style="background:#ffffff;">no</span><span style="background:#ffffff;"> options were granted to employees under the 2021 ESPP.</span></p> 7700000 20400000 1400000 897000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:59.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:16.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:16.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(in thousands)</p></td><td style="vertical-align:bottom;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">   </b></p></td><td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended June 30, 2022</b></p></td><td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended June 30, 2022</b></p></td></tr><tr><td style="vertical-align:top;width:59.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of revenues</p></td><td style="vertical-align:middle;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 341</p></td><td style="vertical-align:middle;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 695</p></td></tr><tr><td style="vertical-align:top;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,969</p></td><td style="vertical-align:middle;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 13,907</p></td></tr><tr><td style="vertical-align:top;width:59.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sales and marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,491</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,484</p></td></tr><tr><td style="vertical-align:top;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Technology and development</p></td><td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 867</p></td><td style="vertical-align:middle;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,264</p></td></tr><tr><td style="vertical-align:top;width:59.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total stock compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:16.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,668</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:16.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 20,350</p></td></tr></table> 341000 695000 4969000 13907000 1491000 3484000 867000 2264000 7668000 20350000 P1Y 40600000 P2Y2M12D 84000 9.86 523000 P3Y <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:80.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:3.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:80.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assumptions</b></p></td><td style="vertical-align:middle;width:3.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:80.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:middle;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:16.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">64.54%</p></td></tr><tr><td style="vertical-align:middle;width:80.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term of award</p></td><td style="vertical-align:middle;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:16.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.5 years</p></td></tr><tr><td style="vertical-align:middle;width:80.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free rate</p></td><td style="vertical-align:middle;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:16.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.39%</p></td></tr><tr><td style="vertical-align:middle;width:80.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield </p></td><td style="vertical-align:middle;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;width:16.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0.00%</p></td></tr></table> 0.6454 P6Y6M 0.0339 0.0000 0.85 0.85 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Note 10  Net Income (Loss) Per Class A Common Share</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Basic loss per share is computed by dividing net loss attributable to Enfusion, Inc. by the weighted-average number of shares of Class A common stock outstanding during the period. Diluted loss per share is computed giving effect to all potentially dilutive shares. Diluted loss per share for all periods presented is the same as basic loss per share as the inclusion of potentially issuable shares would be antidilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Prior to the IPO, the Enfusion, LLC membership structure included Common Units and multiple classes of Preferred Units. The Company analyzed the calculation of earnings per unit for periods prior to the IPO using the two-class method and determined that it resulted in values that would not be meaningful to the users of these Condensed Consolidated Financial Statements. Therefore, earnings per share information has not been presented for periods prior to the IPO on October 20, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A common stock is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:64.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:14.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:14.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months </b></p></td></tr><tr><td style="vertical-align:bottom;width:64.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(in thousands, except per share amounts)</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Ended June 30, 2022</b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Ended June 30, 2022</b></p></td></tr><tr><td style="vertical-align:top;width:64.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Numerator:</i></p></td><td style="vertical-align:top;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:64.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,125)</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (16,649)</p></td></tr><tr><td style="vertical-align:top;width:64.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Net loss attributable to non-controlling interests </p></td><td style="vertical-align:top;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,703</p></td><td style="vertical-align:top;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,962</p></td></tr><tr><td style="vertical-align:top;width:64.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss attributable to Enfusion, Inc.</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,422)</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,687)</p></td></tr><tr><td style="vertical-align:top;width:64.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adjustment to income (loss) attributable to common stockholders</p></td><td style="vertical-align:top;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (234)</p></td><td style="vertical-align:top;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (978)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:64.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator for Basic Earnings per Share</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,656)</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,665)</p></td></tr><tr><td style="vertical-align:top;width:64.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Denominator:</i></p></td><td style="vertical-align:top;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:64.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average shares of Class A common stock outstanding</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 66,287</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 65,935</p></td></tr><tr><td style="vertical-align:top;width:64.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested shares of Class A common stock and RSUs</p></td><td style="vertical-align:top;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 18,294</p></td><td style="vertical-align:top;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 18,054</p></td></tr><tr><td style="vertical-align:top;width:64.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average shares of Class A common stock outstanding--basic</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 84,581</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 83,989</p></td></tr><tr><td style="vertical-align:top;width:64.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss per share of Class A common stock--basic and diluted</b></p></td><td style="vertical-align:top;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_B_4Y9peNGEaf9e61QUigAw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:top;width:14.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.03)</p></td><td style="vertical-align:top;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_RhNbCPuOuUqMeZYDlyLfyw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:top;width:14.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.13)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">The following number of potentially dilutive shares were excluded from the calculation of diluted loss per share because the effect of including such potentially dilutive shares would have been antidilutive:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:64.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:14.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:14.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#0563c1;font-size:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#0563c1;font-size:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:16.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#0563c1;font-size:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:16.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months </b></p></td></tr><tr><td style="vertical-align:bottom;width:64.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(in thousands)</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Ended June 30, 2022</b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Ended June 30, 2022</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:64.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Class B common stock</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:top;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 46,770</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:top;width:14.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 47,121</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:64.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contingently issuable shares of Class A common stock</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 406</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 652</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:64.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock units</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,562</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,561</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:64.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 84</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 84</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:64.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 50,822</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:2.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 51,418</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">Shares of Class B common stock do not share in earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been presented. Shares of Class B common stock are, however, considered potentially dilutive shares of Class A common stock. After evaluating the potential dilutive effect under both the treasury stock method and if-converted method, shares of Class B common stock were determined to be anti-dilutive and have therefore been excluded from the computation of diluted earnings per share of Class A common stock.</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:64.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:14.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:14.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months </b></p></td></tr><tr><td style="vertical-align:bottom;width:64.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(in thousands, except per share amounts)</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Ended June 30, 2022</b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Ended June 30, 2022</b></p></td></tr><tr><td style="vertical-align:top;width:64.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Numerator:</i></p></td><td style="vertical-align:top;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:64.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,125)</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (16,649)</p></td></tr><tr><td style="vertical-align:top;width:64.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Net loss attributable to non-controlling interests </p></td><td style="vertical-align:top;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,703</p></td><td style="vertical-align:top;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,962</p></td></tr><tr><td style="vertical-align:top;width:64.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss attributable to Enfusion, Inc.</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,422)</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,687)</p></td></tr><tr><td style="vertical-align:top;width:64.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adjustment to income (loss) attributable to common stockholders</p></td><td style="vertical-align:top;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (234)</p></td><td style="vertical-align:top;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (978)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:64.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator for Basic Earnings per Share</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,656)</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,665)</p></td></tr><tr><td style="vertical-align:top;width:64.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Denominator:</i></p></td><td style="vertical-align:top;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:64.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average shares of Class A common stock outstanding</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 66,287</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 65,935</p></td></tr><tr><td style="vertical-align:top;width:64.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested shares of Class A common stock and RSUs</p></td><td style="vertical-align:top;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 18,294</p></td><td style="vertical-align:top;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 18,054</p></td></tr><tr><td style="vertical-align:top;width:64.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average shares of Class A common stock outstanding--basic</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 84,581</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 83,989</p></td></tr><tr><td style="vertical-align:top;width:64.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss per share of Class A common stock--basic and diluted</b></p></td><td style="vertical-align:top;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_B_4Y9peNGEaf9e61QUigAw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:top;width:14.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.03)</p></td><td style="vertical-align:top;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_RhNbCPuOuUqMeZYDlyLfyw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:top;width:14.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.13)</p></td></tr></table> -4125000 -16649000 -1703000 -6962000 -2422000 -9687000 -234000 -978000 -2656000 -10665000 66287000 65935000 18294000 18054000 84581000 83989000 -0.03 -0.13 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:64.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:14.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:14.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#0563c1;font-size:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#0563c1;font-size:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:16.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#0563c1;font-size:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:16.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months </b></p></td></tr><tr><td style="vertical-align:bottom;width:64.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(in thousands)</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Ended June 30, 2022</b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Ended June 30, 2022</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:64.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Class B common stock</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:top;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 46,770</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:top;width:14.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 47,121</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:64.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contingently issuable shares of Class A common stock</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 406</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 652</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:64.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock units</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,562</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,561</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:64.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 84</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 84</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:64.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 50,822</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:2.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:14.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 51,418</p></td></tr></table> 46770000 47121000 406000 652000 3562000 3561000 84000 84000 50822000 51418000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 11 Income Taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is taxed as a corporation for income tax purposes and is subject to federal, state, and local taxes on the income allocated to it from Enfusion Ltd. LLC based upon the Company’s economic interest in Enfusion Ltd. LLC. The Company is the sole managing member of Enfusion Ltd. LLC and, as a result, consolidates the financial results of Enfusion Ltd. LLC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Enfusion Ltd. LLC. is a limited liability company taxed as a partnership for income tax purposes. Enfusion Ltd. LLC does not pay any federal income taxes, as income or loss is included in the tax returns of the individual members. Additionally, certain wholly-owned entities taxed as corporations are subject to federal, state, and foreign income taxes in the jurisdictions in which they operate, and accruals for such taxes are included in the Condensed Consolidated Financial Statements. For periods prior to the IPO, the Company’s taxes represent those of Enfusion Ltd. LLC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">The Company’s effective tax rate for the three months ended June 30, 2022 and 2021 was </span><span style="background:#ffffff;">(5.6)%</span><span style="background:#ffffff;"> and </span><span style="background:#ffffff;">5.5%</span><span style="background:#ffffff;">, respectively. The Company’s effective tax rate for the six months ended June 30, 2022 and 2021 was </span><span style="background:#ffffff;">(2.3)%</span><span style="background:#ffffff;"> and </span><span style="background:#ffffff;">6.2%</span><span style="background:#ffffff;">, respectively. In the three and six months ending June 30, 2022, respectively, the Company’s effective tax rate differed from the U.S. statutory tax rate of </span><span style="background:#ffffff;">21%</span><span style="background:#ffffff;"> primarily due to non-controlling interest and having a full valuation allowance in the U.S. Conversely, in the three and six months ending June 30, 2021, respectively, the Company’s effective tax rate differed from the U.S. statutory tax rate of </span><span style="background:#ffffff;">21%</span><span style="background:#ffffff;"> primarily due to the pass-through income generated.  </span></p> -0.056 0.055 -0.023 0.062 0.21 0.21 0.21 0.21 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 12  Related Party Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Parties are considered to be related if one party has the ability to control or exercise significant influence over the other party in making financial or operating decisions. Since transactions with related parties may raise potential or actual conflicts of interest between the related party and the Company, upon the completion of the IPO the Company implemented a related party transaction policy that requires related party transactions to be reviewed and approved by its nominating and corporate governance committee.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company used the proceeds (net of underwriting discounts) from the issuance of 5,526,608 million shares in the IPO ($87.8 million) to purchase an equivalent number of Common Units from the Company’s Pre-IPO Common Unitholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">In connection with the IPO, the Company entered into the Tax Receivable Agreement with the Pre-IPO LLC Members, which provides for the payment by Enfusion Inc. of </span><span style="background:#ffffff;">85%</span><span style="background:#ffffff;"> of certain cash tax benefits that Enfusion, Inc. actually realizes, or in some cases is deemed to realize. As of June 30, 2022 and December 31, 2021, the Company has not recorded a liability under the Tax Receivable Agreement related to the tax benefits originating from the Reorganization Transactions, IPO and subsequent purchase of Enfusion Ltd. LLC units during the year ended December 31, 2021 as it is not probable that the Company will realize such tax benefits.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">On May 6, 2022, a Pre-IPO Common Unitholder delivered an exchange notice pursuant to Article XII of the LLC Operating Agreement, relating to the exchange of </span><span style="background:#ffffff;">1,401,818</span><span style="background:#ffffff;"> Common Units and an equal number of shares of class B common stock for an equal number of shares of Class A common stock. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Pursuant to the terms of the LLC Operating Agreement, the Pre-IPO Common Unitholder surrendered </span><span style="background:#ffffff;">1,401,818</span><span style="background:#ffffff;"> Common Units and an equal number of shares of Class B common stock. In connection therewith, the Company issued </span><span style="background:#ffffff;">1,401,818</span><span style="background:#ffffff;"> shares of Class A common stock to such Pre-IPO Common Unitholder, canceled an equal number of Class B Common Stock, and received an equal number of Common Units, increasing the Company’s ownership of Common Units by </span><span style="background:#ffffff;">1,401,818</span><span style="background:#ffffff;">.</span></p> 5526608 87800000 0.85 1401818 1401818 1401818 1401818 EXCEL 65 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 66 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 67 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 68 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 146 189 1 false 42 0 false 7 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://enfusion.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - Condensed Consolidated Interim Balance Sheets Sheet http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets Condensed Consolidated Interim Balance Sheets Statements 2 false false R3.htm 00105 - Statement - Condensed Consolidated Interim Balance Sheets (Parenthetical) Sheet http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheetsParenthetical Condensed Consolidated Interim Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - Condensed Consolidated Interim Statements of Operations Sheet http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations Condensed Consolidated Interim Statements of Operations Statements 4 false false R5.htm 00300 - Statement - Condensed Consolidated Interim Statements of Comprehensive (Loss) Income Sheet http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveLossIncome Condensed Consolidated Interim Statements of Comprehensive (Loss) Income Statements 5 false false R6.htm 00400 - Statement - Condensed Consolidated Interim Statements of Preferred Units, Stockholders' Equity and Members' Deficit Sheet http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit Condensed Consolidated Interim Statements of Preferred Units, Stockholders' Equity and Members' Deficit Statements 6 false false R7.htm 00500 - Statement - Condensed Consolidated Interim Statements of Cash Flows Sheet http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows Condensed Consolidated Interim Statements of Cash Flows Statements 7 false false R8.htm 10101 - Disclosure - Organization and Description of Business Sheet http://enfusion.com/role/DisclosureOrganizationAndDescriptionOfBusiness Organization and Description of Business Notes 8 false false R9.htm 10201 - Disclosure - Basis of Presentation Sheet http://enfusion.com/role/DisclosureBasisOfPresentation Basis of Presentation Notes 9 false false R10.htm 10301 - Disclosure - Summary of Significant Accounting Policies Sheet http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 10401 - Disclosure - Property and Equipment, Net Sheet http://enfusion.com/role/DisclosurePropertyAndEquipmentNet Property and Equipment, Net Notes 11 false false R12.htm 10501 - Disclosure - Accrued Expenses and Other Current Liabilities Sheet http://enfusion.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities Accrued Expenses and Other Current Liabilities Notes 12 false false R13.htm 10601 - Disclosure - Operating Leases and Service Agreements Sheet http://enfusion.com/role/DisclosureOperatingLeasesAndServiceAgreements Operating Leases and Service Agreements Notes 13 false false R14.htm 10701 - Disclosure - Commitments and Contingencies Sheet http://enfusion.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 14 false false R15.htm 10801 - Disclosure - Preferred Units, Stockholders' Equity and Members' Deficit Sheet http://enfusion.com/role/DisclosurePreferredUnitsStockholdersEquityAndMembersDeficit Preferred Units, Stockholders' Equity and Members' Deficit Notes 15 false false R16.htm 10901 - Disclosure - Stock-Based Compensation Sheet http://enfusion.com/role/DisclosureStockBasedCompensation Stock-Based Compensation Notes 16 false false R17.htm 11001 - Disclosure - Net Income (Loss) Per Class A Common Share Sheet http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShare Net Income (Loss) Per Class A Common Share Notes 17 false false R18.htm 11101 - Disclosure - Income Taxes Sheet http://enfusion.com/role/DisclosureIncomeTaxes Income Taxes Notes 18 false false R19.htm 11201 - Disclosure - Related Party Transactions Sheet http://enfusion.com/role/DisclosureRelatedPartyTransactions Related Party Transactions Notes 19 false false R20.htm 20302 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPolicies 20 false false R21.htm 30303 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPolicies 21 false false R22.htm 30403 - Disclosure - Property and Equipment, Net (Tables) Sheet http://enfusion.com/role/DisclosurePropertyAndEquipmentNetTables Property and Equipment, Net (Tables) Tables http://enfusion.com/role/DisclosurePropertyAndEquipmentNet 22 false false R23.htm 30503 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) Sheet http://enfusion.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables Accrued Expenses and Other Current Liabilities (Tables) Tables http://enfusion.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities 23 false false R24.htm 30603 - Disclosure - Operating Leases and Service Agreements (Tables) Sheet http://enfusion.com/role/DisclosureOperatingLeasesAndServiceAgreementsTables Operating Leases and Service Agreements (Tables) Tables http://enfusion.com/role/DisclosureOperatingLeasesAndServiceAgreements 24 false false R25.htm 30903 - Disclosure - Stock-Based Compensation (Tables) Sheet http://enfusion.com/role/DisclosureStockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://enfusion.com/role/DisclosureStockBasedCompensation 25 false false R26.htm 31003 - Disclosure - Net Income (Loss) Per Class A Common Share (Tables) Sheet http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareTables Net Income (Loss) Per Class A Common Share (Tables) Tables http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShare 26 false false R27.htm 40101 - Disclosure - Organization and Description of Business - IPO and reorganization (Details) Sheet http://enfusion.com/role/DisclosureOrganizationAndDescriptionOfBusinessIpoAndReorganizationDetails Organization and Description of Business - IPO and reorganization (Details) Details 27 false false R28.htm 40301 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) Sheet http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails Summary of Significant Accounting Policies - Narrative (Details) Details 28 false false R29.htm 40302 - Disclosure - Summary of Significant Accounting Policies - Disaggregation of revenue (Details) Sheet http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails Summary of Significant Accounting Policies - Disaggregation of revenue (Details) Details 29 false false R30.htm 40401 - Disclosure - Property and Equipment, Net (Details) Sheet http://enfusion.com/role/DisclosurePropertyAndEquipmentNetDetails Property and Equipment, Net (Details) Details http://enfusion.com/role/DisclosurePropertyAndEquipmentNetTables 30 false false R31.htm 40402 - Disclosure - Property and Equipment, Net - Narrative (Details) Sheet http://enfusion.com/role/DisclosurePropertyAndEquipmentNetNarrativeDetails Property and Equipment, Net - Narrative (Details) Details 31 false false R32.htm 40501 - Disclosure - Accrued Expenses and Other Current Liabilities (Details) Sheet http://enfusion.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails Accrued Expenses and Other Current Liabilities (Details) Details http://enfusion.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables 32 false false R33.htm 40601 - Disclosure - Operating Leases and Service Agreements (Details) Sheet http://enfusion.com/role/DisclosureOperatingLeasesAndServiceAgreementsDetails Operating Leases and Service Agreements (Details) Details http://enfusion.com/role/DisclosureOperatingLeasesAndServiceAgreementsTables 33 false false R34.htm 40701 - Disclosure - Commitments and Contingencies (Details) Sheet http://enfusion.com/role/DisclosureCommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://enfusion.com/role/DisclosureCommitmentsAndContingencies 34 false false R35.htm 40801 - Disclosure - Preferred Units Stockholders' Equity and Members' Deficit (Details) Sheet http://enfusion.com/role/DisclosurePreferredUnitsStockholdersEquityAndMembersDeficitDetails Preferred Units Stockholders' Equity and Members' Deficit (Details) Details 35 false false R36.htm 40901 - Disclosure - Stock-Based Compensation- Narratives (Details) Sheet http://enfusion.com/role/DisclosureStockBasedCompensationNarrativesDetails Stock-Based Compensation- Narratives (Details) Details 36 false false R37.htm 40902 - Disclosure - Stock-Based Compensation- Equity-Based Compensation (Details) Sheet http://enfusion.com/role/DisclosureStockBasedCompensationEquityBasedCompensationDetails Stock-Based Compensation- Equity-Based Compensation (Details) Details 37 false false R38.htm 40903 - Disclosure - Stock-based compensation - Assumptions for Performance-based shares (Details) Sheet http://enfusion.com/role/DisclosureStockBasedCompensationAssumptionsForPerformanceBasedSharesDetails Stock-based compensation - Assumptions for Performance-based shares (Details) Details 38 false false R39.htm 41001 - Disclosure - Net Income (Loss) Per Class A Common Share - Diluted net loss per common unit (Details) Sheet http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareDilutedNetLossPerCommonUnitDetails Net Income (Loss) Per Class A Common Share - Diluted net loss per common unit (Details) Details http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareTables 39 false false R40.htm 41002 - Disclosure - Net Income (Loss) Per Class A Common Share - Dilutive shares (Details) Sheet http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareDilutiveSharesDetails Net Income (Loss) Per Class A Common Share - Dilutive shares (Details) Details http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareTables 40 false false R41.htm 41101 - Disclosure - Income taxes - Narratives (Details) Sheet http://enfusion.com/role/DisclosureIncomeTaxesNarrativesDetails Income taxes - Narratives (Details) Details 41 false false R42.htm 41201 - Disclosure - Related Party Transactions (Details) Sheet http://enfusion.com/role/DisclosureRelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://enfusion.com/role/DisclosureRelatedPartyTransactions 42 false false All Reports Book All Reports enfn-20220630x10q.htm enfn-20220630.xsd enfn-20220630_cal.xml enfn-20220630_def.xml enfn-20220630_lab.xml enfn-20220630_pre.xml enfn-20220630xex10d1.htm enfn-20220630xex10d2.htm enfn-20220630xex10d3.htm enfn-20220630xex10d4.htm enfn-20220630xex10d5.htm enfn-20220630xex10d6.htm enfn-20220630xex10d7.htm enfn-20220630xex10d8.htm enfn-20220630xex31d1.htm enfn-20220630xex31d2.htm enfn-20220630xex32d1.htm enfn-20220630xex32d2.htm http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 71 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "enfn-20220630x10q.htm": { "axisCustom": 0, "axisStandard": 16, "contextCount": 146, "dts": { "calculationLink": { "local": [ "enfn-20220630_cal.xml" ] }, "definitionLink": { "local": [ "enfn-20220630_def.xml" ] }, "inline": { "local": [ "enfn-20220630x10q.htm" ] }, "labelLink": { "local": [ "enfn-20220630_lab.xml" ] }, "presentationLink": { "local": [ "enfn-20220630_pre.xml" ] }, "schema": { "local": [ "enfn-20220630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 321, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 11, "http://xbrl.sec.gov/dei/2021q4": 5, "total": 16 }, "keyCustom": 31, "keyStandard": 158, "memberCustom": 9, "memberStandard": 31, "nsprefix": "enfn", "nsuri": "http://enfusion.com/20220630", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://enfusion.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - Summary of Significant Accounting Policies", "role": "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - Property and Equipment, Net", "role": "http://enfusion.com/role/DisclosurePropertyAndEquipmentNet", "shortName": "Property and Equipment, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": null, "first": true, "lang": "en-US", "name": "enfn:AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - Accrued Expenses and Other Current Liabilities", "role": "http://enfusion.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities", "shortName": "Accrued Expenses and Other Current Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": null, "first": true, "lang": "en-US", "name": "enfn:AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": null, "first": true, "lang": "en-US", "name": "enfn:OperatingLeasesAndServiceAgreementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - Operating Leases and Service Agreements", "role": "http://enfusion.com/role/DisclosureOperatingLeasesAndServiceAgreements", "shortName": "Operating Leases and Service Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": null, "first": true, "lang": "en-US", "name": "enfn:OperatingLeasesAndServiceAgreementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - Commitments and Contingencies", "role": "http://enfusion.com/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10801 - Disclosure - Preferred Units, Stockholders' Equity and Members' Deficit", "role": "http://enfusion.com/role/DisclosurePreferredUnitsStockholdersEquityAndMembersDeficit", "shortName": "Preferred Units, Stockholders' Equity and Members' Deficit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10901 - Disclosure - Stock-Based Compensation", "role": "http://enfusion.com/role/DisclosureStockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11001 - Disclosure - Net Income (Loss) Per Class A Common Share", "role": "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShare", "shortName": "Net Income (Loss) Per Class A Common Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11101 - Disclosure - Income Taxes", "role": "http://enfusion.com/role/DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11201 - Disclosure - Related Party Transactions", "role": "http://enfusion.com/role/DisclosureRelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_0yQVxILzkEODifiArjO-jA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_T1A7dbDDv061l9_8w7bQzQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - Condensed Consolidated Interim Balance Sheets", "role": "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets", "shortName": "Condensed Consolidated Interim Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_0yQVxILzkEODifiArjO-jA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_T1A7dbDDv061l9_8w7bQzQ", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "20302 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30303 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30403 - Disclosure - Property and Equipment, Net (Tables)", "role": "http://enfusion.com/role/DisclosurePropertyAndEquipmentNetTables", "shortName": "Property and Equipment, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "enfn:AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": null, "first": true, "lang": "en-US", "name": "enfn:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30503 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)", "role": "http://enfusion.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables", "shortName": "Accrued Expenses and Other Current Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "enfn:AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": null, "first": true, "lang": "en-US", "name": "enfn:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "enfn:OperatingLeasesAndServiceAgreementsTextBlock", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": null, "first": true, "lang": "en-US", "name": "enfn:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesAndServiceAgreementsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30603 - Disclosure - Operating Leases and Service Agreements (Tables)", "role": "http://enfusion.com/role/DisclosureOperatingLeasesAndServiceAgreementsTables", "shortName": "Operating Leases and Service Agreements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "enfn:OperatingLeasesAndServiceAgreementsTextBlock", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": null, "first": true, "lang": "en-US", "name": "enfn:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesAndServiceAgreementsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30903 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://enfusion.com/role/DisclosureStockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31003 - Disclosure - Net Income (Loss) Per Class A Common Share (Tables)", "role": "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareTables", "shortName": "Net Income (Loss) Per Class A Common Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "us-gaap:NatureOfOperations", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": "INF", "first": true, "lang": null, "name": "enfn:NumberOfSubsidiaries", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_subsidiary_0kcsxQuKREOg3wyGW0b6Ww", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40101 - Disclosure - Organization and Description of Business - IPO and reorganization (Details)", "role": "http://enfusion.com/role/DisclosureOrganizationAndDescriptionOfBusinessIpoAndReorganizationDetails", "shortName": "Organization and Description of Business - IPO and reorganization (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:NatureOfOperations", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": "INF", "first": true, "lang": null, "name": "enfn:NumberOfSubsidiaries", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_subsidiary_0kcsxQuKREOg3wyGW0b6Ww", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "As_Of_12_31_2021_MSgG3HFPOEaj_wqMKckWCg", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_T1A7dbDDv061l9_8w7bQzQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)", "role": "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "shortName": "Summary of Significant Accounting Policies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "As_Of_12_31_2021_MSgG3HFPOEaj_wqMKckWCg", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_T1A7dbDDv061l9_8w7bQzQ", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_C2SKhcqptECcNx5vBGR-tQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_T1A7dbDDv061l9_8w7bQzQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40302 - Disclosure - Summary of Significant Accounting Policies - Disaggregation of revenue (Details)", "role": "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails", "shortName": "Summary of Significant Accounting Policies - Disaggregation of revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember__6JyrWOSOE2sBAKzviMMVg", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_T1A7dbDDv061l9_8w7bQzQ", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_MGsK0e_zv0Oc-RXmVxCgRA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_B4-0Oqs2xUW7vV8b4dkzPQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00105 - Statement - Condensed Consolidated Interim Balance Sheets (Parenthetical)", "role": "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Interim Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_MGsK0e_zv0Oc-RXmVxCgRA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_B4-0Oqs2xUW7vV8b4dkzPQ", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_0yQVxILzkEODifiArjO-jA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_T1A7dbDDv061l9_8w7bQzQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - Property and Equipment, Net (Details)", "role": "http://enfusion.com/role/DisclosurePropertyAndEquipmentNetDetails", "shortName": "Property and Equipment, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_0yQVxILzkEODifiArjO-jA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_T1A7dbDDv061l9_8w7bQzQ", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_0yQVxILzkEODifiArjO-jA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentNet", "reportCount": 1, "unitRef": "Unit_Standard_USD_T1A7dbDDv061l9_8w7bQzQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40402 - Disclosure - Property and Equipment, Net - Narrative (Details)", "role": "http://enfusion.com/role/DisclosurePropertyAndEquipmentNetNarrativeDetails", "shortName": "Property and Equipment, Net - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_C2SKhcqptECcNx5vBGR-tQ", "decimals": "-5", "lang": null, "name": "us-gaap:CapitalizedComputerSoftwareAdditions", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_T1A7dbDDv061l9_8w7bQzQ", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "enfn:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock", "enfn:AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_0yQVxILzkEODifiArjO-jA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedEmployeeBenefitsCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_T1A7dbDDv061l9_8w7bQzQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)", "role": "http://enfusion.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails", "shortName": "Accrued Expenses and Other Current Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "enfn:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock", "enfn:AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_0yQVxILzkEODifiArjO-jA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedEmployeeBenefitsCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_T1A7dbDDv061l9_8w7bQzQ", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "enfn:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesAndServiceAgreementsTableTextBlock", "enfn:OperatingLeasesAndServiceAgreementsTextBlock", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_0yQVxILzkEODifiArjO-jA", "decimals": "-3", "first": true, "lang": null, "name": "enfn:OperatingLeasesAndServiceAgreementsFutureMinimumPaymentsDueRemainderOfFiscalYear", "reportCount": 1, "unitRef": "Unit_Standard_USD_T1A7dbDDv061l9_8w7bQzQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40601 - Disclosure - Operating Leases and Service Agreements (Details)", "role": "http://enfusion.com/role/DisclosureOperatingLeasesAndServiceAgreementsDetails", "shortName": "Operating Leases and Service Agreements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "enfn:OperatingLeasesAndServiceAgreementsTextBlock", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_C2SKhcqptECcNx5vBGR-tQ", "decimals": "-5", "lang": null, "name": "us-gaap:LeaseAndRentalExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_T1A7dbDDv061l9_8w7bQzQ", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_0yQVxILzkEODifiArjO-jA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LossContingencyAccrualAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_T1A7dbDDv061l9_8w7bQzQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40701 - Disclosure - Commitments and Contingencies (Details)", "role": "http://enfusion.com/role/DisclosureCommitmentsAndContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_0yQVxILzkEODifiArjO-jA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LossContingencyAccrualAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_T1A7dbDDv061l9_8w7bQzQ", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "As_Of_10_31_2021_Hzou1vvwrECA4kVsNz2hXg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_ibq3XaMX2ECdogqcS32hWQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40801 - Disclosure - Preferred Units Stockholders' Equity and Members' Deficit (Details)", "role": "http://enfusion.com/role/DisclosurePreferredUnitsStockholdersEquityAndMembersDeficitDetails", "shortName": "Preferred Units Stockholders' Equity and Members' Deficit (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "As_Of_10_31_2021_Hzou1vvwrECA4kVsNz2hXg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_ibq3XaMX2ECdogqcS32hWQ", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_C2SKhcqptECcNx5vBGR-tQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "Unit_Standard_USD_T1A7dbDDv061l9_8w7bQzQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40901 - Disclosure - Stock-Based Compensation- Narratives (Details)", "role": "http://enfusion.com/role/DisclosureStockBasedCompensationNarrativesDetails", "shortName": "Stock-Based Compensation- Narratives (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": "-5", "lang": null, "name": "enfn:PaymentTotalTaxWithholdingShareBasedPaymentArrangement", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_T1A7dbDDv061l9_8w7bQzQ", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_C2SKhcqptECcNx5vBGR-tQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "Unit_Standard_USD_T1A7dbDDv061l9_8w7bQzQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40902 - Disclosure - Stock-Based Compensation- Equity-Based Compensation (Details)", "role": "http://enfusion.com/role/DisclosureStockBasedCompensationEquityBasedCompensationDetails", "shortName": "Stock-Based Compensation- Equity-Based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_enfn_RestrictedStockAndClassaCommonStockVestedMember_xi6nAh7TfkuVAEl1h87Tgg", "decimals": null, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "enfn:ScheduleOfShareBasedPaymentAwardValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ly3nnRk4RUOniBxtXSfagQ", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_lHIqXLA5d0GGFjYPNr1LIA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40903 - Disclosure - Stock-based compensation - Assumptions for Performance-based shares (Details)", "role": "http://enfusion.com/role/DisclosureStockBasedCompensationAssumptionsForPerformanceBasedSharesDetails", "shortName": "Stock-based compensation - Assumptions for Performance-based shares (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "enfn:ScheduleOfShareBasedPaymentAwardValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ly3nnRk4RUOniBxtXSfagQ", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_lHIqXLA5d0GGFjYPNr1LIA", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_C2SKhcqptECcNx5vBGR-tQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_T1A7dbDDv061l9_8w7bQzQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41001 - Disclosure - Net Income (Loss) Per Class A Common Share - Diluted net loss per common unit (Details)", "role": "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareDilutedNetLossPerCommonUnitDetails", "shortName": "Net Income (Loss) Per Class A Common Share - Diluted net loss per common unit (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_C2SKhcqptECcNx5vBGR-tQ", "decimals": "-3", "lang": null, "name": "enfn:AdjustmentsToNetIncomeLossAttributableToCommonStockholders", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_T1A7dbDDv061l9_8w7bQzQ", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_C2SKhcqptECcNx5vBGR-tQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_T1A7dbDDv061l9_8w7bQzQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - Condensed Consolidated Interim Statements of Operations", "role": "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations", "shortName": "Condensed Consolidated Interim Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_C2SKhcqptECcNx5vBGR-tQ", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfRevenue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_T1A7dbDDv061l9_8w7bQzQ", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_C2SKhcqptECcNx5vBGR-tQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_ibq3XaMX2ECdogqcS32hWQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41002 - Disclosure - Net Income (Loss) Per Class A Common Share - Dilutive shares (Details)", "role": "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareDilutiveSharesDetails", "shortName": "Net Income (Loss) Per Class A Common Share - Dilutive shares (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_C2SKhcqptECcNx5vBGR-tQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_ibq3XaMX2ECdogqcS32hWQ", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_C2SKhcqptECcNx5vBGR-tQ", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_lHIqXLA5d0GGFjYPNr1LIA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41101 - Disclosure - Income taxes - Narratives (Details)", "role": "http://enfusion.com/role/DisclosureIncomeTaxesNarrativesDetails", "shortName": "Income taxes - Narratives (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_C2SKhcqptECcNx5vBGR-tQ", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_lHIqXLA5d0GGFjYPNr1LIA", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_10_20_2021_To_10_20_2021_-uAzNGrWZEKF3CM_i33r9A", "decimals": "2", "first": true, "lang": null, "name": "enfn:PercentageOfEntitySShareOfTaxBenefitsUnderTaxReceivableAgreement", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_lHIqXLA5d0GGFjYPNr1LIA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41201 - Disclosure - Related Party Transactions (Details)", "role": "http://enfusion.com/role/DisclosureRelatedPartyTransactionsDetails", "shortName": "Related Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_10_20_2021_To_10_20_2021_-uAzNGrWZEKF3CM_i33r9A", "decimals": "2", "first": true, "lang": null, "name": "enfn:PercentageOfEntitySShareOfTaxBenefitsUnderTaxReceivableAgreement", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_lHIqXLA5d0GGFjYPNr1LIA", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_C2SKhcqptECcNx5vBGR-tQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_T1A7dbDDv061l9_8w7bQzQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - Condensed Consolidated Interim Statements of Comprehensive (Loss) Income", "role": "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveLossIncome", "shortName": "Condensed Consolidated Interim Statements of Comprehensive (Loss) Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_C2SKhcqptECcNx5vBGR-tQ", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_T1A7dbDDv061l9_8w7bQzQ", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_L6kRO_wuQUeS_O0s2ysJNA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_T1A7dbDDv061l9_8w7bQzQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - Condensed Consolidated Interim Statements of Preferred Units, Stockholders' Equity and Members' Deficit", "role": "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit", "shortName": "Condensed Consolidated Interim Statements of Preferred Units, Stockholders' Equity and Members' Deficit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_MemberUnitsMember_L6kRO_wuQUeS_O0s2ysJNA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_T1A7dbDDv061l9_8w7bQzQ", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_T1A7dbDDv061l9_8w7bQzQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00500 - Statement - Condensed Consolidated Interim Statements of Cash Flows", "role": "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows", "shortName": "Condensed Consolidated Interim Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_T1A7dbDDv061l9_8w7bQzQ", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - Organization and Description of Business", "role": "http://enfusion.com/role/DisclosureOrganizationAndDescriptionOfBusiness", "shortName": "Organization and Description of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - Basis of Presentation", "role": "http://enfusion.com/role/DisclosureBasisOfPresentation", "shortName": "Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "enfn-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_9GJASBKxzkGvZHk9f2VEJQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 42, "tag": { "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://enfusion.com/role/DisclosurePropertyAndEquipmentNetNarrativeDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r403" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r407" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r402" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "enfn_AccruedExpensesAndOtherLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://enfusion.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accrued expenses and other current liabilities as on date.", "label": "Accrued Expenses And Other Liabilities, Current", "terseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Total accrued expenses and other current liabilities" } } }, "localname": "AccruedExpensesAndOtherLiabilitiesCurrent", "nsuri": "http://enfusion.com/20220630", "presentation": [ "http://enfusion.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails", "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets" ], "xbrltype": "monetaryItemType" }, "enfn_AccruedExpensesCurrent": { "auth_ref": [], "calculation": { "http://enfusion.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 2.0, "parentTag": "enfn_AccruedExpensesAndOtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of accrued expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Expenses, Current", "terseLabel": "Accrued expenses" } } }, "localname": "AccruedExpensesCurrent", "nsuri": "http://enfusion.com/20220630", "presentation": [ "http://enfusion.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "enfn_AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.", "label": "Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "terseLabel": "Accrued Expenses and Other Current Liabilities" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "nsuri": "http://enfusion.com/20220630", "presentation": [ "http://enfusion.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" ], "xbrltype": "textBlockItemType" }, "enfn_AdjustmentsToNetIncomeLossAttributableToCommonStockholders": { "auth_ref": [], "calculation": { "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareDilutedNetLossPerCommonUnitDetails": { "order": 1.0, "parentTag": "enfn_NetIncomeLossAttributableToCommonStockholdersNetOfAdjustments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of adjustments to income (loss) attributable to common stockholders.", "label": "Adjustments To Net Income (Loss) Attributable To Common Stockholders", "terseLabel": "Adjustment to income (loss) attributable to common stockholders" } } }, "localname": "AdjustmentsToNetIncomeLossAttributableToCommonStockholders", "nsuri": "http://enfusion.com/20220630", "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareDilutedNetLossPerCommonUnitDetails" ], "xbrltype": "monetaryItemType" }, "enfn_CommonUnitsExchanged": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of common units exchanged.", "label": "Common Units Exchanged", "terseLabel": "Common units exchanged (in shares)" } } }, "localname": "CommonUnitsExchanged", "nsuri": "http://enfusion.com/20220630", "presentation": [ "http://enfusion.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "sharesItemType" }, "enfn_CommonUnitsSurrendered": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of common units surrendered.", "label": "Common Units Surrendered", "terseLabel": "Common units surrendered (in shares)" } } }, "localname": "CommonUnitsSurrendered", "nsuri": "http://enfusion.com/20220630", "presentation": [ "http://enfusion.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "sharesItemType" }, "enfn_ContingentlyIssuableClassCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to contingently issuable class a common stock.", "label": "Contingently issuable shares of Class A common stock" } } }, "localname": "ContingentlyIssuableClassCommonStockMember", "nsuri": "http://enfusion.com/20220630", "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareDilutiveSharesDetails" ], "xbrltype": "domainItemType" }, "enfn_DistributionMadeToPartners": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of distributions made to partners.", "label": "Distribution Made to Partners", "negatedLabel": "Distributions to members" } } }, "localname": "DistributionMadeToPartners", "nsuri": "http://enfusion.com/20220630", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "xbrltype": "monetaryItemType" }, "enfn_EmployeeStockPurchasePlan2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the 2021 Employee Stock Purchase Plan.", "label": "2021 ESPP" } } }, "localname": "EmployeeStockPurchasePlan2021Member", "nsuri": "http://enfusion.com/20220630", "presentation": [ "http://enfusion.com/role/DisclosureStockBasedCompensationNarrativesDetails" ], "xbrltype": "domainItemType" }, "enfn_EnfusionLtd.LlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Enfusion Ltd. LLC, a Delaware limited liability, and its wholly owned subsidiaries.", "label": "Enfusion LLC" } } }, "localname": "EnfusionLtd.LlcMember", "nsuri": "http://enfusion.com/20220630", "presentation": [ "http://enfusion.com/role/DisclosureOrganizationAndDescriptionOfBusinessIpoAndReorganizationDetails" ], "xbrltype": "domainItemType" }, "enfn_IncreaseInCommonUnits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of increase in common units.", "label": "Increase in Common Units", "terseLabel": "Increase in common units (in shares)" } } }, "localname": "IncreaseInCommonUnits", "nsuri": "http://enfusion.com/20220630", "presentation": [ "http://enfusion.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "sharesItemType" }, "enfn_MajorCustomerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to major customers.", "label": "Major Customer" } } }, "localname": "MajorCustomerMember", "nsuri": "http://enfusion.com/20220630", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "enfn_ManagedServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information relating to managed services.", "label": "Managed services" } } }, "localname": "ManagedServicesMember", "nsuri": "http://enfusion.com/20220630", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations" ], "xbrltype": "domainItemType" }, "enfn_NetIncomeLossAttributableToCommonStockholdersNetOfAdjustments": { "auth_ref": [], "calculation": { "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareDilutedNetLossPerCommonUnitDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) attributable to common stockholders net of adjustments.", "label": "Net Income (Loss) Attributable To Common Stockholders Net Of Adjustments", "totalLabel": "Numerator for Basic Earnings per Share" } } }, "localname": "NetIncomeLossAttributableToCommonStockholdersNetOfAdjustments", "nsuri": "http://enfusion.com/20220630", "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareDilutedNetLossPerCommonUnitDetails" ], "xbrltype": "monetaryItemType" }, "enfn_NetIncomeLossExcludingPreferredUnits": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to net income (loss) excluding preferred units.", "label": "Net Income (Loss) Excluding Preferred Units", "verboseLabel": "Net Income (Loss)" } } }, "localname": "NetIncomeLossExcludingPreferredUnits", "nsuri": "http://enfusion.com/20220630", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "xbrltype": "monetaryItemType" }, "enfn_NumberOfCustomers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Customers.", "label": "Number of Customers", "terseLabel": "Number of customers" } } }, "localname": "NumberOfCustomers", "nsuri": "http://enfusion.com/20220630", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "enfn_NumberOfSubsidiaries": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of wholly-owned subsidiaries.", "label": "Number Of Subsidiaries", "terseLabel": "Number of wholly-owned subsidiaries." } } }, "localname": "NumberOfSubsidiaries", "nsuri": "http://enfusion.com/20220630", "presentation": [ "http://enfusion.com/role/DisclosureOrganizationAndDescriptionOfBusinessIpoAndReorganizationDetails" ], "xbrltype": "integerItemType" }, "enfn_NumberOfVotingRights": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Voting Rights", "label": "Number of Voting Rights", "terseLabel": "Number of Voting Rights" } } }, "localname": "NumberOfVotingRights", "nsuri": "http://enfusion.com/20220630", "presentation": [ "http://enfusion.com/role/DisclosurePreferredUnitsStockholdersEquityAndMembersDeficitDetails" ], "xbrltype": "integerItemType" }, "enfn_OperatingLeasesAndServiceAgreementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Operating Leases and Service Agreements" } } }, "localname": "OperatingLeasesAndServiceAgreementsAbstract", "nsuri": "http://enfusion.com/20220630", "xbrltype": "stringItemType" }, "enfn_OperatingLeasesAndServiceAgreementsFutureMinimumPaymentsDue": { "auth_ref": [], "calculation": { "http://enfusion.com/role/DisclosureOperatingLeasesAndServiceAgreementsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases and service agreements having a term in excess of one year.", "label": "Operating Leases and Service Agreements, Future Minimum Payments Due", "totalLabel": "Total" } } }, "localname": "OperatingLeasesAndServiceAgreementsFutureMinimumPaymentsDue", "nsuri": "http://enfusion.com/20220630", "presentation": [ "http://enfusion.com/role/DisclosureOperatingLeasesAndServiceAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "enfn_OperatingLeasesAndServiceAgreementsFutureMinimumPaymentsDueFiscalYearMaturityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Operating Leases and Service Agreements, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]", "terseLabel": "Total" } } }, "localname": "OperatingLeasesAndServiceAgreementsFutureMinimumPaymentsDueFiscalYearMaturityAbstract", "nsuri": "http://enfusion.com/20220630", "presentation": [ "http://enfusion.com/role/DisclosureOperatingLeasesAndServiceAgreementsDetails" ], "xbrltype": "stringItemType" }, "enfn_OperatingLeasesAndServiceAgreementsFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [], "calculation": { "http://enfusion.com/role/DisclosureOperatingLeasesAndServiceAgreementsDetails": { "order": 4.0, "parentTag": "enfn_OperatingLeasesAndServiceAgreementsFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases and service agreements having a term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases and Service Agreements, Future Minimum Payments, Due in Three Years", "terseLabel": "2025" } } }, "localname": "OperatingLeasesAndServiceAgreementsFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://enfusion.com/20220630", "presentation": [ "http://enfusion.com/role/DisclosureOperatingLeasesAndServiceAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "enfn_OperatingLeasesAndServiceAgreementsFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [], "calculation": { "http://enfusion.com/role/DisclosureOperatingLeasesAndServiceAgreementsDetails": { "order": 3.0, "parentTag": "enfn_OperatingLeasesAndServiceAgreementsFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases and service agreements having a term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases and Service Agreements, Future Minimum Payments, Due in Two Years", "terseLabel": "2024" } } }, "localname": "OperatingLeasesAndServiceAgreementsFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://enfusion.com/20220630", "presentation": [ "http://enfusion.com/role/DisclosureOperatingLeasesAndServiceAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "enfn_OperatingLeasesAndServiceAgreementsFutureMinimumPaymentsDueNextTwelveMonths": { "auth_ref": [], "calculation": { "http://enfusion.com/role/DisclosureOperatingLeasesAndServiceAgreementsDetails": { "order": 2.0, "parentTag": "enfn_OperatingLeasesAndServiceAgreementsFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases and service agreements having a term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases and Service Agreements, Future Minimum Payments Due, Next Twelve Months", "terseLabel": "2023" } } }, "localname": "OperatingLeasesAndServiceAgreementsFutureMinimumPaymentsDueNextTwelveMonths", "nsuri": "http://enfusion.com/20220630", "presentation": [ "http://enfusion.com/role/DisclosureOperatingLeasesAndServiceAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "enfn_OperatingLeasesAndServiceAgreementsFutureMinimumPaymentsDueRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://enfusion.com/role/DisclosureOperatingLeasesAndServiceAgreementsDetails": { "order": 1.0, "parentTag": "enfn_OperatingLeasesAndServiceAgreementsFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases and service agreements having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases and Service Agreements, Future Minimum Payments Due, Remainder of Fiscal Year", "terseLabel": "2022 (remaining six months)" } } }, "localname": "OperatingLeasesAndServiceAgreementsFutureMinimumPaymentsDueRemainderOfFiscalYear", "nsuri": "http://enfusion.com/20220630", "presentation": [ "http://enfusion.com/role/DisclosureOperatingLeasesAndServiceAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "enfn_OperatingLeasesAndServiceAgreementsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Leases and Service Agreements [Line Items]", "terseLabel": "Operating Leases and Service Agreements" } } }, "localname": "OperatingLeasesAndServiceAgreementsLineItems", "nsuri": "http://enfusion.com/20220630", "presentation": [ "http://enfusion.com/role/DisclosureOperatingLeasesAndServiceAgreementsDetails" ], "xbrltype": "stringItemType" }, "enfn_OperatingLeasesAndServiceAgreementsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to operating leases and service agreements.", "label": "Operating Leases and Service Agreements [Table]" } } }, "localname": "OperatingLeasesAndServiceAgreementsTable", "nsuri": "http://enfusion.com/20220630", "presentation": [ "http://enfusion.com/role/DisclosureOperatingLeasesAndServiceAgreementsDetails" ], "xbrltype": "stringItemType" }, "enfn_OperatingLeasesAndServiceAgreementsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases and service agreements.", "label": "Operating Leases and Service Agreements [Text Block]", "terseLabel": "Operating Leases and Service Agreements" } } }, "localname": "OperatingLeasesAndServiceAgreementsTextBlock", "nsuri": "http://enfusion.com/20220630", "presentation": [ "http://enfusion.com/role/DisclosureOperatingLeasesAndServiceAgreements" ], "xbrltype": "textBlockItemType" }, "enfn_OrganizationAndDescriptionOfBusinessAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Organization and Description of Business" } } }, "localname": "OrganizationAndDescriptionOfBusinessAbstract", "nsuri": "http://enfusion.com/20220630", "xbrltype": "stringItemType" }, "enfn_OtherServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information relating to other services.", "label": "Other" } } }, "localname": "OtherServicesMember", "nsuri": "http://enfusion.com/20220630", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations" ], "xbrltype": "domainItemType" }, "enfn_PaymentTotalTaxWithholdingShareBasedPaymentArrangement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of aggregate cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Total Tax Withholding, Share-based Payment Arrangement", "terseLabel": "Payment of tax withholding obligations for federal payroll taxes" } } }, "localname": "PaymentTotalTaxWithholdingShareBasedPaymentArrangement", "nsuri": "http://enfusion.com/20220630", "presentation": [ "http://enfusion.com/role/DisclosureStockBasedCompensationNarrativesDetails" ], "xbrltype": "monetaryItemType" }, "enfn_PaymentsToAcquireNewlyIssuedCommonUnits": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire newly issued common units from the limited liability company.", "label": "Payments To Acquire Newly Issued Common Units", "terseLabel": "Payments to acquire newly issued common units" } } }, "localname": "PaymentsToAcquireNewlyIssuedCommonUnits", "nsuri": "http://enfusion.com/20220630", "presentation": [ "http://enfusion.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "enfn_PercentageOfEntitySShareOfTaxBenefitsUnderTaxReceivableAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percent of entity's share of tax benefits.", "label": "Percentage of Entity's Share of Tax Benefits Under Tax Receivable Agreement", "terseLabel": "Percentage of Entity's Share of Tax Benefits Under Tax Receivable Agreement" } } }, "localname": "PercentageOfEntitySShareOfTaxBenefitsUnderTaxReceivableAgreement", "nsuri": "http://enfusion.com/20220630", "presentation": [ "http://enfusion.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "percentItemType" }, "enfn_PlatformSubscriptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information relating to platform subscriptions.", "label": "Platform subscriptions" } } }, "localname": "PlatformSubscriptionsMember", "nsuri": "http://enfusion.com/20220630", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations" ], "xbrltype": "domainItemType" }, "enfn_PreferredUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to preferred units", "label": "Preferred Units" } } }, "localname": "PreferredUnitsMember", "nsuri": "http://enfusion.com/20220630", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "xbrltype": "domainItemType" }, "enfn_PurchaseOfCommonUnits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase of common units from common unit holders.", "label": "Purchase Of Common Units", "terseLabel": "Purchase of Common Units" } } }, "localname": "PurchaseOfCommonUnits", "nsuri": "http://enfusion.com/20220630", "presentation": [ "http://enfusion.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "sharesItemType" }, "enfn_RestrictedStockAndClassaCommonStockVestedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Restricted Stock And Class A Common Stock Vested.", "label": "Restricted Stock Units And Class A Common Stock Vested" } } }, "localname": "RestrictedStockAndClassaCommonStockVestedMember", "nsuri": "http://enfusion.com/20220630", "presentation": [ "http://enfusion.com/role/DisclosureStockBasedCompensationEquityBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "enfn_RestrictedStockSharesIssuedUponExchangeOfSharesInShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of restricted stock issued upon exchange of shares.", "label": "Restricted Stock, Shares Issued Upon Exchange of Shares (in Shares)", "verboseLabel": "Share exchange (in shares)" } } }, "localname": "RestrictedStockSharesIssuedUponExchangeOfSharesInShares", "nsuri": "http://enfusion.com/20220630", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "xbrltype": "sharesItemType" }, "enfn_RestrictedStockSharesIssuedUponExchangeOfSharesValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of restricted stock issued upon exchange of shares.", "label": "Restricted Stock, Shares Issued Upon Exchange of Shares, Value", "terseLabel": "Share exchange" } } }, "localname": "RestrictedStockSharesIssuedUponExchangeOfSharesValue", "nsuri": "http://enfusion.com/20220630", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "xbrltype": "monetaryItemType" }, "enfn_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of accrued expenses and other current liabilities.", "label": "Schedule of Accrued Expenses And Other Current Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses and other current liabilities" } } }, "localname": "ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock", "nsuri": "http://enfusion.com/20220630", "presentation": [ "http://enfusion.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "enfn_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesAndServiceAgreementsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases and service agreements.", "label": "Schedule of Future Minimum Rental Payments for Operating Leases and Service Agreements [Table Text Block]", "terseLabel": "Schedule of future aggregate minimum rental payments" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesAndServiceAgreementsTableTextBlock", "nsuri": "http://enfusion.com/20220630", "presentation": [ "http://enfusion.com/role/DisclosureOperatingLeasesAndServiceAgreementsTables" ], "xbrltype": "textBlockItemType" }, "enfn_ScheduleOfShareBasedPaymentAwardValuationAssumptionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of share-based award, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardValuationAssumptionsTableTextBlock", "nsuri": "http://enfusion.com/20220630", "presentation": [ "http://enfusion.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "enfn_ServiceAgreementsMonthlyBasePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of monthly base payments under service agreements.", "label": "Service Agreements, Monthly Base Payments", "terseLabel": "Monthly base payments" } } }, "localname": "ServiceAgreementsMonthlyBasePayments", "nsuri": "http://enfusion.com/20220630", "presentation": [ "http://enfusion.com/role/DisclosureOperatingLeasesAndServiceAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "enfn_TechnologyAndDevelopmentExpense": { "auth_ref": [], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense relating to technology and development during the period.", "label": "Technology And Development Expense", "terseLabel": "Technology and development" } } }, "localname": "TechnologyAndDevelopmentExpense", "nsuri": "http://enfusion.com/20220630", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "enfn_TemporaryEquityDistributions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in temporary equity from distributions.", "label": "Temporary Equity, Distributions", "negatedLabel": "Distributions to members" } } }, "localname": "TemporaryEquityDistributions", "nsuri": "http://enfusion.com/20220630", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "xbrltype": "monetaryItemType" }, "srt_AmericasMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Americas" } } }, "localname": "AmericasMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_AsiaPacificMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Asia Pacific (APAC)" } } }, "localname": "AsiaPacificMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r158", "r236", "r239", "r371" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r194", "r201", "r246", "r247", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r368", "r372", "r396", "r397" ], "lang": { "en-us": { "role": { "label": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureOperatingLeasesAndServiceAgreementsDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r194", "r201", "r246", "r247", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r368", "r372", "r396", "r397" ], "lang": { "en-us": { "role": { "label": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureOperatingLeasesAndServiceAgreementsDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r158", "r236", "r239", "r371" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureOrganizationAndDescriptionOfBusinessIpoAndReorganizationDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureOrganizationAndDescriptionOfBusinessIpoAndReorganizationDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r155", "r236", "r237", "r339", "r367", "r369" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r155", "r236", "r237", "r339", "r367", "r369" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r194", "r201", "r245", "r246", "r247", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r368", "r372", "r396", "r397" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureOperatingLeasesAndServiceAgreementsDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r194", "r201", "r245", "r246", "r247", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r368", "r372", "r396", "r397" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureOperatingLeasesAndServiceAgreementsDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r156", "r157", "r236", "r238", "r370", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosurePropertyAndEquipmentNetNarrativeDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r156", "r157", "r236", "r238", "r370", "r381", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosurePropertyAndEquipmentNetNarrativeDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r29", "r331" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r382" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r5", "r18", "r159", "r160" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "auth_ref": [ "r10", "r11", "r32" ], "calculation": { "http://enfusion.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 1.0, "parentTag": "enfn_AccruedExpensesAndOtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Employee Benefits, Current", "terseLabel": "Accrued compensation" } } }, "localname": "AccruedEmployeeBenefitsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Expenses and Other Current Liabilities" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r27", "r173" ], "calculation": { "http://enfusion.com/role/DisclosurePropertyAndEquipmentNetDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Less accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r21", "r43", "r44", "r45", "r355", "r377", "r378" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r42", "r45", "r51", "r52", "r53", "r93", "r94", "r95", "r297", "r373", "r374", "r408" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r19", "r267", "r331" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r93", "r94", "r95", "r264", "r265", "r266", "r304" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net (loss) income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r249", "r261", "r269" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "verboseLabel": "Total stock compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureStockBasedCompensationEquityBasedCompensationDetails", "http://enfusion.com/role/DisclosureStockBasedCompensationNarrativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r62", "r76", "r195", "r321" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of debt-related costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r116" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities amount" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareDilutiveSharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r116" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareDilutiveSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r116" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareDilutiveSharesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r89", "r144", "r147", "r153", "r166", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r291", "r298", "r309", "r329", "r331", "r341", "r354" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r7", "r9", "r39", "r89", "r166", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r291", "r298", "r309", "r329", "r331" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:", "terseLabel": "Current Assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r251", "r263" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureStockBasedCompensationAssumptionsForPerformanceBasedSharesDetails", "http://enfusion.com/role/DisclosureStockBasedCompensationEquityBasedCompensationDetails", "http://enfusion.com/role/DisclosureStockBasedCompensationNarrativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r80", "r81", "r82" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Accrued Property, Plant and Equipment" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalUnitsMember": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Type of ownership interest in a corporation. Class of capital units or capital shares.", "label": "Capital Units" } } }, "localname": "CapitalUnitsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosurePreferredUnitsStockholdersEquityAndMembersDeficitDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CapitalizedComputerSoftwareAdditions": { "auth_ref": [ "r170" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Additions made to capitalized computer software costs during the period.", "label": "Capitalized Computer Software, Additions", "terseLabel": "Capitalized software development costs" } } }, "localname": "CapitalizedComputerSoftwareAdditions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosurePropertyAndEquipmentNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedComputerSoftwareAmortization1": { "auth_ref": [ "r398", "r399" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for amortization of capitalized computer software costs.", "label": "Capitalized Computer Software, Amortization", "terseLabel": "Amortization expense related to software development costs" } } }, "localname": "CapitalizedComputerSoftwareAmortization1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosurePropertyAndEquipmentNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r4", "r25", "r78" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r72", "r78", "r83" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, end of period", "periodStartLabel": "Cash, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r72", "r312" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosure of non-cash investing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r87", "r89", "r109", "r110", "r111", "r113", "r115", "r123", "r124", "r125", "r166", "r183", "r187", "r188", "r189", "r192", "r193", "r199", "r200", "r204", "r208", "r309", "r405" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosurePreferredUnitsStockholdersEquityAndMembersDeficitDetails", "http://enfusion.com/role/DisclosureRelatedPartyTransactionsDetails", "http://enfusion.com/role/DisclosureStockBasedCompensationNarrativesDetails", "http://enfusion.com/role/DocumentDocumentAndEntityInformation", "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets", "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheetsParenthetical", "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosurePreferredUnitsStockholdersEquityAndMembersDeficitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r178", "r179", "r180", "r182", "r383" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Class A" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosurePreferredUnitsStockholdersEquityAndMembersDeficitDetails", "http://enfusion.com/role/DisclosureRelatedPartyTransactionsDetails", "http://enfusion.com/role/DisclosureStockBasedCompensationNarrativesDetails", "http://enfusion.com/role/DocumentDocumentAndEntityInformation", "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets", "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheetsParenthetical", "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.", "label": "Common Class B" } } }, "localname": "CommonClassBMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareDilutiveSharesDetails", "http://enfusion.com/role/DisclosurePreferredUnitsStockholdersEquityAndMembersDeficitDetails", "http://enfusion.com/role/DocumentDocumentAndEntityInformation", "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets", "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheetsParenthetical", "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r93", "r94", "r304" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DocumentDocumentAndEntityInformation", "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "verboseLabel": "Common stock par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosurePreferredUnitsStockholdersEquityAndMembersDeficitDetails", "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r17", "r215" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r17", "r331" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r47", "r49", "r50", "r59", "r349", "r363" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveLossIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive (loss) income attributable to Enfusion, Inc." } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveLossIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "auth_ref": [ "r47", "r49", "r58", "r289", "r290", "r302", "r348", "r362" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveLossIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "terseLabel": "Comprehensive loss attributable to non-controlling interests" } } }, "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveLossIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r47", "r49", "r57", "r288", "r302", "r347", "r361" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveLossIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Total other comprehensive (loss) income" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveLossIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer equipment and software" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r133", "r134", "r158", "r307", "r308", "r382" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r133", "r134", "r158", "r307", "r308", "r379", "r382" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r133", "r134", "r158", "r307", "r308", "r379", "r382" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r133", "r134", "r158", "r307", "r308" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Total net revenues percent" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r133", "r134", "r158", "r307", "r308", "r382" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r85", "r293" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r64", "r89", "r166", "r183", "r184", "r185", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r309" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "Total cost of revenues" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cost of Revenue [Abstract]", "terseLabel": "COST OF REVENUES:" } } }, "localname": "CostOfRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of revenues" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureStockBasedCompensationEquityBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r131", "r158" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r76", "r171" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization expense" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosurePropertyAndEquipmentNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r76", "r142" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of total net revenues by geographic region" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureStockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DistributionMadeToLimitedLiabilityCompanyLLCMemberCashDistributionsPaid": { "auth_ref": [ "r222" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash distribution paid to unit-holder of limited liability company (LLC).", "label": "Distribution Made to Limited Liability Company (LLC) Member, Cash Distributions Paid", "negatedLabel": "Payment of Member distributions" } } }, "localname": "DistributionMadeToLimitedLiabilityCompanyLLCMemberCashDistributionsPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EMEAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Regions of Europe, Middle East and Africa.", "label": "Europe, Middle East and Africa (EMEA)" } } }, "localname": "EMEAMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Per Class A Common Share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r60", "r98", "r99", "r100", "r101", "r102", "r106", "r109", "r113", "r114", "r115", "r119", "r120", "r305", "r306", "r350", "r364" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per Class A common shares attributable to Enfusion, Inc., Basic", "verboseLabel": "Net loss per share of Class A common stock-basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareDilutedNetLossPerCommonUnitDetails", "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r60", "r98", "r99", "r100", "r101", "r102", "r109", "r113", "r114", "r115", "r119", "r120", "r305", "r306", "r350", "r364" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per Class A common shares attributable to Enfusion, Inc., Diluted", "verboseLabel": "Net loss per share of Class A common stock- diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareDilutedNetLossPerCommonUnitDetails", "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r116", "r117", "r118", "r121" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Income (Loss) Per Class A Common Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r312" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate (as a percent)" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesNarrativesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r90", "r272", "r280" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "U.S. statutory tax rate (as a percent)" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxesNarrativesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Management Incentive Plans" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureStockBasedCompensationEquityBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Stock based compensation recognition period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureStockBasedCompensationEquityBasedCompensationDetails", "http://enfusion.com/role/DisclosureStockBasedCompensationNarrativesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r262" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureStockBasedCompensationEquityBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r262" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Nonvested award option" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureStockBasedCompensationNarrativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee stock option" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareDilutiveSharesDetails", "http://enfusion.com/role/DisclosureStockBasedCompensationAssumptionsForPerformanceBasedSharesDetails", "http://enfusion.com/role/DisclosureStockBasedCompensationNarrativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Units, Stockholders' Equity and Members' Deficit" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r51", "r52", "r53", "r93", "r94", "r95", "r97", "r103", "r105", "r122", "r167", "r215", "r222", "r264", "r265", "r266", "r276", "r277", "r304", "r314", "r315", "r316", "r317", "r318", "r319", "r373", "r374", "r375", "r408" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosurePreferredUnitsStockholdersEquityAndMembersDeficitDetails", "http://enfusion.com/role/DocumentDocumentAndEntityInformation", "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r65" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureStockBasedCompensationEquityBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeographicConcentrationRiskMember": { "auth_ref": [ "r132", "r382" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).", "label": "Geographic Region" } } }, "localname": "GeographicConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r63", "r89", "r144", "r146", "r149", "r152", "r154", "r166", "r183", "r184", "r185", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r309" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Amounts Attributable to Parent, Disclosures [Abstract]", "terseLabel": "Net loss per Class A common shares attributable to Enfusion, Inc.:" } } }, "localname": "IncomeAmountsAttributableToReportingEntityDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r55", "r144", "r146", "r149", "r152", "r154", "r340", "r345", "r352", "r365" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "(Loss) income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Interim Statements of Operations" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r175", "r177" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureStockBasedCompensationEquityBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r177" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureStockBasedCompensationEquityBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r90", "r273", "r274", "r275", "r278", "r281", "r283", "r284", "r285" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r91", "r104", "r105", "r143", "r271", "r279", "r282", "r366" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "verboseLabel": "Income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r79" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Income taxes paid in cash" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r75" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r75" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r75" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accrued expenses and other liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Change in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPartnersCapitalRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Partners' Capital [Roll Forward]", "terseLabel": "Members' Equity (Deficit)" } } }, "localname": "IncreaseDecreaseInPartnersCapitalRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r75" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Temporary Equity [Roll Forward]", "terseLabel": "Preferred Units" } } }, "localname": "IncreaseDecreaseInTemporaryEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r54", "r141", "r320", "r321", "r351" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r70", "r73", "r79" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest paid in cash" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseAndRentalExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "Operating Leases, Rent Expense", "terseLabel": "Expense related to lease agreements" } } }, "localname": "LeaseAndRentalExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureOperatingLeasesAndServiceAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r172" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r31", "r89", "r148", "r166", "r183", "r184", "r185", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r292", "r298", "r299", "r309", "r329", "r330" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "Liabilities" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r24", "r89", "r166", "r309", "r331", "r343", "r358" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES, PREFERRED UNITS, STOCKHOLDERS' EQUITY AND MEMBERS' DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r33", "r89", "r166", "r183", "r184", "r185", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r292", "r298", "r299", "r309", "r329", "r330", "r331" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r181" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Loss Contingency Accrual", "terseLabel": "Accruals for contingencies" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MemberUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ownership interest in limited liability company (LLC).", "label": "Members' Equity" } } }, "localname": "MemberUnitsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_MembersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Members' Equity [Abstract]", "terseLabel": "Stockholders' Equity:" } } }, "localname": "MembersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r37", "r89", "r166", "r183", "r187", "r188", "r189", "r192", "r193", "r309", "r342", "r357" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Non-controlling interests" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.", "label": "Noncontrolling Interest, Ownership Percentage by Parent", "terseLabel": "Ownership Percentage" } } }, "localname": "MinorityInterestOwnershipPercentageByParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureOrganizationAndDescriptionOfBusinessIpoAndReorganizationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r126", "r138" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "Organization and Description of Business" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureOrganizationAndDescriptionOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r72" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r72" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r72", "r74", "r77" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash (used) provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r2", "r46", "r48", "r53", "r56", "r77", "r89", "r96", "r98", "r99", "r100", "r101", "r104", "r105", "r112", "r144", "r146", "r149", "r152", "r154", "r166", "r183", "r184", "r185", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r306", "r309", "r346", "r360" ], "calculation": { "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareDilutedNetLossPerCommonUnitDetails": { "order": 2.0, "parentTag": "enfn_NetIncomeLossAttributableToCommonStockholdersNetOfAdjustments", "weight": 1.0 }, "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net (loss) income attributable to Enfusion, Inc." } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareDilutedNetLossPerCommonUnitDetails", "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r46", "r48", "r53", "r104", "r105", "r295", "r301" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "negatedLabel": "Less: Net loss attributable to non-controlling interests", "terseLabel": "Net loss attributable to non-controlling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareDilutedNetLossPerCommonUnitDetails", "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareDilutedNetLossPerCommonUnitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements Not Yet Adopted" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r93", "r94", "r95", "r222", "r286" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r66" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total non-operating income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "NON-OPERATING INCOME (EXPENSE):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "OPERATING EXPENSES:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r144", "r146", "r149", "r152", "r154" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "(Loss) income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r3", "r303" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r38", "r331" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r28" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": { "auth_ref": [ "r41", "r43", "r310", "r311", "r313" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveLossIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax", "terseLabel": "Foreign currency translation loss" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveLossIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r40" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "verboseLabel": "Foreign currency translation loss" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive loss, net of income tax:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveLossIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r34" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r67" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income (expense)" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r69" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedTerseLabel": "Payment of withholding taxes on stock-based compensation", "terseLabel": "Payment for employee payroll tax withholding obligations on stock-based compensation" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureStockBasedCompensationNarrativesDetails", "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r68" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r251", "r263" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureStockBasedCompensationNarrativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureStockBasedCompensationNarrativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosurePreferredUnitsStockholdersEquityAndMembersDeficitDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r6", "r8", "r168", "r169" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r2", "r46", "r48", "r53", "r71", "r89", "r96", "r104", "r105", "r144", "r146", "r149", "r152", "r154", "r166", "r183", "r184", "r185", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r288", "r294", "r296", "r301", "r302", "r306", "r309", "r352" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveLossIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net income (loss)", "netLabel": "Net loss", "totalLabel": "Net (loss) income", "verboseLabel": "Net (loss) income" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareDilutedNetLossPerCommonUnitDetails", "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows", "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveLossIncome", "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r27", "r174" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r176", "r384", "r385", "r386" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosurePropertyAndEquipmentNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r26", "r172" ], "calculation": { "http://enfusion.com/role/DisclosurePropertyAndEquipmentNetDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Total property and equipment, cost" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosurePropertyAndEquipmentNetDetails", "http://enfusion.com/role/DisclosurePropertyAndEquipmentNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r12", "r13", "r174", "r331", "r353", "r359" ], "calculation": { "http://enfusion.com/role/DisclosurePropertyAndEquipmentNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Total property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosurePropertyAndEquipmentNetDetails", "http://enfusion.com/role/DisclosurePropertyAndEquipmentNetNarrativeDetails", "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r12", "r174" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosurePropertyAndEquipmentNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r12", "r172" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProvisionForOtherCreditLosses": { "auth_ref": [ "r75", "r344" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to credit loss from transactions other than loan and lease transactions.", "label": "Provision for Other Credit Losses", "terseLabel": "Provision for bad debts" } } }, "localname": "ProvisionForOtherCreditLosses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesPolicyTextBlock": { "auth_ref": [ "r161", "r163", "r164", "r165" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.", "label": "Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable" } } }, "localname": "ReceivablesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r322", "r323", "r324", "r327", "r328" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureRelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Technology and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureStockBasedCompensationEquityBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units", "terseLabel": "Restricted Stock Units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareDilutiveSharesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r20", "r222", "r267", "r331", "r356", "r376", "r378" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r93", "r94", "r95", "r97", "r103", "r105", "r167", "r264", "r265", "r266", "r276", "r277", "r304", "r373", "r375" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated Deficit/Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r139", "r140", "r145", "r150", "r151", "r155", "r156", "r158", "r235", "r236", "r339" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "verboseLabel": "Total revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails", "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerMember": { "auth_ref": [ "r133", "r158" ], "lang": { "en-us": { "role": { "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.", "label": "Revenues" } } }, "localname": "RevenueFromContractWithCustomerMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r86", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r244" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r225" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Revenue remaining performance obligation" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "auth_ref": [ "r226" ], "lang": { "en-us": { "role": { "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "terseLabel": "Remaining performance obligation satisfaction period" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "auth_ref": [ "r226" ], "lang": { "en-us": { "role": { "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "REVENUES:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r116" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of effect of dilutive shares antidilutive" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock": { "auth_ref": [ "r110", "r115", "r120" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the effect of income (loss) on basic earnings per share.", "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block]", "terseLabel": "Schedule of reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r249", "r260", "r269" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureStockBasedCompensationEquityBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r249", "r260", "r269" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of stock compensation expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r27", "r174" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosurePropertyAndEquipmentNetDetails", "http://enfusion.com/role/DisclosurePropertyAndEquipmentNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r325", "r326" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r251", "r263" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureStockBasedCompensationAssumptionsForPerformanceBasedSharesDetails", "http://enfusion.com/role/DisclosureStockBasedCompensationNarrativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r35", "r87", "r123", "r124", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r204", "r208", "r213", "r216", "r217", "r218", "r219", "r220", "r221", "r222" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosurePreferredUnitsStockholdersEquityAndMembersDeficitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and Marketing Expense", "terseLabel": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingAndMarketingExpenseMember": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling and marketing expense.", "label": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureStockBasedCompensationEquityBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r75" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based compensation expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vested (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureStockBasedCompensationEquityBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureStockBasedCompensationAssumptionsForPerformanceBasedSharesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r256" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureStockBasedCompensationAssumptionsForPerformanceBasedSharesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureStockBasedCompensationAssumptionsForPerformanceBasedSharesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Management Incentive Plans" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureStockBasedCompensationAssumptionsForPerformanceBasedSharesDetails", "http://enfusion.com/role/DisclosureStockBasedCompensationNarrativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Options granted to employees" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureStockBasedCompensationNarrativesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r248", "r253" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureStockBasedCompensationAssumptionsForPerformanceBasedSharesDetails", "http://enfusion.com/role/DisclosureStockBasedCompensationEquityBasedCompensationDetails", "http://enfusion.com/role/DisclosureStockBasedCompensationNarrativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average grants in period" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureStockBasedCompensationNarrativesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r255", "r268" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term of award" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureStockBasedCompensationAssumptionsForPerformanceBasedSharesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Purchase price of common stock, percent" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureStockBasedCompensationNarrativesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance at end of period (in shares)", "periodStartLabel": "Balance at Beginning of period (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r84", "r92" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.", "label": "Software development costs" } } }, "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r15", "r16", "r17", "r87", "r89", "r109", "r110", "r111", "r113", "r115", "r123", "r124", "r125", "r166", "r183", "r187", "r188", "r189", "r192", "r193", "r199", "r200", "r204", "r208", "r215", "r309", "r405" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosurePreferredUnitsStockholdersEquityAndMembersDeficitDetails", "http://enfusion.com/role/DisclosureRelatedPartyTransactionsDetails", "http://enfusion.com/role/DisclosureStockBasedCompensationNarrativesDetails", "http://enfusion.com/role/DocumentDocumentAndEntityInformation", "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets", "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheetsParenthetical", "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r36", "r51", "r52", "r53", "r93", "r94", "r95", "r97", "r103", "r105", "r122", "r167", "r215", "r222", "r264", "r265", "r266", "r276", "r277", "r304", "r314", "r315", "r316", "r317", "r318", "r319", "r373", "r374", "r375", "r408" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosurePreferredUnitsStockholdersEquityAndMembersDeficitDetails", "http://enfusion.com/role/DocumentDocumentAndEntityInformation", "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareDilutiveSharesDetails", "http://enfusion.com/role/DisclosureOrganizationAndDescriptionOfBusinessIpoAndReorganizationDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets", "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheetsParenthetical", "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations", "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Interim Statements of Cash Flows" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Interim Balance Sheets" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Interim Statements of Comprehensive (Loss) Income" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Interim Statements of Preferred Units, Stockholders' Equity and Members' Deficit" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r93", "r94", "r95", "r122", "r339" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareDilutiveSharesDetails", "http://enfusion.com/role/DisclosureOrganizationAndDescriptionOfBusinessIpoAndReorganizationDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets", "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheetsParenthetical", "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations", "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r16", "r17", "r215", "r222" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Stock issued (in shares)", "verboseLabel": "Issuance of Units, net of issuance costs (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureRelatedPartyTransactionsDetails", "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r16", "r17", "r215", "r222" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "verboseLabel": "Issuance of restricted shares (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r215", "r222" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Issuance of restricted shares" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r16", "r17", "r222", "r250", "r254" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "verboseLabel": "Share-based compensation, net of taxes paid" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r17", "r22", "r23", "r89", "r162", "r166", "r309", "r331" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total stockholders' equity attributable to Enfusion, Inc." } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r0", "r1", "r52", "r89", "r93", "r94", "r95", "r97", "r103", "r166", "r167", "r222", "r264", "r265", "r266", "r276", "r277", "r286", "r287", "r300", "r304", "r309", "r314", "r315", "r319", "r374", "r375", "r408" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at Beginning of period", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets", "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r88", "r200", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r214", "r222", "r224" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "Preferred Units, Stockholders' Equity and Members' Deficit" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosurePreferredUnitsStockholdersEquityAndMembersDeficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.", "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "terseLabel": "Stock exchange ratio" } } }, "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosurePreferredUnitsStockholdersEquityAndMembersDeficitDetails", "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "pureItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TaxesPayableCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://enfusion.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 3.0, "parentTag": "enfn_AccruedExpensesAndOtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Taxes Payable, Current", "terseLabel": "Accrued taxes" } } }, "localname": "TaxesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Temporary Equity [Abstract]", "verboseLabel": "Preferred Units:" } } }, "localname": "TemporaryEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [ "r183", "r187", "r188", "r189", "r192", "r193" ], "calculation": { "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at Beginning of period", "terseLabel": "Preferred units carrying amount", "verboseLabel": "Total Preferred Units" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosurePreferredUnitsStockholdersEquityAndMembersDeficitDetails", "http://enfusion.com/role/StatementCondensedConsolidatedInterimBalanceSheets", "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityNetIncome": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of net income or loss attributable to temporary equity interest.", "label": "Temporary Equity, Net Income", "terseLabel": "Net income" } } }, "localname": "TemporaryEquityNetIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Outstanding", "periodEndLabel": "Balance at end of period (in shares)", "periodStartLabel": "Balance at Beginning of period (in shares)", "verboseLabel": "Preferred units, outstanding (in shares)" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureRelatedPartyTransactionsDetails", "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfPreferredUnitsStockholdersEquityAndMembersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r127", "r128", "r129", "r130", "r135", "r136", "r137" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r108", "r115" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted Average number of Class A common shares outstanding, Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": { "auth_ref": [ "r106", "r107" ], "calculation": { "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareDilutedNetLossPerCommonUnitDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).", "label": "Weighted Average Number of Shares Issued, Basic", "terseLabel": "Weighted-average shares of Class A common stock outstanding" } } }, "localname": "WeightedAverageNumberOfSharesIssuedBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareDilutedNetLossPerCommonUnitDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r106", "r115" ], "calculation": { "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareDilutedNetLossPerCommonUnitDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted Average number of Class A common shares outstanding, Basic", "totalLabel": "Weighted-average shares of Class A common stock outstanding--basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareDilutedNetLossPerCommonUnitDetails", "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "terseLabel": "Weighted Average number of Class A common shares outstanding:", "verboseLabel": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareDilutedNetLossPerCommonUnitDetails", "http://enfusion.com/role/StatementCondensedConsolidatedInterimStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesRestrictedStock": { "auth_ref": [ "r107" ], "calculation": { "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareDilutedNetLossPerCommonUnitDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of shares of restricted stock determined by relating the portion of time within a reporting period that restricted shares have been outstanding to the total time in that period. Restricted shares are subject to sales, contractual, regulatory or other restrictions that prevent or inhibit the holder from freely disposing of them before the restriction ends.", "label": "Weighted Average Number of Shares, Restricted Stock", "terseLabel": "Vested shares of Class A common stock and RSUs" } } }, "localname": "WeightedAverageNumberOfSharesRestrictedStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://enfusion.com/role/DisclosureNetIncomeLossPerClassCommonShareDilutedNetLossPerCommonUnitDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2646-109256" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r121": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r138": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r176": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r182": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r224": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r244": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r285": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613674-111683" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r303": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28129-110885" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r328": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(25))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(21))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04.16)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128487-111756" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r400": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r401": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r402": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r403": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r404": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r405": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r406": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r407": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a-c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(23))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r92": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" } }, "version": "2.1" } ZIP 72 0001558370-22-012979-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-22-012979-xbrl.zip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ʻ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end